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Abstract 
Prostate cancer (PCa) represents a significant clinical challenge because it is difficult to 
predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 
112 primary and metastatic PCa samples. From joint analysis of these cancers with those 
from previous studies, 930 cancers in total, we identified evidence for 22 novel putative 
coding driver genes, as well as evidence for  NEAT1 and FOXA1 acting as drivers through 
non-coding mutations. Through the temporal dissection of aberrations, we identified driver 
mutations specifically associated with steps in the progression of PCa, for example 
establishing loss of CHD1 and BRCA2 as early events in cancer development of ETS fusion 
negative cancers. Computational chemogenomic (CanSAR) analysis of PCa mutations 
identified eleven targets of current drugs, eight of investigational drugs and fifty four 
compounds that may be active and should be considered candidates for future clinical trials.   
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INTRODUCTION 
Prostate cancer is the most common solid cancer in men (diagnosed in 12%) and often fatal 
(9% of male cancer deaths). It is difficult to manage clinically due to a poor current 
understanding of what dictates its highly variable natural history, and of what underlies the 
development of castration-resistant disease1. Extensive data on the structure of prostate 
cancer genomes have been published2-6, including work from our own consortium7-10. 
These studies have identified a number of genetically distinct subgroups, including cancers 
with ERG, ETV1, ETV4, FLI1, SPOP, FOXA1 and IDH1 alterations. Overlapping with 
these categories, cancers may have alterations in PI3K and DNA repair pathways, with the 
latter significantly over-represented in advanced disease4. However, we have relatively 
limited understanding of the ordering of genetic events with the exception that ETS gene 
alteration appears to represent an early event, whilst mutations of AR are later, sometimes 
convergent, events, occurring in advanced and metastatic disease. Indeed, we have very 
little understanding of the evolution of mutational processes, the various genetic paths that 
cancers traverse on their way to progression, the levels of heterogeneity at different stages 
of development or the effect of these factors on clinical outcome.   
Gene status has been used in studies designed to improve the poor predictive value of 
conventional clinical markers (PSA, Gleason sum, stage) and to develop disease 
management strategies. For example, genetic alteration of BRCA1/211, PTEN deletion12, 
amplification of AURKA together with the MYCN gene13, and coordinated loss of MAP3K7 
and CHD114 have been reported to have prognostic value. A number of commercial 
prognostic tests based on gene expression profiles are also available [ProlarisTM 15, 
DecipherTM 16 and OncotypeDxTM 17] and a classification framework has been proposed18. 
Improvements in the treatment of castration-resistant disease have been made through 
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better targeting of AR regulation using abiraterone19 and enzalutamide20, whilst PARP 
inhibitors are effective against cancers harbouring BRCA1/2 mutations and other defects in 
DNA repair pathways21. However, a significant recent improvement in the treatment of 
newly diagnosed advanced prostate cancer has been achieved through using docetaxel in 
combination with hormone therapy, a re-tasking of conventional therapy22. 
In the present study, we use previously unpublished whole genome DNA sequencing data 
in combination with published data to provide new insights into the mechanism of 
progression of prostate cancer to lethal disease, and to design novel molecular-based 
strategies for drug targeting. 
RESULTS 
We whole genome sequenced cancerous and matched normal samples from 87 primary 
prostate cancers from the UK and 5 from Shanghai, China together with 10 hormone-naïve 
prostate metastases and 10 castration-resistant metastases from the USA. Analysis (see 
Online Methods) reveals insights into the nature and order of acquisition of driver alterations, 
heterogeneity of genomic heterogeneity in primary and metastatic cancers, changes in 
mutational signatures during progression, and potential drug targets. In addition, we 
identified coding and non-coding drivers by combining single nucleotide variants (SNVs) and 
small insertions/deletions (indels) within our dataset with those from TCGA4 (425 samples), 
the COSMIC database23 (243 samples) and Stand Up to Cancer24 (SU2C-PCF, 150 samples) 
to give a combined dataset, hereafter referred to as the ‘joint dataset’, comprising 710 
primary cancers and 220 metastases. Supplementary Table 1 summarises the genes affected 
in both our study and the joint dataset. 
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For the 112 cancer-normal pairs in our cohort, we identified 392,753 substitutions, 54,952 
small insertion/deletions (indels) and 10,921 chromosomal rearrangements (Fig. 1). The 
mean genome-wide substitution rate across the whole dataset was 1.23/Mb, with a significant 
difference in mutational burden between the primary (0.99) and metastatic (2.30) samples 
(P=4.4x10-15, Online Methods). Moreover, within the metastatic subset, mutation burden was 
higher in men treated with androgen deprivation therapy (ADT or CRPC) with metastases 
than the treatment-naïve cases (2.98 vs 1.61, P=0.015). There were also significantly more 
rearrangements in metastatic than in primary samples (P=0.0059), whilst the proportion of 
breakpoints attributed to a chromoplexy-like event25 was indistinguishable between the two 
groups. Within the metastatic group, the ADT samples had more rearrangements than did the 
hormone-naïve (P=0.027), with no difference in the proportion of chromoplexy-like events 
(Fig. 1). 
Genes of interest were identified through a comprehensive set of analyses to identify: excess 
of non-synonymous mutations in coding regions; excess missense mutations within a gene, 
indicative of an oncogenic driver; excess of mutations in non-coding regions; regions with an 
excess of structural variants in either ETS+ or ETS- cancers; and regions with recurrent copy 
number aberrations in either ETS+ or ETS- cancers. Overall, we identified 73 genes with 
evidence for involvement in prostate cancer development (Fig. 2, Table 1, Supplementary 
Table 2). Based on a literature search, each gene was assigned a high, medium or low level of 
previous supporting evidence (Table 1, Supplementary Table 2). In addition to 22 genes with 
little or no previous evidence of involvement in prostate cancer (Table 1, ‘low’ previous 
evidence), we provide corroborating evidence for 8 further genes previously lacking strong 
evidence of driving prostate cancer (Table 1, ‘medium’ previous evidence). 
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Coding drivers 
We identified 28 genes with an excess of non-synonymous coding mutations, five of which 
are previously unknown drivers in prostate cancer (Supplementary Table 2). TBL1XR1 was 
enriched in truncating SNVs and indels and is also located in a genomic region enriched for 
rearrangements in ETS+ cancers (chr3: 172-179Mb) (Fig. 3). These rearrangements result in 
loss of heterozygosity (LOH) or, in one case, homozygous deletion, suggesting a cancer 
suppressor role for this gene. Another significantly mutated gene primarily affected by 
truncating mutations was ZMYM3, which encodes a component of CoREST, a transcriptional 
repressor complex including REST (RE-1 silencing transcription factor) and involved in 
suppression of neuronal differentiation-related genes in non-nervous tissues26. In addition, 
two further CRPC samples from the SU2C-PCF study24 had nonsense mutations and one 
sample within our study had a 70kb exonic deletion in REST.  
Two other genes with recurrent truncating mutations were IL6ST and CASZ1 (Fig. 3). The 
latter is a putative cancer suppressor in neuroblastoma27 while the former encodes 
glycoprotein 130, the signal-transducing subunit of the interleukin 6 (IL6) receptor. The 
pattern of mutations we observe in the joint dataset for IL6ST is dominated by truncating 
events. Moreover, this gene is located in a genomic region recurrently rearranged in ETS+ 
cancers, resulting in either LOH or homozygous deletion (four cases of each), suggesting a 
cancer suppressive role. TBX3, which has previously been reported to harbor mutations in 
breast cancer28, exhibited a mixed pattern of mutations with mostly missense mutations and 
two cancers harbouring truncating events. 
Analysis of missense mutations identified mutations in seven further genes, of which two are 
newly reported (Supplementary Table 2). CNOT3 exhibited mutation hotspots in two amino 
acid positions, p.E20K (4/932 samples) and p.E70K (5/932 samples), as well as a nonsense 
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mutation in a single sample (Fig. 3). CNOT3 has a known cancer suppressive function in T-
cell acute lymphoblastic leukaemia29. Enrichment for missense mutations was identified in 
RPL11 a ribosomal protein and a putative cancer suppressor upstream of the MDM2/TP53 
pathway30. In contrast to previous studies, the enrichment for missense mutations in both 
CNOT3 and RPL11 suggests oncogenic, rather than tumor suppressor, roles in prostate 
cancer.  
A comparison between coding mutations in the metastatic and primary samples within the 
joint dataset identified enrichment in metastases for mutations in TP53, AR, KMT2C, 
KMT2D, RB1, APC, BRCA2, CDK12, ZFHX3, CTNNB1, PIK3CB (Supplementary Table 2), 
confirming previous studies3,24. 
Non-coding drivers 
Analysis of the non-coding components of the genome identified two regions with 
statistically significant enrichment for mutations. NEAT1, a lncRNA recently reported to be 
associated with PCa progression31, was mutated in 13/112 ICGC cases with a significant 
over-representation in patients with metastatic disease (6/20 metastases vs. 7/91 primaries, 
Fisher exact test, P=0.012, Fig. 3). Interestingly, out of the metastatic cases NEAT1 mutations 
were found only in patients that had undergone ADT, consistent with the link between high 
NEAT1 expression and resistance to AR-targeting therapies31. Notably, two of these six cases 
had two separate NEAT1 mutations. The FOXA1 promoter also had significant evidence of 
selection. This gene modulates AR-regulated transcriptional signalling32 and has been found 
to harbor recurrent coding mutations in previous studies5. In our series, we identified 14 
samples with coding and 6 samples with non-coding mutations, with two samples (PD14721a 
and PD12813a) bearing both a coding and a non-coding mutation. Interestingly, we also 
identified mutations in the FOXP1 promoter, a gene with known cancer-suppressive effect in 
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prostate tumorigenesis33, in three samples, but this was insufficient to reach statistical 
significance.  
Structural variant enrichment in ETS+ and ETS- cancers 
The density of rearrangements varies across the genome as a result of a variety of factors 
including chromatin state, GC content, gene density, replication timing and repetitive 
sequence. In order to remove the effect of these various factors, we segmented inter-
breakpoint distance across the genome separately in ETS+ and ETS- cancers and identified 
regions with differential enrichment for rearrangements between the two subtypes. The 
functional importance of many of these regions was supported by an excess of truncating 
mutations or CNAs.  
In addition to regions previously identified as enriched for rearrangements in ETS+ cancers 
(FOXP1, RYBP, SHQ1, PTEN, and TP53)34-37, two unreported regions were identified. The 
region chr5:55-59Mb covers the genes PPAP2A, PDE4D, MAP3K1 and IL6ST (Fig. 3). In 
IL6ST we also detected significant enrichment for coding mutations, suggesting this is the 
main target of the aberrations. In chr3:171:178Mb, TBL1XR1 is similarly enriched for both 
rearrangements and truncating mutations. 
In ETS- cancers, we confirmed a previously reported enrichment for rearrangements 
containing CHD1(38,39). A target of enriched rearrangements in the region chr1:149-158Mb is 
likely ETV3. In 5/9 cancers, ETV3 was exclusively affected by these events (4 LOH by 
deletion and 1 by translocation). Additionally, one cancer had a truncating mutation 
(p.R413fs*3) and two had missense mutations (p.A73V and p.L37Q). In total, 12 patients had 
localised alteration, 10 of whom had ETS- cancers. In addition, eleven tumors, 8 of them 
ETS-, had LOH covering ETV3. Moreover, within the joint dataset, there are four cancer 
samples with truncating mutations in this gene. In contrast to ETV4, the nature of variants in 
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ETV3 is indicative of a tumor suppressive role in PCa.  Manual inspection of the recurrently 
rearranged region chr3:76-84Mb identified ROBO1 and ROBO2 as possible targets (Fig. 3). 
In total 16/112 samples had an event affecting one or other of these genes, and in four 
samples both were affected. Previously implicated in pancreatic ductal adenocarcinoma40, 
these two genes have not been previously reported in the context of PCa. 
Events enriched at chr6:80-114Mb indicate that ZNF292 is a possible target. 11/112 patients 
(5 ETS+ and 6 ETS-) had loss of at least one chromosome copy and in two patients there was 
a homozygous loss specifically targeting ZNF292. Moreover, the joint dataset contained 
5/932 samples with a truncating mutation, further suggesting a cancer suppressive function 
for this gene in PCa. Another gene affected by recurrent rearrangements on 6q was SENP6, a 
small ubiquitin-like modifier (SUMO)-specific protease that removes SUMO polypeptides 
from conjugated proteins41, and possibly plays a role in AR function42. Of note, 4/5 
rearrangements in this region affected SENP6 only, leading to a significant reduction in 
expression (Supplementary Fig. 1). Finally, located at chr6:126Mb, the nuclear receptor co-
activator NCOA7 was altered in six samples, with one sample having homozygous loss.  
Further regions enriched in ETS- cancers were chr2:133-144Mb (LRP1B), chr8:112-114 
(CSMD3) and chr8:40-41Mb (MYST3). The first two genes are very large and fall within 
reported fragile sites43. Nevertheless, preferential enrichment of breakpoints in ETS- cancers 
may suggest either that underlying structure, such as AR binding sites or nucleosome 
structure, or epistatic interactions between ETS fusion and other rearrangements affect the 
occurrence of rearrangements at these loci. Samples containing structural variants affecting 
MYST3 were found to have significantly reduced RNA expression (Supplementary Fig. 1).  
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Timing of copy number aberrations 
In order to identify routes to progression in PCa, we developed a novel approach to order the 
occurrence of copy number aberrations by combining information on: the clonality of copy 
number aberrations; timing relative to whole genome duplication; timing of homozygous 
deletions relative to neighboring hemizygous losses. Information from all tumors was 
combined using a Bradley-Terry model, to give the most likely ordering of events. By 
applying a set of logical rules (see Online Methods), we deciphered the temporal ordering of 
the subclonal CNAs within each cancer. In general, homozygous deletions appear late in 
oncogenesis, corroborating previous findings that homozygous deletions are associated with 
more advanced disease44-46. Clear differences emerge in the evolution of PCa in the ETS+ 
and ETS- subsets.  Where present, the deletion between the TMPRSS2 and ERG genes in 
ETS+ cancers was an early (generally clonal) event, as was gain of chr8q within the locus 
112 – 137Mb (Fig. 4a). The earliest homozygous deletions in ETS+ cancers include chr5: 
55Mb-59Mb, corroborating the rearrangements targeting PPAP2A, PDE4D, MAP3K1 and 
IL6ST, and chr10:89Mb-90Mb, which covers PTEN (Figs. 3 and 4a). 
In ETS- cancers losses at chr5:60–100Mb (CHD1 and RGMB), chr13:32-91Mb (which 
includes BRCA2, RB1 and FOXO1), and chr6:73-120Mb are followed by losses at chr2:124-
142Mb, then by gains at chr3:100-187Mb, and then whole chromosome gain of chr7 (Fig. 
4b).  Loss of CHD1 has been previously implicated in the initiation of ETS- prostate cancers, 
preventing ERG re-arrangement in the prostate38 and our data confirm the exclusivity 
between ETS positivity and homozygous loss of CHD1 (Fig. 4c).  
In both ETS-positive and ETS-negative cancers, whole genome duplication (WGD) was 
correlated with the loss of chromosomal segments at: chr1:94Mb, chr2:140Mb, chr12:12Mb, 
chr16:85Mb and chr17:7Mb (Fig. 4c). From timing analysis, these losses appear to occur co-
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synchronously with WGD in most cases. Gains at chr8:101Mb occurred prior to WGD, 
chr3:131Mb occurred synchronously, and gains at chr7:88Mb tended to follow WGD. 
Timing point mutations and indels 
Point substitutions and indels were clustered according to their cancer cell fraction (CCF) 
using a Bayesian Dirichlet process47. The proportion of substitutions identified as subclonal 
showed considerable variation across cancers, but was significantly higher in primary than 
metastatic samples (Fig. 5a, P=0.022, Wilcoxon rank sum test), as was the proportion of 
subclonal indels (P=0.00033) and the fraction of the genome with subclonal copy number 
aberrations (P=0.0037, Supplementary Fig. 2). This is apparent evidence for a bottleneck in 
acquiring metastatic potential rather than a response to treatment, since levels of 
heterogeneity in untreated metastases are no lower than in androgen-deprived metastases 
(Fig. 5a). 
The levels of heterogeneity observed in substitutions and indels were correlated (Fig. 5a, 
Pearson r = 0.57, P=2.3x10-9). Higher levels of heterogeneity were observed amongst indels 
than substitutions (P=2.4x10-8). However, it cannot be ruled out that variant calling of indels 
may have greater sensitivity for low allele frequency variants than calling of point 
substitutions. 
Driver mutations were identified as clonal or subclonal according to the cluster to which they 
were assigned, with 84 classified as clonal and 22 (21%) as subclonal. Our power to detect 
subclonal mutations is limited by sequencing depth and the real number of subclonal driver 
mutations is likely to be much higher. The driver mutations identified as subclonal include 
two mutations in APC in the same sample, PD14713a. Interestingly, this cancer has 
undergone clonal loss of one copy of chr5q, followed by mutations in APC in 2 different 
subclones (Fig. 5b and Supplementary Fig. 3), suggesting convergent evolution. Five other 
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samples each have two subclonal drivers: PD12808a has a missense mutation in ZNF292 and 
an essential splice site mutation in SMAD2; PD13401a has a nonsense mutation in PPP1R3A 
and a mutation in the promoter of NEAT1; PD13402a has a nonsense mutation in USP34 and 
an essential splice site mutation in ABI3BP (Fig. 5b); PD12820a has a missense mutation in 
USP48 and an essential splice site mutation in ASXL2; PD13389a has a frameshift mutation 
in PHF12 and an essential splice site mutation in TBX3 (not shown). 
Subclonal mutations are also seen in several common drivers including one in TP53 
(PD13339a) and one in PTEN (PD12840a). On the other hand, SPOP was mutated in 10 
samples, always clonally and always in ETS- tumors (Fig. 2).  
Mutational signatures 
Analysis of the mutational signatures by non-negative matrix factorisation (NMF) revealed 
that, in addition to the ubiquitous ‘clock-like’ signatures 1 and 5, there was presence of the 
previously described signatures 2, 3, 8, 13 and 1848. Signature-3-positive samples were 
enriched for germline/somatic mutations in BRCA1/2 genes (4/6 samples) as reported 
previously48 (Fig. 1). However, the presence of high levels of microhomology (MH)-
mediated deletions was even more strongly correlated with the presence of BRCA mutations 
(6/6 samples). Separating the mutations into early clonal, late clonal and subclonal epochs, as 
described in Online Methods, revealed that the proportion of signature 1 mutations decreases 
over time, suggesting an increase of cancer-associated mutagenic processes relative to innate 
processes in normal cells (P=2.2x10-16, test for trend in proportions). 
Signature 13, previously associated with the activity of the AID/APOBEC family of cytidine 
deaminases, was over-represented in advanced disease, 45% (9/20) in metastases vs. 14% 
(14/92) in primaries, (Fisher exact test, P=5.6x10-3). Similarly, signature 18, which has been 
previously associated with failure of base excision repair and to the accumulation of 
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mutations from 8-Oxoguanine damage49, was enriched in advanced disease, 40% (8/20) in 
metastases vs. 11% (10/92) in primaries (Fisher exact test, P=3.8x10-3). In a recent report of 
560 breast cancer whole-genomes, signature 8 correlated with DNA damage repair 
deficiency50. Androgen signalling is known to positively regulate multiple genes involved in 
DNA repair51,52, while androgen deprivation impairs DNA double-strand break repair53. In 
support of these previous reports, we have found that the proportion of mutations assigned to 
signature 8 is consistently higher amongst later appearing (subclonal) populations of cells 
(55% ± 24%) than earlier (clonal) populations (28% ± 12%) (t-test, P=1.3×10-4, 
Supplementary Table 3). The proportion of metastases with evidence for the action of 
signature 8 was higher than that for primary tumors, although not reaching statistical 
significance (8/20 metastases, 25/92 primaries, Fisher exact test P=0.28). Increased 
prevalence of DNA-damage related genes in metastatic prostate cancer as well as the 
observations made in this study warrant an extensive study of mutational signatures in 
therapy-naïve disease and CRPC in a larger dataset to explore the relevance of check-point 
inhibition as an alternative therapy for advanced prostate cancer. 
Clinical correlates 
CDH12 and ANTXR2 alterations were significantly associated with time to biochemical 
recurrence (Benjamin-Hochberg adjusted P = 0.0060 (CDH1) & 0.012 (ANTXR2), HR = 9.3 
& 7.7, Cox regression model, Fig. 6), and were significant predictors of biochemical 
recurrence independent of cofactors Gleason, PSA at prostatectomy, and pathological T-stage 
(P = 0.00061 (CDH1) & 0.0015 (ANTXR2), HR = 7.3 & 6.5, Cox regression model, 
Supplementary Table 4). A Cox regression model containing a combination of CDH12, 
ANTXR2, SPOP, IL6ST, DLC1 & MTUS1 mutations was determined to be an optimal 
predictor of time to biochemical recurrence and was a significant improvement over a 
baseline model of Gleason, PSA at prostatectomy, and pathological T-stage (model χ2 test, P 
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= 0.00053). The number of mutational signatures identified in a cancer was negatively 
correlated with time to biochemical recurrence in prostatectomy patients (P = 0.014, HR = 
3.0; Cox proportional hazards model on number of processes greater than 3, Supplementary 
Fig. 4) and is an independent predictor (P = 0.0061, HR = 3.6; Cox proportional hazards 
model). The number of substitutions detected was also an independent prognostic biomarker 
(P=0.031, HR=1.005; Cox proportional hazards model). The numbers of both samples and 
events within this study are modest and further analysis of larger cohorts is required to 
establish firmly these findings. 
Druggable targets in the prostate cancer disease network 
A key opportunity arising from systematic analyses of cancer genomics is the early 
objective identification of therapeutic intervention strategies. To this end, we applied 
established chemogenomic technologies using the canSAR knowledgebase54 to map and 
pharmacologically annotate the cellular network of the prostate disease genes we identified 
in this study. We derived the network using curated protein-protein and transcriptional 
interaction data. We included the protein products of the genes identified in this study and 
other key proteins that either directly interact with several of these proteins or directly 
affect their function (see Online Methods and Supplementary Fig. 5 for details). This 
resulted in a focussed prostate network of 163 proteins. We annotated each of these 
proteins with drug information and annotated them based on multiple assessments of 
‘druggability’: the likelihood of the protein to be amenable to small molecule drug 
intervention. (Table 2 and Supplementary Table 5). We find that PCa driver genes are 
embedded in a highly druggable cellular network that contains eleven targets of approved 
therapies and eight targets of investigational drugs. As well as the Androgen Receptor 
(AR) and the Glutocorticoid Receptor (GR), the network contains targets of drugs 
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approved for other indications, several of which (e.g. BRAF, ESR1, RARA, RXRA, 
HDAC3) are under clinical investigation for PCa.  
Eight proteins within the prostate network are targets of drugs currently in clinical trials. In 
particular, the ataxia-telangiectasia mutated (ATM) inhibitor AZD-0156, currently in Phase 
1 for safety assessment, is a likely candidate for exploration in PCa due to the recently 
described role of DNA damage repair, particularly in advanced PCas21,55. The network 
highlights targets of PI3 Kinase pathway inhibitors (PI3K, AKT1) that are undergoing 
clinical investigation in PCa, as well as IDH1 and MDM2 drug targets.  
To give an indication of the potential of these drugs, we analysed the most recent systematic 
drug sensitivity data (GDSC- 56- http://www.cancerrxgene.org/). Eighteen drugs acting on our 
network were tested in GDSC on prostate cancer cell lines. Of these, 5 showed significant 
effect on growth inhibition in at least one cell line, and all 18 showed weak activity in at least 
one cell line (Supplementary Table 6). However, to validate fully the potential of these drugs, 
extensive drug sensitivity testing needs to be performed in disease-relevant cancer models 
that correctly reflect the patient population. 
Potential future opportunities for PCa therapy are also highlighted by 15 proteins that are 
under active chemical biology or drug discovery investigation (Table 2). These include the 
Inositol 1,4,5-trisphosphate receptor type 2 (IP3R2) and Menin (MEN1), a component of the 
MLL/SET1 histone methyltransferase complex. Mice with MEN1 mutations develop PCa57 
and recent data have shown that menin expression is involved in CRPC58. A further 50 of the 
proteins are predicted to be druggable and therefore potentially amenable to drug discovery. 
These include the known PCa protein SPOP, the transcription activator BRG1 (SMARCA4); 
CDK12; and the CREB binding protein CREBBP.  
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In summary, we find that 74 of the 163 proteins central to the prostate disease network are 
either targets of existing drugs or have the potential to be targeted in the future. To maintain 
an up-to-date-view of this analysis, we provide a link to a live-page in canSAR  
http://cansar.icr.ac.uk/cansar/publications/sequencing_prostate_cancers_identifies_new_canc
er_genes_routes_progression_and_drug_targets/ (link via google chrome) 
 
DISCUSSION  
The analysis of whole genome sequence data from 112 prostate cancers has revealed many of 
the genetic factors underlying the processes of carcinogenesis, progression, metastasis and 
the acquisition of drug resistance. Supporting evidence has been provided for thirty candidate 
driver genes with limited or no previous support, including the non-coding drivers NEAT1 
and FOXA1. 
Through the timing of genomic aberrations, we have a picture of the possible routes to 
progression in PCa. Most driver mutations may occur either clonally or subclonally, but 
mutations in SPOP and ETS-fusions occur early in cancer development and are exclusively 
clonal. Whereas the gain of 8q and ETS fusion appear to be sufficient to drive a dominant 
clonal expansion, ETS- cancers typically need a combination of large-scale losses, acquired 
over an extended period of time. Known cancer drivers are frequently observed subclonally 
and two competing drivers are seen in several cancers. Less heterogeneity of aberrations is 
observed in metastatic than primary cancers, likely resulting from a bottleneck in achieving 
metastatic potential.  
We observe changes in the mutational processes operative upon cancers during progression. 
Signature 8 was operative to a greater extent at later stages, and was enriched in subclonal 
expansions, while signatures 13 and 18 were enriched in metastatic cancers. Cancers with 
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germline or somatic BRCA1/BRCA2 mutations were enriched for signature 3, demonstrating 
the effect of double-strand repair defects throughout cancer evolution. 
Survival analysis reveals that losses of CDH12 and ANTXR2 result in poorer recurrence-free 
survival. We identify 84 PCa associated proteins that are either targets for currently available 
drugs or new potential targets for therapeutic development. 
Analysis of the whole-genome sequences of over a hundred prostate cancers has started to 
reveal the complex evolutionary pathways of these cancers. The early acquisition of 
individual driver aberrations including ETS-fusions and whole genome duplications strongly 
affects the acquisition of subsequent aberrations. Acquisition of individual mutations affects 
both the subsequent likelihood of metastasis and response to treatment. Network analyses 
using the candidate driver genes here identified, in addition to previously known drivers, 
targets that can be exploited for immediate clinical investigation with existing drugs as well 
as targets for new drug discovery, giving potential for the results of genome analysis to be 
translated rapidly into therapeutic innovation and patient benefit.   
 
ONLINE METHODS 
Patient Cohorts, Samples and Ethics 
92 cancer samples from prostatectomy patients treated at The Royal Marsden NHS 
Foundation Trust, London, at the Addenbrooke’s Hospital, Cambridge, at Oxford University 
Hospitals NHS Trust, and at Changhai Hospital, Shanghai, China were collected as described 
previously59,60. Clinical details for the patients are shown in Supplementary Table 7. Ethical 
approval was obtained from the respective local ethics committees and from The Trent 
Multicentre Research Ethics Committee. All patients were consented to ICGC standards 
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https://icgc.org/. 20 men from PELICAN (Project to ELIminate lethal CANcer)61, an  
integrated clinical-molecular autopsy study of metastatic prostate cancer,  were the subjects 
of the current study. Subjects consented to participate in the Johns Hopkins Medicine IRB-
approved study between 1995 and 2005. (Supplementary Table 7). A17 had a germline 
BRCA1 mutation, as previously reported62. 
DNA preparation and DNA sequencing 
DNA from whole blood samples and frozen tissue was extracted and quantified using a ds-
DNA assay (UK-Quant-iT™ PicoGreen® dsDNA Assay Kit for DNA) following the 
manufacturer’s instructions with a Fluorescence Microplate Reader (Biotek SynergyHT, 
Biotek). Acceptable DNA had a concentration of at least 50ng/μl in TE (10mM Tris/1mM 
EDTA), was between 1.8-2.0 with an OD 260/280. WGS was performed at Illumina, Inc. 
(Illumina Sequencing Facility, San Diego, CA USA) or the BGI (Beijing Genome Institute, 
Hong Kong), as described previously, to a target depth of 50X for the cancer samples and 
30X for matched controls59.  
 The Burrows-Wheeler Aligner (BWA) was used to align the sequencing data to the GRCh37 
reference human genome63. Sequencing data have been deposited at the European Genome-
phenome Archive (EGAS00001000262). 
Variant Calling Pipeline 
Substitutions, insertions and deletions were detected using the Cancer Genome Project 
Wellcome Trust Sanger Institute pipeline as described previously59. In brief, substitutions 
were detected using CaVEMan with a cut-off ‘somatic’ probability of 95%. Post-processing 
filters were applied. Insertions and deletions were called using a modified version of Pindel64. 
Variant allele frequencies of all indels were corrected by local realignment of unmapped 
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reads against the mutant sequence. Structural variants were detected using Brass59. A positive 
ETS status was assigned if a breakpoint between ERG, ETV1 or ETV4 and previously 
reported partner DNA sequences was detected. 
Data availability 
Sequencing data that support the findings of this study have been deposited in the European 
Genome-phenome Archive with the accession code EGAS00001000262 
(https://www.ebi.ac.uk/ega/studies/EGAS00001000262). See Supplementary Table 7 for 
sample specific EGA accession codes. 
Code availability 
The CGP pipeline may be downloaded from https://github.com/cancerit/dockstore-cgpwgs. 
The Battenberg pipeline may be downloaded from https://github.com/Wedge-
Oxford/battenberg. 
Mutation burdens 
Mutation burdens were compared between primary and metastatic samples and between ADT 
and hormone-naïve samples using a negative binomial generalised linear model (GLM), 
implemented with the R package MASS. Sample type was found to be an independent 
predictor of number of SNVs, as was age at time of sampling. 
Timing of copy number events 
We developed a novel approach to order the occurrence of copy number aberrations by 
combining three sources of information: 
• Clonality of copy number aberrations 
• Timing relative to whole genome duplication 
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• Timing of homozygous deletions relative to neighboring hemizygous losses. 
Information from all tumors was combined using a Bradley-Terry model, to give the most 
likely ordering of events during progression of PCa. 
The Battenberg algorithm was used to detect clonal and subclonal somatic copy-number 
alterations (CNAs) and to estimate ploidy and cancer content from the next-generation 
sequencing data as previously described65. Briefly, germline heterozygous SNPs were 
phased using Impute2, and a- and b- alleles were assigned. Data were segmented using 
piecewise constant fitting66 and subclonal copy-number segments were identified via a t-
test as those with b-allele frequencies that differed significantly from the values expected 
of a clonal copy number state. Ploidy and cancer purity were estimated with the same 
method used by ASCAT67. 
In this cohort, we defined WGD samples as those that had an average ploidy greater than 3. 
For tumors that had not undergone WGD, gains were defined as those regions that had at 
least one allele with copy number greater than 1, while losses were defined as those segments 
that undergone LOH. For tumors that had undergone WGD, losses were called in those 
segments with at least one allele with copy number of less than 2, whereas gains were called 
for those with an allelic copy number greater than 2. An extension of this logic was used for 
subclonal copy number segments – the evolving cellular fraction was always defined as that 
which deviated away from overall ploidy (defined as 2 for non-WGD samples and 4 for 
WGD samples). For example, if 75% of cells within a non-WGD tumor have a copy number 
of 3 + 1 at a given genomic loci, with the remaining 25% of cells having a copy number of 2 
+ 1, then we assume there has been clonal gain to 2 + 1, and then a subclone containing 75% 
of cells has undergone a further gain. 
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Three independent approaches were used to extract evolutionary data from each cancer 
sample. The first involved ordering clustered sub-clonal cancer fractions, the second used 
implicit ordering of clonal HDs in relation to losses, and the third estimated the relative 
timing of whole genome duplication. The logical arguments used within each approach were 
considered in turn: 
1. Battenberg algorithm-derived estimates for the cellular fraction and standard 
deviation of each subclonal aberration were input to a Markov Chain Monte Carlo 
hierarchical Bayesian Dirichlet process to group linked events together in an unsupervised 
manner. This defined clusters of different cell populations, each present at a calculated cancer 
cell fraction. The pigeonhole principle was then used to determine the hierarchical 
relationship between these clusters. Using this process, gains, losses and HDs were ordered 
with the following caveat to ensure that only independent events are ordered: if there was a 
clonal and subclonal gain (or loss) at the same locus, then only the clonal or initial gain (or 
loss) was ordered. 
2. Homozygous deletions have implicitly occurred after loss of heterozygosity at the 
same locus. 
3. The parsimony principle was used to define the allele counts that correspond to early 
and late changes in relation to WGD. For losses, if the minor allele copy number equals 0, 
then the loss occurred prior to WGD. Otherwise the loss occurred after WGD.  Regarding 
gains, if the major allele copy number is twice or greater than ploidy, then the gain occurred 
prior to WGD. Otherwise, the gain occurred after WGD. 
The above arguments allow us to gain insights into the order of copy number events within 
each individual tumor sample. To establish a consensus order across a cohort of tumor 
samples requires the ordering data to be integrated across all samples.  As specific copy 
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number events (location of breakpoints and the individual copy number states) tend to be 
unique to individual samples, we defined reference copy number segments that occurred 
recurrently.  These were then used to build an overall contingency table. 
The reference genomic segments were defined as regions that were recurrently aberrant. 
Regions of significant recurrence (false detection rate (FDR), P < 0.05) were determined by 
performing 100,000 simulations, placing the copy number aberrations detected from each 
sample in random locations within the genome. The process was repeated for gains, LOH and 
HDs and the randomly generated copy number landscape compared to that arising from this 
cohort provided significance levels.  Each significantly aberrant region was initially 
segmented using all breakpoints from all the events that contributed to that region. For 
instance, the significantly enriched region for LOH: chr8: 0-44Mb contains over 300 
breakpoints drawn from from all the samples which contain LOH at chromosome 8p. We 
computed significantly recurrent regions and reference segments for both ETS+ and ETS- 
sample subgroups. 
Performing pair-wise comparisons between all segmented results using the Bradley-Terry 
method described below proved computationally expensive and therefore the total number of 
segments used in the pairwise comparison was rationalised by grouping reference segments 
to make combined segments of minimum length 1 MB. 
We then considered each tumor sample in turn.  If any copy number event overlapped the 
reference genomic segments and was ordered in relation to any other event (that also 
overlapped regions of significance), those overlapped reference segments were ordered in 
comparison to other overlapped reference segments. In addition to these reference segments, 
the TMRPSS2-ERG deletion was ordered more stringently by considering only those 
segments that could result in the gene fusion, and not merely overlap the locus. In this 
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manner, a contingency table of contests was constructed, using reference genomic segments 
as the variables. We built contingency tables for both ETS+ and ETS- tumor samples to 
determine whether their evolutionary trajectory differed significantly. .   
An implementation of the Bradley-Terry model of pairwise comparison in R68 with bias 
reduced maximum likelihood estimated the ability or overall order of each individual 
reference segment. 
Subclonal Analysis 
The fraction of each cancer genome with subclonal copy number aberrations was calculated 
as the total amount of the genome with subclonal CNA, as identified by the Battenberg 
algorithm, divided by the total amount of the genome that had copy number aberrations. One 
sample (PD13397a, Supplementary Table 8) was identified as having very low cellularity, as 
it had a completely flat copy number profile and only 411 identified SNVs. Since CNAs 
could not called in this sample, it was not possible to adjust allele frequencies to CCFs and 
this sample was excluded from subclonality analysis. Point substitutions and indels were 
separately clustered using a Bayesian Dirichlet process, as previously described47. Clonal 
variants are expected to cluster at a CCF close to 1.0. However, in 18 tumors (Supplementary 
Table 8), there was no cluster in the range [0.95,1.05]. The likely cause of a shift in CCF is 
inaccuracy in copy number calling and these samples therefore failed quality control and 
were excluded from subclonality analysis. From Markov Chain Monte Carlo sampling carried 
out within the Dirichlet process model, the posterior probability of each variant having a CCF 
below 0.95 was estimated. Variants with a probability above 80% were designated as 
‘subclonal’, those with probability below 20% were designated ‘clonal’ and those with 
intermediate probabilities were designated as ‘uncertain’. The fraction of subclonal variants 
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used in Fig. 5 and Supplementary Fig. 2 was then calculated after excluding uncertain 
variants. 
Mutational Spectra 
The mutational spectra, defined by the triplets of nucleotides around each mutation  of each 
sample were deconvoluted into mutational processes as previously described48,69. Clonal and 
subclonal variants were separated, as defined above.  Further separation of clonal mutations 
was performed for mutations in genomic regions that had undergone copy number gains. 
These mutations were classified as ‘early’ or ‘late’ depending whether their observed allele 
frequencies were more likely to indicate their presence on 2 or 1 chromosome copies, 
respectively, as assessed by binomial probability. Assignment of mutations to mutational 
signatures was carried out on each subset of mutations (early, late, clonal, subclonal), as well 
as on all mutations from each sample (Supplementary Table 3). 
Clinical survival analyses 
A Cox regression model was fitted to 71 features: every gene with mutations (breakpoints, 
subs or indels) with a potential functional impact (missense, nonsense, start-lost, inframe, 
frameshift, or occurred in a non-coding transcript) or a CNA highlighted by the copy number 
aberration analysis that occurred in three of more prostatectomy patients. The endpoint was 
biochemical recurrence. P-values were adjusted for multiple testing using the Benjamini-
Hochberg method. Multivariate analyses were performed on all genes found to be significant 
using discretised Gleason (6, 7, 8 or 9), pathological T-stage (T2, T3) and PSA at 
prostatectomy as cofactors. Gene selection for the optimal predictor of time to biochemical 
recurrence was determined using Lasso70, a shrinkage and selection method for linear 
regression, starting with all genes that had a significant association with time to biochemical 
recurrence. Standard algorithms were used for survival analyses and statistical associations. 
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Identifying novel oncogenes 
The joint dataset was compiled from the aggregation of variants called within our samples 
with 3 other datasets, yielding a total of 930 samples, comprised of 710 primary and 220 
metastatic samples: 
• TCGA4, 425 primary cancer samples, whole exome sequencing with SureSelect 
Exome v3 baits on Illumina HiSeq 2000, average coverage ~100X 
• COSMIC database22, 243 samples, curated set of mutations from several sources, 
http://cancer.sanger.ac.uk/cosmic 
• Stand Up to Cancer23 (SU2C-PCF), 150 metastatic castrate resistant samples, paired-
end, whole exome sequencing with SureSelect Exome v4 baits on Illumina 
HiSeq2000, average coverage ~160X 
To identify coding and non-coding drivers from substitutions and indels, we used two 
previously described methods50. Coding drivers on the joint dataset (930 cancers) were 
identified using dNdScv, a dN/dS method designed to quantify positive selection in cancer 
genomes. dNdScv models somatic mutations in a given gene as a Poisson process. Inferences 
on selection are carried out separately for missense substitutions, truncating substitutions 
(nonsense and essential splice site mutations) and indels, and then combined into a global P-
value per gene. Non-coding recurrence was studied using NBR. Both dNdScv and NBR 
model the variation of the mutation rate across the genome using a negative binomial 
regression with covariates. First, Poisson regression is used to obtain maximum-likelihood 
estimates for the 192 rate parameters (rj) describing each of the possible trinucleotide 
substitutions in a strand-specific manner. rj = nj/Lj , where nj is the total number of mutations 
observed across samples of a given trinucleotide class (j) and Lj is the number of available 
sites for each trinucleotide. These rates are used to estimate the total number of mutations 
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across samples expected under neutrality in each element considering the mutational 
signatures active in the cohort and the sequence of the elements (Eh = Σj rjLj,h). This estimate 
assumes no variation of the mutation rate across elements in the genome. Second, a negative 
binomial regression is used to refine this estimate of the background mutation rate of an 
element, using covariates and Eh as an offset. Both methods identify genes or non-coding 
regions with higher than expected mutation recurrence, correcting for gene length, sequence 
composition, mutation signatures acting across patients and for the variation of the mutation 
rate along the genome. A QQ-plot confirmed that P-values obtained from this method in this 
cohort were not subject to inflation and consequent over-calling of driver genes 
(Supplementary Fig. 6). 
Chromoplexy, characterized by highly clustered genomic breakpoints that occur in chains and 
are sometimes joined by deletion bridges, has been shown to be prevalent in PCa25. To 
identify rearrangement drivers, we first used ChainFinder25 to account for any bias towards 
regions with chromoplexy and identified ‘unique’ rearranged regions per sample taking the 
mid-point between all the breakpoints ChainFinder assigns to the same chromoplexy event. 
Next, separately aggregating the ICGC samples with and without ERG fusions, we calculated 
inter-breakpoint distance and performed piecewise constant fitting (PCF)66 to identify 
genomic regions which were recurrently rearranged in multiple samples. Rearranged regions 
with potential functional impact were identified using two criteria: a minimum 3-fold 
difference in the number of SVs per MB of ERG+ and ERG- samples; region contains at least 
one gene with multiple samples with truncating events, i.e. homozygous deletion, stop codon, 
frameshift indel or essential splice site mutation. In addition, several identified regions were 
significantly enriched for LOH in either ETS+ or ETS- samples, from copy number analysis 
(see above). The variants identified in key regions are depicted in Fig. 3. 
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Chemogenomics annotation of the prostate cancer network 
To construct the network, we used the 82 protein products of the genes identified in this study 
(hereon referred to as Prostate Proteins) to seed a search for all possible interacting proteins 
in the canSAR interactome54. This interactome contains merged and curated data from the 
IMeX consortium71, Phosphosite (http://www.phosphosite.org/), and other databases. It 
includes: 
 1) interactions where there were more than two publications reporting experiments 
demonstrating the binary interaction between the two proteins 
2) interactions where there is 3D protein structural evidence of a direct complex 
3) interactions where there are at least two publications reporting that one protein is a 
substrate of the other 
4) interactions where there are at least two papers reporting that one protein is the product of 
a gene under the direct regulatory control of the other 
It excludes the following: 
A) interactions that were inferred from a large immunoprecipitation experiment without 
follow-up to demonstrate the specific binary interaction 
B) interactions inferred from text mining 
C) interactions inferred from co-occurrence in publications or from gene expression 
correlation. 
The initial prostate cancer seeded network resulted in a large collection of 3366 proteins that 
have some experimental evidence of interacting with at least one Prostate Protein. When we 
added extra proteins into the network, we wanted to ensure that we only add proteins that are 
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more likely to function primarily through interaction with the proteins in the network rather 
than just be generic major hubs. To this end, we carried out the following steps: Starting with 
the input (prostate protein) list, we obtained all possible first neighbours. We then computed, 
for each new protein, the proportion of its first neighbours that are in the original input list. 
To define the proteins that are most likely to function through our network, we calculated the 
chances of these proportions occurring in a random network. We did this by randomising our 
interactome 10,000 times and computing how often the observed proportions can be achieved 
by chance (empirical p-value). We corrected the p-values for multiple testing and retained 
only proteins that have corrected FDR p-values less than 0.05. (Supplementary Fig. 5). We 
performed network minimisation to maintain only proteins that are strongly connected to 
more than one Prostate Protein or whose only connection is to one of the Prostate Proteins. 
We identified a Prostate Cancer network of 163 proteins. Using canSAR’s Cancer Protein 
Annotation Tool (CPAT)72, we annotated the 163 proteins with pharmacological and 
druggability data. We labelled proteins that are: 1) targets of approved drugs; 2) targets of 
drugs under clinical investigation, 3) targets of preclinical or discovery stage compounds that 
are active at concentrations equal to or less than 100 nM against the protein of interest 4) 
proteins that we predict to be druggable using our structural druggability prediction 
protocols72-75 but that have few or no published active inhibitors – these are potential targets 
for future drug discovery. 
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FIGURE LEGENDS 
Figure 1. Mutational landscape of prostate cancers. From top-to-bottom: mutation status 
of DNA repair genes, ETS fusion status and sample type; proportion of mutations assigned to 
each signature48; number of somatic point substitutions identified in each sample; proportion 
of small insertions/deletions associated with microhomology or repetitive regions; number of 
insertions, deletions and complex insertions/deletions in each sample; total number of 
structural variants in each sample, separated into inversions, translocations, deletions and 
tandem duplications. Sample ordering is reported in Supplementary Table 7.  
Figure 2. Landscape of driver genes in prostate cancer. Genes were identified using three 
different methods: upper panel shows genes that have undergone genetic aberration in at least 
6 samples; middle panel shows genes with aberrations enriched in either ERG+ or ERG- 
cancers (Fisher exact test for PTEN, TP53, SPOP, 3p13, PDE4D, PPAP2A; ROBO1 and 
ROBO2 are in a region enriched for SVs in ETS- tumors; IL6ST is in a region enriched for 
SVs in ETS+ tumors); lower panel shows genes enriched in metastatic samples (Fisher exact 
test). DDR = DNA damage response, ‘hemi.loss’ = loss of heterozygosity resulting from 
copy number change, ‘homo.loss’ = homozygous deletion resulting from copy number 
aberration, ‘two allele loss + sub/indel’ indicates genes in triploid regions bearing aberrations 
of all 3 gene copies. Sample ordering is reported in Supplementary Table 7. 
Figure 3. Putative novel driver genes. Putative drivers are shown in red and genomic 
aberrations are displayed as: missense SNVs – circles; nonsense SNVs – open triangles; 
essential splice site mutations – open squares;  indels – closed squares; non-coding mutations 
– closed triangles; simple SV - yellow cross; chromoplexy event – blue cross; region enriched 
for loss of heterozygosity, with height proportional to the number samples containing LOH - 
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pink shading; region enriched for homozygous deletions, with height proportional to the 
number of samples containing homozygous deletion – blue shading. 
Figure 4.  Temporal evolution of copy number aberrations in ETS+ and ETS- prostate 
cancer. For (a) ETS+ cancers, and (b) ETS- cancers: Left: The landscape of copy number 
aberrations with genomic loci plotted against fraction of cancers.  Loss-of-heterozygosity is 
depicted in blue, homozygous deletions in black, gains in red, TMPRSS2-ERG deletion in 
brown and whole genome duplication in green.  Right: The temporal evolution of 
significantly recurrent (p < 0.05) copy number aberrations by genomic loci over time (mean 
with 95% confidence intervals, log precedence relative to arbitrary reference). Lower values 
indicate earlier events (c) Pairwise associations among copy number aberrations. Recurrently 
aberrant regions with a false discovery rate < 0.1 are shown. Associations are indicated by 
odds ratio (OR) with brown colors depicting mutually exclusive events and blue-green colors 
depicting correlated events.  Genomic loci annotated by: type of aberration (G=gain, L=loss, 
HD=homozygous deletion); chromosome; median position in Mb. For focal events the 
putative target genes are annotated. 
Figure 5. Heterogeneity and subclonal mutations. (a) Metastatic tumors have less 
heterogeneity than primary tumors, whether assessed from SNVs or indels. Each dot 
represents a different sample, colored by sample type. x-axis = fraction of point substitutions 
that are subclonal, y-axis = fraction of indels that are subclonal, contour lines calculated using 
R package kde2d. (b) Samples with multiple subclonal mutations in driver genes. Fraction of 
cancer cells carrying mutation is shown as grey histogram for all mutations and as red ovals 
for mutations in known driver genes. Mutations are clustered using a Dirichlet process as 
previously described47, with thick plum-colored lines indicating fitted distribution and pale 
blue regions indicating 95% posterior confidence intervals. Peaks with a subclonal fraction 
close to 1 are clonal, whereas peaks at lower subclonal fractions indicate subclonal mutations. 
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Figure 6. Clinical outcome. Kaplan-Meier plots for biochemical recurrence.  Kaplan-
Meier plots of recurrent mutated genes where there is a significant correlation with time to 
biochemical recurrence after prostatectomy (P < 0.05; Cox regression model; Benjamin-
Hochberg multiple testing correction). Clinical information was available for 89 
prostatectomy samples with WGS data, with a median follow up of 1108 days in which 
biochemical recurrence occurred in 26 patients. The mutations in both genes consisted of a 
frameshift deletion in one sample and structural variants in the remaining samples. 
Table 1. Putative driver genes. Genes were identified in our study using several methods, 
detailed in the last column: dN/dS; enrichment for SVs or CNAs in ETS+ or ETS- cancers; 
enrichment for truncating mutations or homozygous deletions, clinical correlation. From a 
PubMed literature search, prior evidence for each gene being a driver of prostate cancer was 
classified as ‘low’ if the gene has not been previously reported as playing a role in prostate 
cancer tumorigenesis or progression. Isolated alterations may have been observed or 
biological evidence for importance may have been presented as indicated in the prior 
evidence column. Prior evidence was classified as ‘medium’ for genes reported previously as 
playing a role in prostate carcinogenesis or progression but currently lacking statistical 
support based on genetic alterations. Evidence considered included presence of multiple 
genetic alterations, SNP associations, and known cancer genes in other tissues. The high 
confidence genes are those that are widely accepted to represent cancer genes and to be 
altered in prostate cancer: this would include genes such as HRAS, SPOP, IDH1 etc. In each 
case there are two or more of the following: statistical verification of higher incidence, 
biological experiments, clinical correlations, confirmation in multiple studies, recognition as 
cancer genes in other cancer types. dN/dS = non-synonymous: synonymous ratio, calculated 
for all SNVs and indels; dN/dS (missesnse) = non-synonymous: synonymous ratio, calculated 
for missense SNVs only; SV = structural variant; CNA = copy number aberration; SNV = 
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single nucleotide variant; indel = small insertion/deletion; ETS = E26 transformation-
specific. 
Table 2. Drug targets identified from CanSAR analysis. Proteins in bold typeface are 
derived from genes identified as prostate drivers in this study or proteins that have a 
significant known interaction with these proteins. 
 
SUPPLEMENTARY FIGURE AND TABLE LEGENDS 
Supplementary Figure 1. RNA expression of novel driver genes. Data are taken from the 
CamCaP study, which includes 40 samples from this study. All genes identified as novel 
within this study and bearing structural variants in at least 2 samples are shown. P-values are 
from Wilcoxon rank sum test. 
Supplementary Figure 2. Heterogeneity of point substitutions and copy number 
aberrations. Each dot represents a different sample, colored by sample type. x-axis = amount 
of each genome that has subclonal CNA divided by the total amount of each genome that is 
copy-number aberrant, y-axis = fraction of point substitutions that are subclonal, contour 
lines calculated using R package kde2d. 
Supplementary Figure 3. Multiple driver mutations in APC. (a) Mutations in APC gene in 
PD14713a are mutually exclusive, indicating that they have occurred in separate subclonal 
populations. Each blue or yellow string represents a forward or backward read, with somatic 
variants shown in red. Mutations in the left-hand and right-hand red boxed regions never 
occur on the same reads.  (b) PD14713a is haploid on chromosome 5q, so the mutual 
exclusivity of APC mutations cannot be explained by occurrence in different chromosome 
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copies. Purple lines show total copy number, blue lines show minor allele specific copy 
number, called by the Battenberg algorithm.  
Supplementary Figure 4. Prognostic biomarkers. (a) Kaplan-Meier plot of the number of 
mutational processes detected vs time to biochemical recurrence (b) Correlation between the 
number of processes detected and the number of substitutions detected. There was a 
significant positive correlation (r = 0.31, P = 0.0027; Spearman’s correlation). The number of 
mutational signatures identified in a cancer was negatively correlated with time to 
biochemical recurrence in prostatectomy patients (P = 0.014, HR = 3.0; Cox proportional 
hazards model on number of processes greater than three. The number of substitutions 
detected was also an independent prognostic biomarker (P = 0.031, HR = 1.0005; Cox 
proportional hazards model).  
Supplementary Figure 5. Processes used in the canSAR analysis. 
Supplementary Figure 6. dN/dS analysis. QQ plot of the P-values derived from dN/dS 
analysis show no sign of inflation. Four genes (of 20,184) had p-values = 0 and are not shown 
on this plot.  
Supplementary Table 1. Summary of sample specific genetic aberrations. Worksheet 1 
reports the number of genetic aberrations identified in each gene this study, separated by 
type: essential splice site, frameshift, inframe, missense, nonsense, silent, stop-lost, 
homozygous deletion, rearrangement. We also report the number of samples with multiple 
hits resulting in homozygous loss. Worksheet 2 reports the number of genetic aberrations 
identified in each gene across the joint dataset. Worksheet 3 reports the samples within our 
dataset that bear homozygous losses in each gene. Worksheet 4 contains results of dNdScv 
analysis to identify coding drivers. Novel drivers are shown with red text. Significant q-
values (FDR < 0.1) from analysing either missense SNVs or all SNVs and indels are shown 
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with green shading. Effect sizes (dN/dS values) are reported separately for missense, 
nonsense, essential splice site and indel variants. Worksheet 5 contains results of NBR 
analysis to identify non-coding drivers. Significant regions (FDR < 0.1) are shown with blue / 
purple shading. 
Supplementary Table 2.  Classification of Driver Genes. See Table 1. 
Supplementary Table 3. Mutational signature analysis. For each sample, the number of 
somatic mutations attributed to each signature is shown in worksheet 1. Worksheet 2 reports 
the number of mutations assigned to each signature, broken down into temporal categories 
(early, late, clonal, subclonal) as described in Online Methods. 
Supplementary Table 4. Survival analyses. Cox regression model results for the presence 
of recurrent in genes with time to biochemical recurrence after prostatectomy as endpoint. 
Multivariate analysis was performed taking into account cofactors Gleason (6-9), PSA at 
prostatectomy, and pathological T-stage (T2, T3). Clinical information was available for 89 
prostatectomy samples with WGS data, with a median follow up of 1108 days in which 
biochemical recurrence occurred in 26 patients. Red background shading indicates features 
that have a significant association with outcome in both univariate analyses after multiple 
testing correction and multivariate analyses. Dark grey shading indicates features that are 
only significant without multiple testing correction. Light grey shading indicates features that 
are significant in univariate but not in multivariate analyses. 
Supplementary Table 5. Druggability analysis. Genes identified using the CanSAR 
software. Genes are color-coded: bright green = target of an approved drug; dark green = 
target of an investigational drug; yellow = target that is being investigated chemically; red = 
no chemical information in public databases, but predicted to be druggable using our 
structure-based method. 
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Supplementary Table 6. Drug sensitivity data. Of the drugs identified through CanSAR 
analysis, 18 are reported in the Genomics of Drug Sensitivity in Cancer database. Of these, 5 
showed significant effect on growth inhibition in at least one cell line, and all 18 showed 
weak activity in at least one cell line. 
Supplementary Table 7. Clinical and Molecular Details of Cancers Subject to DNA 
Sequencing. The order of samples in Fig. 1 and Fig. 2 are in the columns fig1_order and 
fig2_order. 
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Prior evidence Evidence in our study 
ADAM28 SV, CNA low 76biological evidence SVs and CNA in ETS+ 
ANTXR2 SV, SNV/indel low none clinical correlation 
ASH1L SV, SNV/indel low 25 truncating mutations, SVs in ETS- 
CDH12 SV low none clinical correlation 
FOXO1 CNA low 77biological evidence CNA in ETS- 
IL6ST SV low 78biological evidence dN/dS, SVs and CNA in ETS+, clinical 
correlation 
LCE2B SNV/indel low none dN/dS (missense) 
MAP3K1 SV, CNA low none SVs, CNA in ETS+ 
MYST3 SV low 25 SVs in ETS-, RNA expression 
NCOA7 SV low none SVs in ETS- 
NDST4 SNV/indel low none dN/dS (missense) 
NEAT1 non-coding low 31biological evidence non-coding 
PDE4D SV low 79SNP data SVs and CNA in ETS+ 
PPAP2A SV low 79SNP data SVs and CNA in ETS+ 
PPP2R2A SV low 80biological evidence SVs and CNAs in ETS+ 
ROBO1 SV low 81biological evidence SVs in ETS+ 
ROBO2 SV low 25 SVs in ETS+ 
RPL11 SNV/indel low 25 dN/dS (missense) 
SENP6 SV low 42biological evidence enriched SVs, RNA expression 
TBL1XR1 SNV/indel,SV low 82known AR co-regulator 
biological evidence 
dN/dS 
USP28 SV, CNA, 
SNV/indel 
low none SVs, CNA, SNV/indel 
ZNF292 SV, CNA 
SNV/indel,  
low 25 enriched SVs, homozygous deletions, 
truncating mutations 
ARID1A SNV/indel medium 83 dN/dS 
CASZ1 SNV/indel medium COSMIC, TCGA and SU2C dN/dS 
CNOT3 SNV/indel medium 84Mut. in leukemia dN/dS (missense) 
LRP1B SV, CNA medium 79SNP data SVs and CNA in ETS- 
PIK3R1 SNV/indel medium 24 dN/dS 
RGMB CNA medium 38deletions CNA in ETS- 
TBX3 SNV/indel medium known breast cancer gene dN/dS 
ZMYM3 SNV/indel medium COSMIC SU2C dN/dS 
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Table 2 
Target of approved drug 
AR, BRAF, ESR1, HDAC3, KCNH2, MAP2K1, NR3C1, RARA, RARB, RARG, RXRA 
 Target of investigational drug 
AKT1, ATM, LRRK2, MDM2, PDE4D, PIK3CA, PIK3CB, TP53 
 Target being investigated chemically 
AHR, BRCA1, CTNNB1, HRAS, IDH1, ITPR1, ITPR2, JUN, MAP3K1, MEN1, NCOR1, 
NCOR2, NR4A1, PIK3R1, PPP2R2A 
 Predicted target by structure-based method 
ANTXR2, APC, ARNT, ASH1L, BRCA2, CBFA2T2, CDH12, CDK12, CHD1, CREBBP, 
DLC1, DOCK10, ERG, ESCO1, ETV3, FOXA1, FOXG1, FOXO1, FOXO4, FOXP1, 
GATA1, GATA2, HDGF, HNF4A, IL6ST, KAT6A, KDM4A, KDM6A, KMT2C, KMT2D, 
NEDD4L, NKX3-1, PIAS1, PIAS2, PTEN, RB1, RNF43, SKI, SMAD2, SMAD3, SMAD4, 












Sign3: DSB by HR (BRCA1/2)
Sign5: age−related
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wildtype n = 85 (22 events)
mutant n = 4 (4 events)
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ensg gene source ess_splframes inframemissen nonsensilent start-lostop-lo
ENSG0000015ERG cgp 0 0 0 1 0 0 0 0
ENSG0000017PTEN cgp 1 1 1 6 0 0 0 0
ENSG0000014TP53 cgp 0 6 0 6 1 0 0 0
ENSG0000011CDKN1B cgp 0 0 0 0 3 0 0 0
ENSG0000011PDE4D cgp 0 0 0 0 1 0 0 0
ENSG0000016ROBO1 cgp 0 0 0 0 0 2 0 0
ENSG0000018ROBO2 cgp 0 0 0 2 0 1 0 0
ENSG0000018ZNF292 cgp 0 0 0 1 0 0 0 0
ENSG0000012FOXA1 cgp 0 3 6 5 0 0 0 0
ENSG0000006PPAP2A cgp 0 1 0 0 0 0 0 0
ENSG0000011ETV3 cgp 0 1 0 2 0 0 0 0
ENSG0000004ADAM28 cgp 0 1 0 0 0 2 0 0
ENSG0000013IL6ST cgp 0 1 0 0 0 0 0 0
ENSG0000008MYST3 cgp 0 0 0 0 1 0 0 0
ENSG0000022PPP2R2A cgp 1 0 0 0 0 0 0 0
ENSG0000016AR cgp 0 0 0 3 0 0 0 0
ENSG0000013APC cgp 0 1 0 0 1 1 0 0
ENSG0000011ASH1L cgp 0 1 0 0 0 0 0 0
ENSG0000016DLC1 cgp 0 0 0 1 0 0 0 0
ENSG0000019NCOR2 cgp 0 0 0 1 0 0 0 0
ENSG0000015CDH12 cgp 0 1 0 0 0 0 0 0
ENSG0000005KMT2C cgp 0 2 1 3 2 1 0 0
ENSG0000011SENP6 cgp 0 0 0 1 0 0 0 0
ENSG0000016ANTXR2 cgp 0 1 0 0 0 0 0 0
ENSG0000005ARID4B cgp 0 0 0 2 0 0 0 0
ENSG0000014ASXL2 cgp 1 0 0 1 0 0 0 0
ENSG0000013DOCK10 cgp 0 0 0 2 0 0 0 0
ENSG0000013RB1 cgp 0 0 0 2 0 0 0 0
ENSG0000014ZFHX3 cgp 0 2 0 1 0 0 0 0
ENSG0000017TBL1XR1 cgp 2 0 0 1 0 0 0 0
ENSG0000014ATM cgp 0 1 0 0 1 0 0 0
ENSG0000013BRCA2 cgp 0 0 1 0 0 1 0 0
ENSG0000016CDK12 cgp 0 2 0 0 0 0 0 0
ENSG0000014KDM6A cgp 0 2 0 1 1 0 0 0
ENSG0000014NCOR1 cgp 0 0 0 1 0 0 0 0
ENSG0000011ARID1A cgp 0 1 0 0 1 0 0 0
ENSG0000015CTNNB1 cgp 0 0 1 1 0 0 0 0
ENSG0000017SMAD2 cgp 1 0 0 1 0 0 0 0
ENSG0000014SMAD4 cgp 0 1 0 0 0 0 0 0
ENSG0000014ZMYM3 cgp 0 1 0 1 0 0 0 0
homodn_rearr_icgc chr start end strand
0 56 21 39751949 40033704 -1
13 28 10 89622870 89731687 1
1 19 17 7565257 7590856 -1
0 15 12 12867992 12875305 1
3 13 5 58264865 59817947 -1
0 11 3 78646390 79816965 -1
0 11 3 77089294 77699114 1
3 11 6 87862551 87973914 1
0 10 14 38059189 38064239 -1
1 10 5 54720682 54830878 -1
0 9 1 157090983 157108266 -1
0 8 8 24151580 24212726 1
3 8 5 55230925 55290821 -1
0 8 8 41799567 41909505 -1
2 8 8 26149007 26230196 1
0 7 X 66763874 66950461 1
0 6 5 112043195 112203279 1
0 6 1 155305052 155532324 -1
1 6 8 13162116 13372429 -1
0 6 12 124808957 125052010 -1
0 5 5 21750777 22853731 -1
1 5 7 151832007 152133628 -1
0 5 6 76311225 76427997 1
0 4 4 80898662 80994477 -1
0 4 1 235330210 235490802 -1
1 4 2 25960557 26101385 -1
0 4 2 225629807 225907330 -1
3 4 13 48877887 49056122 1
0 4 16 72816784 73082274 -1
1 3 3 176738542 176915048 -1
0 2 11 108175402 108186638 1
2 2 13 32889611 32973347 1
0 2 17 37617739 37690800 1
0 2 X 44732423 44971847 1
1 2 17 15933408 16118874 -1
0 1 1 27022522 27108601 1
0 1 3 41236328 41301587 1
0 1 18 45359466 45457517 -1
0 1 18 48556583 48611415 1










































gene source ess_splice frameshift inframe missense nonsense silent start-lost
ADAM28 tcga 0 1 1 0 0 1 0
ERG cgp 0 0 0 1 0 0 0
ANTXR2 tcga 0 0 0 0 1 0 0
ANTXR2 SU2C-PCF 0 2 0 0 0 0 0
PTEN cgp 1 1 1 6 0 0 0
APC SU2C-PCF 0 7 0 1 3 0 0
APC tcga 0 2 0 2 5 0 0
APC COSMIC 0 7 0 0 4 1 0
TP53 cgp 0 6 0 6 1 0 0
AR tcga 0 0 0 3 0 0 0
AR SU2C-PCF 0 0 1 26 0 6 0
AR COSMIC 0 0 0 5 0 0 0
CDKN1B cgp 0 0 0 0 3 0 0
ARID1A COSMIC 0 0 1 2 1 0 0
ARID1A tcga 0 0 3 3 1 1 0
ARID1A SU2C-PCF 0 1 0 4 0 0 0
PDE4D cgp 0 0 0 0 1 0 0
ARID4B tcga 0 1 0 1 0 2 1
ARID4B SU2C-PCF 0 0 0 1 0 0 0
ROBO1 cgp 0 0 0 0 0 2 0
ASH1L tcga 0 3 0 2 3 1 0
ASH1L SU2C-PCF 0 0 0 0 1 2 0
ASH1L COSMIC 0 1 0 2 1 0 0
ROBO2 cgp 0 0 0 2 0 1 0
ASXL2 COSMIC 0 0 0 2 2 0 0
ASXL2 tcga 0 1 0 1 0 0 0
ASXL2 SU2C-PCF 0 1 0 3 0 2 0
ZNF292 cgp 0 0 0 1 0 0 0
ATM SU2C-PCF 0 3 0 1 4 0 0
ATM tcga 0 3 0 16 0 2 0
ATM COSMIC 0 3 0 5 0 0 0
FOXA1 cgp 0 3 6 5 0 0 0
BRCA2 tcga 0 4 0 3 0 2 0
BRCA2 COSMIC 0 0 0 1 1 1 0
BRCA2 SU2C-PCF 0 8 0 2 0 0 0
PPAP2A cgp 0 1 0 0 0 0 0
CDH12 SU2C-PCF 0 0 0 1 0 0 0
CDH12 COSMIC 0 0 0 1 0 1 0
CDH12 tcga 0 0 0 4 1 0 0
ETV3 cgp 0 1 0 2 0 0 0
CDK12 tcga 1 3 0 6 2 1 0
CDK12 COSMIC 0 2 0 1 0 0 0
CDK12 SU2C-PCF 0 5 0 2 2 3 0
ADAM28 cgp 0 1 0 0 0 2 0
IL6ST cgp 0 1 0 0 0 0 0
CDKN1B SU2C-PCF 0 2 0 0 0 0 0
CDKN1B tcga 0 4 0 0 1 0 0
CDKN1B COSMIC 0 3 0 1 0 1 0
CHD1 tcga 0 3 0 3 1 2 0
CHD1 COSMIC 0 0 0 2 1 0 0
CHD1 SU2C-PCF 0 2 0 2 1 0 0
CTNNB1 COSMIC 0 0 0 4 0 1 0
CTNNB1 tcga 0 0 0 11 0 0 0
CTNNB1 SU2C-PCF 0 0 0 6 0 0 0
MYST3 cgp 0 0 0 0 1 0 0
DLC1 tcga 0 0 0 3 0 1 0
DLC1 COSMIC 0 0 0 2 0 1 0
DLC1 SU2C-PCF 0 0 0 5 0 1 0
PPP2R2A cgp 1 0 0 0 0 0 0
DOCK10 COSMIC 0 0 0 1 0 0 0
DOCK10 SU2C-PCF 0 0 0 2 1 1 0
DOCK10 tcga 0 0 0 4 2 1 0
AR cgp 0 0 0 3 0 0 0
APC cgp 0 1 0 0 1 1 0
ERG tcga 0 0 0 0 0 1 0
ERG SU2C-PCF 0 0 0 1 0 0 0
ASH1L cgp 0 1 0 0 0 0 0
ETV3 tcga 0 1 0 1 1 0 0
ETV3 COSMIC 0 0 0 0 1 0 0
DLC1 cgp 0 0 0 1 0 0 0
FOXA1 SU2C-PCF 0 5 4 9 0 1 0
FOXA1 tcga 0 4 5 12 0 2 0
FOXA1 COSMIC 0 1 0 5 0 0 0
FOXP1 tcga 0 1 1 0 2 2 0
FOXP1 COSMIC 0 0 1 1 0 0 0
NCOR2 cgp 0 0 0 1 0 0 0
IL6ST tcga 1 2 0 2 0 0 0
IL6ST COSMIC 0 0 0 1 2 0 0
KDM6A tcga 3 3 0 2 1 1 0
KDM6A COSMIC 0 3 0 5 0 1 0
KDM6A SU2C-PCF 0 2 0 2 0 0 0
CDH12 cgp 0 1 0 0 0 0 0
KMT2C SU2C-PCF 0 2 0 12 8 5 0
KMT2C tcga 1 4 0 8 5 3 0
KMT2C COSMIC 0 2 0 7 1 3 0
KMT2C cgp 0 2 1 3 2 1 0
MAP3K1 tcga 0 0 0 1 0 0 0
MAP3K1 SU2C-PCF 0 0 0 0 0 1 0
MTUS1 SU2C-PCF 0 0 0 1 0 0 0
MTUS1 tcga 0 0 1 1 1 0 0
SENP6 cgp 0 0 0 1 0 0 0
MYST3 tcga 0 0 0 3 0 0 0
MYST3 COSMIC 0 0 0 1 0 0 0
NCOA7 SU2C-PCF 0 0 0 1 1 0 0
NCOR1 SU2C-PCF 0 1 1 0 0 0 0
NCOR1 tcga 0 3 1 3 1 2 0
NCOR1 COSMIC 0 0 0 2 1 1 0
ANTXR2 cgp 0 1 0 0 0 0 0
ARID4B cgp 0 0 0 2 0 0 0
NCOR2 COSMIC 0 0 0 0 1 1 0
NCOR2 SU2C-PCF 0 1 0 7 1 9 0
NCOR2 tcga 0 1 1 2 1 0 0
NKX3-1 COSMIC 0 0 0 2 0 0 0
NKX3-1 tcga 0 1 0 4 0 0 0
ASXL2 cgp 1 0 0 1 0 0 0
PDE4D SU2C-PCF 0 0 0 1 0 0 0
PIK3R1 COSMIC 0 1 0 0 0 0 0
PIK3R1 SU2C-PCF 0 0 1 1 0 0 0
PIK3R1 tcga 0 0 0 1 0 0 0
DOCK10 cgp 0 0 0 2 0 0 0
PPAP2A tcga 0 0 0 1 1 0 0
PPAP2A SU2C-PCF 0 1 0 3 0 0 0
PPAP2A COSMIC 0 0 1 0 0 0 0
RB1 cgp 0 0 0 2 0 0 0
ZFHX3 cgp 0 2 0 1 0 0 0
PTEN SU2C-PCF 0 5 0 1 3 0 0
PTEN COSMIC 0 2 1 5 3 0 0
PTEN tcga 1 7 1 4 1 0 0
TBL1XR1 cgp 2 0 0 1 0 0 0
RB1 COSMIC 0 3 0 0 1 0 0
RB1 tcga 1 1 0 1 0 1 0
RB1 SU2C-PCF 0 3 0 0 1 0 0
ATM cgp 0 1 0 0 1 0 0
ROBO1 SU2C-PCF 0 0 0 5 0 4 0
ROBO1 tcga 0 1 0 5 0 1 0
BRCA2 cgp 0 0 1 0 0 1 0
ROBO2 COSMIC 0 0 0 3 0 1 0
ROBO2 SU2C-PCF 0 1 0 2 0 0 0
ROBO2 tcga 0 0 0 4 1 0 0
RYBP tcga 1 0 0 4 0 0 0
CDK12 cgp 0 2 0 0 0 0 0
SENP6 tcga 0 0 0 0 0 1 0
SHQ1 COSMIC 0 0 0 1 0 0 0
SMAD2 COSMIC 0 0 0 1 1 0 0
SMAD2 tcga 0 1 0 1 0 0 0
KDM6A cgp 0 2 0 1 1 0 0
SMAD4 tcga 0 0 0 4 0 0 0
SMAD4 COSMIC 0 0 0 1 1 0 0
SMAD4 SU2C-PCF 0 0 0 0 0 1 0
NCOR1 cgp 0 0 0 1 0 0 0
ARID1A cgp 0 1 0 0 1 0 0
TBL1XR1 COSMIC 0 1 0 0 0 0 0
TBL1XR1 SU2C-PCF 0 1 0 0 0 0 0
TBL1XR1 tcga 1 1 0 0 0 0 0
CTNNB1 cgp 0 0 1 1 0 0 0
TP53 COSMIC 0 5 0 31 3 0 0
TP53 SU2C-PCF 0 14 4 33 6 0 0
TP53 tcga 6 7 0 33 0 0 0
USP28 COSMIC 0 0 0 5 0 0 0
USP28 SU2C-PCF 0 3 0 0 1 0 0
USP28 tcga 0 0 1 0 1 0 0
ZBTB16 SU2C-PCF 0 0 0 1 1 1 1
ZBTB16 tcga 0 0 0 2 0 0 0
SMAD2 cgp 1 0 0 1 0 0 0
ZFHX3 COSMIC 0 3 0 5 2 4 0
ZFHX3 SU2C-PCF 0 4 0 4 2 4 0
ZFHX3 tcga 0 6 0 5 3 5 0
ZMYM3 COSMIC 0 3 0 4 0 0 0
ZMYM3 SU2C-PCF 0 1 0 1 0 0 0
ZMYM3 tcga 1 4 0 3 1 0 0
SMAD4 cgp 0 1 0 0 0 0 0
ZMYM3 cgp 0 1 0 1 0 0 0
ZNF292 COSMIC 0 0 0 3 0 0 0
ZNF292 SU2C-PCF 0 1 0 0 1 1 0
ZNF292 tcga 0 1 0 2 2 1 0
stop-lost chr start end strand ensg
0 8 24151580 24212726 1 ENSG00000042980
0 21 39751949 40033704 -1 ENSG00000157554
0 4 80898662 80994477 -1 ENSG00000163297
0 4 80898662 80994477 -1 ENSG00000163297
0 10 89622870 89731687 1 ENSG00000171862
0 5 112043195 112203279 1 ENSG00000134982
0 5 112043195 112203279 1 ENSG00000134982
0 5 112043195 112203279 1 ENSG00000134982
0 17 7565257 7590856 -1 ENSG00000141510
0 X 66763874 66950461 1 ENSG00000169083
0 X 66763874 66950461 1 ENSG00000169083
0 X 66763874 66950461 1 ENSG00000169083
0 12 12867992 12875305 1 ENSG00000111276
0 1 27022522 27108601 1 ENSG00000117713
0 1 27022522 27108601 1 ENSG00000117713
0 1 27022522 27108601 1 ENSG00000117713
0 5 58264865 59817947 -1 ENSG00000113448
0 1 235330210 235490802 -1 ENSG00000054267
0 1 235330210 235490802 -1 ENSG00000054267
0 3 78646390 79816965 -1 ENSG00000169855
0 1 155305052 155532324 -1 ENSG00000116539
0 1 155305052 155532324 -1 ENSG00000116539
0 1 155305052 155532324 -1 ENSG00000116539
0 3 77089294 77699114 1 ENSG00000185008
0 2 25960557 26101385 -1 ENSG00000143970
0 2 25960557 26101385 -1 ENSG00000143970
0 2 25960557 26101385 -1 ENSG00000143970
0 6 87862551 87973914 1 ENSG00000188994
0 11 108175402 108186638 1 ENSG00000149311
0 11 108175402 108186638 1 ENSG00000149311
0 11 108175402 108186638 1 ENSG00000149311
0 14 38059189 38064239 -1 ENSG00000129514
0 13 32889611 32973347 1 ENSG00000139618
0 13 32889611 32973347 1 ENSG00000139618
0 13 32889611 32973347 1 ENSG00000139618
0 5 54720682 54830878 -1 ENSG00000067113
0 5 21750777 22853731 -1 ENSG00000154162
0 5 21750777 22853731 -1 ENSG00000154162
0 5 21750777 22853731 -1 ENSG00000154162
0 1 157090983 157108266 -1 ENSG00000117036
0 17 37617739 37690800 1 ENSG00000167258
0 17 37617739 37690800 1 ENSG00000167258
0 17 37617739 37690800 1 ENSG00000167258
0 8 24151580 24212726 1 ENSG00000042980
0 5 55230925 55290821 -1 ENSG00000134352
0 12 12867992 12875305 1 ENSG00000111276
0 12 12867992 12875305 1 ENSG00000111276
0 12 12867992 12875305 1 ENSG00000111276
0 5 98190908 98262240 -1 ENSG00000153922
0 5 98190908 98262240 -1 ENSG00000153922
0 5 98190908 98262240 -1 ENSG00000153922
0 3 41236328 41301587 1 ENSG00000153922
0 3 41236328 41301587 1 ENSG00000153922
0 3 41236328 41301587 1 ENSG00000153922
0 8 41799567 41909505 -1 ENSG00000083168
0 8 13162116 13372429 -1 ENSG00000164741
0 8 13162116 13372429 -1 ENSG00000164741
0 8 13162116 13372429 -1 ENSG00000164741
0 8 26149007 26230196 1 ENSG00000221914
0 2 225629807 225907330 -1 ENSG00000135905
0 2 225629807 225907330 -1 ENSG00000135905
0 2 225629807 225907330 -1 ENSG00000135905
0 X 66763874 66950461 1 ENSG00000169083
0 5 112043195 112203279 1 ENSG00000134982
0 21 39751949 40033704 -1 ENSG00000157554
0 21 39751949 40033704 -1 ENSG00000157554
0 1 155305052 155532324 -1 ENSG00000116539
0 1 157090983 157108266 -1 ENSG00000117036
0 1 157090983 157108266 -1 ENSG00000117036
0 8 13162116 13372429 -1 ENSG00000164741
0 14 38059189 38064239 -1 ENSG00000129514
1 14 38059189 38064239 -1 ENSG00000129514
0 14 38059189 38064239 -1 ENSG00000129514
0 3 71003844 71633140 -1 ENSG00000114861
0 3 71003844 71633140 -1 ENSG00000114861
0 12 124808957 125052010 -1 ENSG00000196498
0 5 55230925 55290821 -1 ENSG00000134352
0 5 55230925 55290821 -1 ENSG00000134352
0 X 44732423 44971847 1 ENSG00000147050
0 X 44732423 44971847 1 ENSG00000147050
0 X 44732423 44971847 1 ENSG00000147050
0 5 21750777 22853731 -1 ENSG00000154162
0 7 151832007 152133628 -1 ENSG00000055609
0 7 151832007 152133628 -1 ENSG00000055609
0 7 151832007 152133628 -1 ENSG00000055609
0 7 151832007 152133628 -1 ENSG00000055609
0 5 56111401 56191979 1 ENSG00000095015
0 5 56111401 56191979 1 ENSG00000095015
0 8 17501304 17658426 -1 ENSG00000129422
0 8 17501304 17658426 -1 ENSG00000129422
0 6 76311225 76427997 1 ENSG00000112701
0 8 41799567 41909505 -1 ENSG00000083168
0 8 41799567 41909505 -1 ENSG00000083168
0 6 126111909 126253176 1 ENSG00000111912
0 17 15933408 16118874 -1 ENSG00000141027
0 17 15933408 16118874 -1 ENSG00000141027
0 17 15933408 16118874 -1 ENSG00000141027
0 4 80898662 80994477 -1 ENSG00000163297
0 1 235330210 235490802 -1 ENSG00000054267
0 12 124808957 125052010 -1 ENSG00000196498
0 12 124808957 125052010 -1 ENSG00000196498
0 12 124808957 125052010 -1 ENSG00000196498
0 8 23536206 23540402 -1 ENSG00000167034
0 8 23536206 23540402 -1 ENSG00000167034
0 2 25960557 26101385 -1 ENSG00000143970
0 5 58264865 59817947 -1 ENSG00000113448
0 5 67511548 67597649 1 ENSG00000145675
0 5 67511548 67597649 1 ENSG00000145675
0 5 67511548 67597649 1 ENSG00000145675
0 2 225629807 225907330 -1 ENSG00000135905
0 5 54720682 54830878 -1 ENSG00000067113
0 5 54720682 54830878 -1 ENSG00000067113
0 5 54720682 54830878 -1 ENSG00000067113
0 13 48877887 49056122 1 ENSG00000139687
0 16 72816784 73082274 -1 ENSG00000140836
0 10 89622870 89731687 1 ENSG00000171862
0 10 89622870 89731687 1 ENSG00000171862
0 10 89622870 89731687 1 ENSG00000171862
0 3 176738542 176915048 -1 ENSG00000177565
0 13 48877887 49056122 1 ENSG00000139687
0 13 48877887 49056122 1 ENSG00000139687
0 13 48877887 49056122 1 ENSG00000139687
0 11 108175402 108186638 1 ENSG00000149311
0 3 78646390 79816965 -1 ENSG00000169855
0 3 78646390 79816965 -1 ENSG00000169855
0 13 32889611 32973347 1 ENSG00000139618
0 3 77089294 77699114 1 ENSG00000185008
0 3 77089294 77699114 1 ENSG00000185008
0 3 77089294 77699114 1 ENSG00000185008
0 3 72423744 72911065 -1 ENSG00000163602
0 17 37617739 37690800 1 ENSG00000167258
0 6 76311225 76427997 1 ENSG00000112701
0 3 72798428 72911065 -1 ENSG00000144736
0 18 45359466 45457517 -1 ENSG00000175387
0 18 45359466 45457517 -1 ENSG00000175387
0 X 44732423 44971847 1 ENSG00000147050
0 18 48556583 48611415 1 ENSG00000141646
0 18 48556583 48611415 1 ENSG00000141646
0 18 48556583 48611415 1 ENSG00000141646
0 17 15933408 16118874 -1 ENSG00000141027
0 1 27022522 27108601 1 ENSG00000117713
0 3 176738542 176915048 -1 ENSG00000177565
0 3 176738542 176915048 -1 ENSG00000177565
0 3 176738542 176915048 -1 ENSG00000177565
0 3 41236328 41301587 1 ENSG00000153922
0 17 7565257 7590856 -1 ENSG00000141510
1 17 7565257 7590856 -1 ENSG00000141510
0 17 7565257 7590856 -1 ENSG00000141510
0 11 113668598 113746256 -1 ENSG00000048028
0 11 113668598 113746256 -1 ENSG00000048028
0 11 113668598 113746256 -1 ENSG00000048028
0 11 113931288 114121397 1 ENSG00000109906
0 11 113931288 114121397 1 ENSG00000109906
0 18 45359466 45457517 -1 ENSG00000175387
0 16 72816784 73082274 -1 ENSG00000140836
0 16 72816784 73082274 -1 ENSG00000140836
0 16 72816784 73082274 -1 ENSG00000140836
0 X 70459474 70474996 -1 ENSG00000147130
0 X 70459474 70474996 -1 ENSG00000147130
0 X 70459474 70474996 -1 ENSG00000147130
0 18 48556583 48611415 1 ENSG00000141646
0 X 70459474 70474996 -1 ENSG00000147130
0 6 87862551 87973914 1 ENSG00000188994
0 6 87862551 87973914 1 ENSG00000188994
0 6 87862551 87973914 1 ENSG00000188994
gene source chr start end strand n_rearr_icgc
ERG cgp 21 39751949 40033704 -1 56
PTEN cgp 10 89622870 89731687 1 28
TP53 cgp 17 7565257 7590856 -1 19
CDKN1B cgp 12 12867992 12875305 1 15
PDE4D cgp 5 58264865 59817947 -1 13
ROBO1 cgp 3 78646390 79816965 -1 11
ROBO2 cgp 3 77089294 77699114 1 11
ZNF292 cgp 6 87862551 87973914 1 11
FOXA1 cgp 14 38059189 38064239 -1 10
PPAP2A cgp 5 54720682 54830878 -1 10
ETV3 cgp 1 157090983 157108266 -1 9
ADAM28 cgp 8 24151580 24212726 1 8
IL6ST cgp 5 55230925 55290821 -1 8
MYST3 cgp 8 41799567 41909505 -1 8
PPP2R2A cgp 8 26149007 26230196 1 8
AR cgp X 66763874 66950461 1 7
APC cgp 5 112043195 112203279 1 6
ASH1L cgp 1 155305052 155532324 -1 6
DLC1 cgp 8 13162116 13372429 -1 6
NCOR2 cgp 12 124808957 125052010 -1 6
CDH12 cgp 5 21750777 22853731 -1 5
KMT2C cgp 7 151832007 152133628 -1 5
SENP6 cgp 6 76311225 76427997 1 5
ANTXR2 cgp 4 80898662 80994477 -1 4
ARID4B cgp 1 235330210 235490802 -1 4
ASXL2 cgp 2 25960557 26101385 -1 4
DOCK10 cgp 2 225629807 225907330 -1 4
RB1 cgp 13 48877887 49056122 1 4
ZFHX3 cgp 16 72816784 73082274 -1 4
TBL1XR1 cgp 3 176738542 176915048 -1 3
ATM cgp 11 108175402 108186638 1 2
BRCA2 cgp 13 32889611 32973347 1 2
CDK12 cgp 17 37617739 37690800 1 2
KDM6A cgp X 44732423 44971847 1 2
NCOR1 cgp 17 15933408 16118874 -1 2
ARID1A cgp 1 27022522 27108601 1 1
CTNNB1 cgp 3 41236328 41301587 1 1
SMAD2 cgp 18 45359466 45457517 -1 1
SMAD4 cgp 18 48556583 48611415 1 1
ZMYM3 cgp X 70459474 70474996 -1 1
rearr_icgc_su ensg homodel_icgcmultiple_hit_ multiple_hit_ multiple_hit_ multiple_hit_
PD9168a<TM ENSG0000015 0 1 PD13412a 1 PD13412a
PD11331a<smENSG0000017PD12808a,PD 5 PD12844a,PD 5 PD13392a,PD
PD11329a<smENSG0000014PD11329d 1 PD14728a 12 PD12818a,PD
PD11332a<smENSG0000011 0 1 PD12809a 0
PD11330a<smENSG0000011PD14734a,PD 1 PD14728a 1 PD14728a
PD11332a<smENSG0000016 0 0 - 0
PD11328a<traENSG0000018 0 0 - 0
PD12817a<smENSG0000018PD14728a,PD 0 - 0
PD11328a<ta ENSG0000012 0 4 PD12337a,PD 0
PD11332a<truENSG0000006PD14734a 0 - 0
PD12337a<smENSG0000011 0 0 - 0
PD12829a<smENSG0000004 0 0 - 1 PD11332a
PD12817a<smENSG0000013PD14734a,PD 0 - 1 PD14726a
PD12808a<smENSG0000008 0 0 - 1 PD12842a
PD12829a<smENSG0000022PD13412c,PD 0 - 0
PD12845a<coENSG0000016 0 2 PD12337a,PD 0
PD12809a<smENSG0000013 0 0 - 2 PD14728a,PD
PD11328a<traENSG0000011 0 0 - 0
PD12836a<smENSG0000016PD13408a 0 - 1 PD13388a
PD14728a<smENSG0000019 0 0 - 0
PD11328a<coENSG0000015 0 0 - 0
PD11328a<coENSG0000005PD13412a 0 - 0
PD12838a<smENSG0000011 0 0 - 1 PD11329a
PD13390a<smENSG0000016 0 0 - 0
PD12836a<smENSG0000005 0 0 - 0
PD11331a<smENSG0000014PD14706a 1 PD11331a 1 PD11331a
PD11332a<smENSG0000013 0 0 - 0
PD11335a<smENSG0000013PD12834a,PD 1 PD11335a 2 PD11329a,PD
PD11330a<traENSG0000014 0 0 - 0
PD13387a<1kENSG0000017PD14717a 0 - 0
PD9169a<inv_ENSG0000014 0 1 PD13401a 1 PD12843a
PD11335a<smENSG0000013PD14731a,PD 0 - 2 PD12829a,PD
PD14722a<smENSG0000016 0 0 - 0
PD11328a<smENSG0000014 0 1 PD11328a 0
PD13380a<smENSG0000014PD14725a 0 - 1 PD12838a
PD14728a<smENSG0000011 0 0 - 0
PD11328a<ta ENSG0000016 0 0 - 0
PD14706a<smENSG0000017 0 0 - 0
PD14727a<invENSG0000014 0 0 - 1 PD11335a











































GENE SYN MIS NON SPLICE INDEL dNdS_mis dNdS_NON
TP53 0 105 10 6 33 147.432737 253.692241
SPOP 0 94 0 0 3 141.013749 0
PTEN 0 16 7 6 17 25.4268052 136.30721
FOXA1 3 30 0 0 29 9.81109971 0
CDKN1B 1 1 4 0 9 1.6831457 107.081529
MLL2 5 24 12 1 23 2.13464222 17.1632806
APC 2 4 14 0 14 0.70166849 26.8214594
CDK12 4 10 4 1 13 1.9532142 10.1645074
MLL3 13 39 16 0 15 1.4316258 7.27393243
KDM6A 1 6 2 3 8 2.59995615 9.88863037
ZFHX3 14 15 7 1 15 0.6685532 5.64165771
ATM 2 22 5 0 10 3.56247943 9.55277643
RB1 1 3 2 2 5 1.51157057 9.86031155
CHD1 2 7 3 3 5 1.52378026 7.19824641
ZMYM3 0 5 1 1 6 3.43593539 11.8402402
TBL1XR1 0 1 0 2 4 1.12232122 0
AR 6 34 0 0 1 5.90940047 0
ARID1A 1 9 3 0 6 2.64331568 16.3404042
BRCA2 4 7 1 0 13 0.80289319 1.69629446
IL6ST 0 4 2 1 3 3.15735344 20.6534624
CTNNB1 1 22 0 0 0 10.7914381 0
CASZ1 1 6 2 0 9 1.81674498 19.3498255
RNF43 1 4 3 0 2 2.07003675 22.399243
PIK3CA 3 23 0 0 1 5.71483253 0
SMAD2 0 3 1 1 1 4.33979878 14.7113888
FOXP1 2 1 2 1 3 0.39154464 9.62607296
PIK3R1 0 2 0 2 2 1.50442841 0
TBX3 0 9 0 0 3 5.0925344 0
BRAF 0 11 0 0 1 8.04169209 0
IDH1 0 9 0 0 0 10.9808339 0
HRAS 0 6 0 0 0 14.8899243 0
CNOT3 1 12 1 0 0 5.3551647 8.93810103
NDST4 1 13 0 0 1 4.71827098 0
RPL11 0 6 0 0 1 18.3361561 0
LCE2B 0 6 0 0 0 20.6936968 0
dNdS_SPLICE dNdS_INDEL pMIS pALL qMIS qALL
222.714656 249.191884 0 0 0 0
0 23.90303 0 0 0 0
208.43008 126.399663 3.55E-10 0 0 0
0 195.094571 1.05E-09 2.47E-07 0 0
0 141.209958 0.12944 6.53E-06 0.16 0
4.99600593 12.979872 0.013501 3.97E-09 0.157 0
0 15.6104792 0.077096 1.13E-08 0.157 0
11.1802402 27.2814769 0.035413 0.000404 0.157 0
0 9.47480798 0.040913 1.26E-06 0.157 0
26.6982637 17.2254931 0.038754 7.88E-05 0.157 0
11.491477 12.9629448 0.062368 0.003805 0.157 0
0 9.88737324 0.001329 0.000141 0.06 0
14.1298896 15.8337048 0.086896 0.00151 0.157 0
14.2079143 8.82794742 0.06582 0.000228 0.157 0
18.6788792 13.3435247 0.032762 0.007936 0.157 0.001
38.2370089 22.9809546 0.095498 0.008221 0.157 0.001
0 3.40510979 1.39E-07 1.96E-05 0 0.003
0 8.22957819 0.027956 0.003337 0.157 0.003
0 11.9662882 0.086593 0.951295 0.157 0.003
16.6133537 9.99043049 0.029148 0.00079 0.157 0.003
0 0 7.60E-08 1.15E-05 0 0.005
0 15.9572425 0.093542 0.023145 0.188 0.013
0 7.92852346 0.057405 0.00265 0.157 0.029
0 2.8414227 6.78E-06 0.000568 0.001 0.047
34.3258381 6.43665368 0.020019 0.001868 0.157 0.068
6.61571033 13.2009916 0.072952 0.074323 0.157 0.068
36.4268504 8.32750722 0.097486 0.009524 0.157 0.072
0 12.5614972 0.003977 0.086703 0.131 0.081
0 3.90194564 0.000172 0.008109 0.01 0.277
0 0 4.39E-05 0.002694 0.003 0.347
0 0 6.01E-05 0.003482 0.004 0.383
0 0 0.000688 0.004104 0.036 0.43
0 3.52154498 0.001038 0.032659 0.05 0.617
0 16.2156234 1.61E-05 0.001172 0.026 0.679
0 0 8.49E-06 0.000686 0.017 1
region exp_subs exp_indels obs_subs obs_indels local_t local_t_ind
Exon_FOXA1 0.288113 0.001691 5 8 0.915694 10.03441
Exon_TP53 0.18919 0.001598 7 3 0.55651 5.325007
Exon_SPOP 0.138802 0.001392 11 0 0.700511 6.543536
Exon_PTEN 0.128824 0.001406 7 2 0.619405 5.688691
UTR3_FOXA1 0.147241 0.002362 3 5 0.915694 10.03441
Exonflanks_ARSD 0.157829 0.00236 8 0 0.526025 2.565645
ENSG00000245532 (NEAT1 3.890444 0.049559 9 6 0.604275 5.619608
Exon_CDK12 0.539239 0.005222 0 3 0.578958 7.817554
ENSG00000182021 2.401588 0.03194 13 0 0.893604 22.28641
ENSG00000229178 0.53852 0.005144 1 3 0.866064 6.453148
Exon_TBX3 0.403789 0.002589 0 2 0.953099 6.451043
Exon_CDKN1B 0.117888 0.000858 3 0 0.647826 7.143755
ENSG00000258414 2.100838 0.032824 3 5 0.982415 10.03441
UTR3_PDE4DIP 0.900626 0.015101 5 2 0.682246 14.82315
ENSG00000264734 1.706188 0.023407 9 1 1.042655 9.322698
ENSG00000264698 0.009584 0.000157 2 0 1.0041 7.806753
ENSG00000238385 0.011969 0.0002 2 0 0.930626 10.59962
ENSG00000235887 0.225929 0.002884 2 2 1.295134 33.94427
ENSG00000261466 1.088951 0.013304 11 0 1.984319 44.83325
ENSG00000232527 3.988412 0.050662 12 5 1.246748 31.93861
ENSG00000249388 3.531467 0.044789 6 4 0.783395 8.080765
Exon_EIF1AX 0.049635 0.000505 2 0 0.554568 2.488115
Exon_DDX6 0.160903 0.001684 1 1 0.67603 6.913211
Exon_TPM4 0.191569 0.001464 1 1 0.615317 5.897858
Exon_MDM2 0.166635 0.001914 3 0 0.814391 6.131522
UTR5_CREBRF 0.018882 0.000345 1 1 0.779091 5.996343
Exon_TFF3 0.072721 0.000654 4 0 0.599197 4.369566
UTR3_POM121L7 0.089106 0.001246 4 0 0.694481 10.1365
UTR3_PRRC2C 0.169462 0.002724 4 1 1.051891 9.221754
Promoter_STIL 0.189626 0.002708 2 1 0.621343 6.540899
Promoter_FOXP1 0.547081 0.007785 0 3 0.784195 6.510009
Promoter_FOXA2 0.121902 0.001576 4 0 1.051928 7.740274
pval_subs pval_indelspval_both qval_subs qval_indelsqval_both exclude_gecv_predicte
0.000319 6.05E-05 3.62E-07 0.537846 0.044211 0.001833 TRUE 0.314365
8.83E-07 0.000177 3.68E-09 0.005959 0.044211 2.49E-05 TRUE 0.148177
1.07E-11 1 2.80E-10 2.16E-07 1 4.80E-06 TRUE 0.124167
8.00E-08 0.00023 4.74E-10 0.00081 0.044211 4.80E-06 TRUE 0.106928
0.00113 0.000144 2.70E-06 1 0.029464 0.026358 TRUE 0.156821
2.10E-08 1 3.92E-07 0.000424 1 0.00792 FALSE 0.124463
0.070491 0.000405 0.000327 1 0.005583 0.035152 FALSE 2.400613
1 0.000351 0.003142 1 0.044211 0.299535 TRUE 0.431183
0.00059 1 0.00498 0.901242 1 0.036212 FALSE 1.840881
0.394703 0.000256 0.00103 1 0.005583 0.035152 FALSE 0.404354
1 0.000321 0.002901 1 0.044211 0.299535 TRUE 0.456058
0.000885 1 0.007109 0.716933 1 0.390017 TRUE 0.100452
0.340483 0.000383 0.001298 1 0.005583 0.035292 FALSE 1.72122
0.011521 0.000538 8.05E-05 1 0.029464 0.1519 TRUE 0.815375
0.001956 0.000563 1.62E-05 1 0.005583 0.034651 FALSE 1.462461
5.80E-05 1 0.000624 0.310037 1 0.035152 FALSE 0.007981
9.03E-05 1 0.000931 0.321596 1 0.035152 FALSE 0.009433
0.026002 0.000249 8.38E-05 1 0.005583 0.034859 FALSE 0.234011
1.13E-05 1 0.00014 0.121131 1 0.034859 FALSE 1.890893
0.019598 0.000428 0.000106 1 0.005583 0.034859 FALSE 3.983905
0.199386 0.000441 0.000909 1 0.005583 0.035152 FALSE 2.492293
0.001966 1 0.014217 1 1 0.763467 TRUE 0.038806
0.141141 0.000416 0.000631 1 0.044211 0.299535 TRUE 0.140721
0.164168 0.000394 0.000688 1 0.044211 0.299535 TRUE 0.15841
0.00225 1 0.01597 1 1 0.850812 TRUE 0.165587
0.01825 1.06E-05 3.17E-06 1 0.004252 0.030395 FALSE 0.017694
1.26E-05 1 0.000155 0.063923 1 0.258294 FALSE 0.059245
1.37E-05 1 0.000167 0.26772 1 0.181396 FALSE 0.081361
0.000152 0.000438 1.16E-06 1 0.029464 0.022699 FALSE 0.198432
0.024531 0.000593 0.000176 1 0.054112 0.402543 TRUE 0.169028
1 0.00049 0.004223 1 0.054112 0.402543 TRUE 0.546891
0.000115 1 0.001162 0.681941 1 0.402543 TRUE 0.147135
cv_predictepval_subs_pval_indelspval_both_qval_subs_qval_indelsqval_both_qval_both_
0.015625 0.000255 1.84E-16 0 0.420988 3.73E-12 0 0
0.011529 6.03E-08 8.19E-07 1.56E-12 0.000407 0.00829 1.58E-08 5.58E-10
0.010704 3.60E-13 1 1.07E-11 7.27E-09 1 7.19E-08 2.54E-09
0.010336 7.18E-09 8.19E-05 1.71E-11 7.26E-05 0.414184 8.67E-08 3.06E-09
0.024018 0.001191 2.01E-10 7.20E-12 1 3.92E-06 1.40E-07 5.13E-09
0.014794 1.63E-09 1 3.46E-08 3.29E-05 1 0.000698 0.000673
0.36631 0.0029 1.54E-05 8.02E-07 1 0.084275 0.008568 0.008568
0.042939 1 3.98E-05 0.000443 1 0.268395 1 0.063262
0.446832 2.53E-06 1 3.51E-05 0.027004 1 0.18752 0.18752
0.039252 0.328037 1.58E-05 6.82E-05 1 0.084275 0.242755 0.242755
0.019813 1 0.000297 0.002709 1 0.750953 1 0.32233
0.006812 0.000429 1 0.003758 0.511003 1 1 0.383354
0.287283 0.252791 4.68E-05 0.000146 1 0.166643 0.390034 0.390034
0.199246 0.006834 0.019098 0.001298 1 1 1 0.462711
0.199359 0.000118 0.177736 0.000247 0.252156 1 0.527597 0.527597
0.00126 3.43E-05 1 0.000387 0.135176 1 0.63947 0.63947
0.001791 4.79E-05 1 0.000525 0.135176 1 0.63947 0.63947
0.063045 0.024838 0.002231 0.000599 1 1 0.63947 0.63947
0.441212 5.06E-05 1 0.000551 0.135176 1 0.63947 0.63947
1.025565 0.004631 0.009469 0.000484 1 1 0.63947 0.63947
0.363764 0.057831 0.001146 0.000704 1 1 0.683568 0.683568
0.003135 0.001081 1 0.008465 0.948785 1 1 0.755504
0.013206 0.127053 0.013072 0.012291 1 1 1 0.819501
0.010881 0.141278 0.01079 0.011412 1 1 1 0.819501
0.014403 0.001713 1 0.012625 1 1 1 0.819501
0.002554 0.017234 0.000453 9.96E-05 1 0.23587 0.954002 0.911757
0.004488 3.46E-06 1 4.69E-05 0.017491 1 0.189952 0.916242
0.012737 7.66E-06 1 9.79E-05 0.149348 1 0.63621 0.919425
0.026499 0.000218 0.026105 7.44E-05 0.808592 1 0.63621 0.919425
0.023011 0.019765 0.022293 0.003845 1 1 1 0.952062
0.066035 1 0.000461 0.004 1 1 1 0.952062




































 evidence gene mutation_type prior_evidence evidence_in_our_study tumor suppressor / oncogene?
low ADAM28 SV, CNA 1 biological evidence SVs and CNA in ETS+ tumor suppressor
low ANTXR2 SV,SNV/indel none clinical correlation tumor suppressor
low ASH1L SV,SNV/indel 2 truncating mutations, SVs in ETS- tumor suppressor
low CDH12 SV none clinical correlation tumor suppressor
low FOXO1 CNA 3 biological evidence CNA in ETS- tumor suppressor
low IL6ST SV 4 biological evidence dN/dS, SVs and CNA in ETS+, clinical c tumor suppressor
low LCE2B SNV/indel none dN/dS (missense) tumor suppressor
low MAP3K1 SV, CNA none SVs, CNA in ETS+ tumor suppressor
low MYST3 SV 2 SVs in ETS-, RNA expression tumor suppressor
low NCOA7 SV none SVs in ETS- tumor suppressor
low NDST4 SNV/indel none dN/dS (missense) oncogene
low NEAT1 Non-coding 5 biological evidence non-coding oncogene
low PDE4D SV 6 SNP data SVs and CNA in ETS+ tumor suppressor
low PPAP2A SV 6 SNP data SVs and CNA in ETS+ tumor suppressor
low PPP2R2A SV 7 biological evidence SVs and CNAs in ETS+ tumor suppressor
low ROBO1 SV 8 biological evidence SVs in ETS+ tumor suppressor
low ROBO2 SV 2 SVs in ETS+ tumor suppressor
low RPL11 SNV/indel 2 dN/dS (missense) oncogene
low SENP6 SV 9 biological evidence enriched SVs, RNA expression tumor suppressor
low TBL1XR1 SNV/indel,SV 10 known AR co-regulator, biolo  dN/dS tumor suppressor
low USP28 SV, CNA, SNV/indel none SVs, CNA, SNV/indel tumor suppressor
low ZNF292 SV,SNV/indel, CNA 2 enriched SVs, homozygous deletions, tr  tumor suppressor
medium ARID1A SNV/indel 11 dN/dS tumor suppressor
medium ASXL2 SNV/indel TCGA, COSMIC and SU2C Not identified in this study tumor suppressor
medium CASZ1 SNV/indel COSMIC, TCGA and SU2C dN/dS tumor suppressor
medium CNOT3 SNV/indel 12 mutated in leukemia dN/dS (missense) oncogene
medium DOCK10 SNV/indel,SV TCGA, COSMICand SUC2C Not identified in this study tumor suppressor
medium LRP1B SV, CNA 6 SVs and CNA in ETS- tumor suppressor
medium PIK3R1 SNV/indel 13 dN/dS tumor suppressor
medium RGMB CNA 14 CNA in ETS- tumor suppressor
15 tumor suppressormedium SMAD4 SNV/indel Not identified in this study
16
medium TBX3 SNV/indel known breast cancer gene dN/dS tumor suppressor
medium ZMYM3 SNV/indel COSMIC SU2C dN/dS tumor suppressor
high AKT1 SNV/indel known prostate cancer gene Not identified in this study
high APC SV,SNV/indel known prostate cancer gene dN/dS, enriched in metastases
high AR SV,SNV/indel known prostate cancer gene dN/dS, enriched in metastases
high ARID4B SV,SNV/indel, CNA TCGA LOH
17
18
high BRAF SNV/indel 19 dN/dS (missense)
17
18
high CDK12 SNV/indel known prostate cancer gene dN/dS, enriched in metastases
high CDKN1B SV,SNV/indel known tumor supressor gene dN/dS
high CHD1 SV known prostate cancer gene dN/dS, SVs and CNA in ETS-
high CSMD3 SV 20 SVs in ETS-
high CTNNB1 SNV/indel known prostate cancer gene dN/dS, enriched in metastases
high DLC1 SNV/indel known prostate cancer gene clinical correlation
high ERG SV known prostate cancer gene enriched SVs and CNA
high ETV3 SV, CNAs, SNV/indel 16 SVs, CNAs, SNS/indel in ETS- tumor supressor
high FOXA1 SV,SNV/indel, non-coding known prostate cancer gene dN/dS, non-coding oncogene
high FOXP1 SV known prostate cancer gene dN/dS, SVs in ETS+
high HRAS SNV/indel Known cancer gene dN/dS (missense)
high IDH1 SNV/indel known cancer gene dN/dS (missense)
high KDM6A SNV/indel,SV known prostate cancer gene dN/dS
high KMT2C SNV/indel known prostate cancer gene enriched in metastases
high KMT2D SNV/indel known prostate cancer gene enriched in metastases
high MLL2 SNV/indel 16 dN/dS
high MLL3 SNV/indel known cancer gene dN/dS
high MTUS1 SNV/indel known prostate cancer gene clinical correlation
high NCOR1 SNV/indel known prostate cancer gene known prostate cancer gene
high NCOR2 SNV/indel,SV known AR regulator known AR regulator
high NKX3-1 SV known prostate cancer gene enriched SVs
high PIK3CA SNV/indel known prostate cancer gene dN/dS
high PIK3CB SNV/indel known prostate cancer gene enriched in metastases
tumor suppressor
high BRCA2 SNV/indel,SV, CNA dN/dS, enriched in metastases, CNA in 
medium SMAD4 SNV/indel Not identified in this study
high ATM SNV/indel dN/dS
high PTEN SV,SNV/indel known prostate cancer gene dN/dS, CNA in ETS+
high RB1 SNV/indel known prostate cancer gene dN/dS, enriched in metastases
high RNF43 SNV/indel 18 dN/dS
high RYBP SV known prostate cancer gene SVs in ETS+
high SHQ1 SV known prostate cancer gene SVs in ETS+
high SMAD2 SNV/indel known cancer gene dN/dS
high SPOP SNV/indel known prostate cancer gene dN/dS, clinical correlation
high TP53 SNV/indel,SV known prostate cancer gene dN/dS, enriched in metastases, SVs in ETS+
high ZBTB16 SV reported SVs in 25808865 SVs
high ZFHX3 SNV/indel,SV known prostate cancer gene dN/dS, enriched in metastases
1 Rudnicka, C. et al.  Overexpression and knock-down studies highlight that a disintegrin and metalloproteinase 28 controls proliferation and migratio          
2 Baca, S.C. et al.  Punctuated evolution of prostate cancer genomes. Cell  153, 666-77 (2013).
3 Zhang, H. et al.  FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res  71, 3257-67 (2011).
4 Malinowska, K. et al.  Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr     
5 Chakravarty, D. et al.  The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun  5, 5383 (20
6 FitzGerald, L.M. et al.  Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and spor         
7 Zhao, W., Cao, L., Zeng, S., Qin, H. & Men, T. Upregulation of miR-556-5p promoted prostate cancer cell proliferation by suppressing PPP2R2A e      
8 Parray, A. et al.  ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-            
9 Kaikkonen, S. et al.  SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gen           
10 Daniels, G. et al.  TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth. Endocr     
11 Jones, S. et al.  Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat  33, 100-3 (2012).
12 Collart, M.A., Kassem, S. & Villanyi, Z. Mutations in the NOT Genes or in the Translation Machinery Similarly Display Increased Resistance to Hist       
13 Gao, D. et al.  Organoid cultures derived from patients with advanced prostate cancer. Cell  159, 176-87 (2014).
14 Burkhardt, L. et al.  CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res  73, 2795-805 (2013).
15 Ding, Z. et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature  470, 269-73 (2011).
16 Grasso, C.S. et al.  The mutational landscape of lethal castration-resistant prostate cancer. Nature  487, 239-43 (2012).
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Supplementary Table 3
Sample Name Signature1 Signature2 Signature3 Signature5 Signature8 Signature1
PD11328a 1174 302 0 3314 2053 165
PD11329a 2456 161 0 2560 0 170
PD11330a 2294 276 0 2983 2799 368
PD11331a 1651 0 0 1320 0 0
PD11332a 1688 229 0 1767 1909 290
PD11333a 1960 0 0 1999 0 0
PD11334a 2400 0 0 2204 0 0
PD11335a 1346 0 9493 3622 0 223
PD12337a 2959 530 0 9450 0 940
PD12806a 1511 0 0 1044 0 0
PD12807a 531 113 0 1257 615 0
PD12808a 1479 0 0 776 2075 189
PD12809a 875 132 0 1954 0 0
PD12810a 562 116 0 879 1584 0
PD12811a 582 0 0 1926 733 169
PD12812a 496 132 0 1510 3715 342
PD12813a 1340 0 0 1445 0 0
PD12814a 1762 0 0 1218 0 0
PD12815a 498 0 0 1025 0 0
PD12816a 663 0 0 642 490 0
PD12817a 773 156 0 2322 0 0
PD12818a 1288 0 0 1033 0 0
PD12819a 1165 0 0 1044 0 0
PD12820a 2212 0 0 575 0 0
PD12821a 990 0 0 1497 0 0
PD12822a 909 82 0 959 0 0
PD12823a 174 0 0 368 334 47
PD12824a 837 124 0 1909 0 145
PD12825a 1384 0 0 1270 0 0
PD12826a 200 0 0 230 731 0
PD12828a 1610 0 0 1403 0 0
PD12829a 967 110 0 1622 0 0
PD12830a 1011 0 0 2358 0 0
PD12831a 1266 0 0 772 0 0
PD12832a 1470 0 0 1196 0 0
PD12834a 774 136 0 1869 0 0
PD12835a 1885 0 0 1157 0 0
PD12836a 2144 0 0 978 0 0
PD12837a 1521 0 0 1424 0 0
PD12838a 2338 0 0 977 0 0
PD12840a 783 0 0 1173 774 0
PD12841a 802 67 0 945 0 44
PD12842a 1803 0 0 1590 0 0
PD12843a 1995 444 0 4717 2255 367
PD12844a 686 194 0 3003 0 0
PD12845a 4921 0 0 2034 0 0
PD13380a 401 198 1463 1098 1732 0
PD13381a 1824 0 0 1724 0 0
PD13382a 1179 0 0 1264 983 0
PD13383a 591 0 0 1427 481 0
PD13384a 826 0 0 1058 0 0
PD13386a 766 0 0 986 0 0
PD13387a 1610 0 0 1124 0 0
PD13388a 2609 0 0 1510 0 0
PD13389a 1727 0 0 993 0 0
PD13390a 910 0 0 1217 0 0
PD13391a 1545 0 0 710 0 0
PD13392a 674 0 0 490 327 0
PD13393a 1193 146 0 1248 0 0
PD13394a 612 149 0 2451 0 0
PD13395a 678 0 0 1892 811 142
PD13396a 1842 0 0 828 0 0
PD13397a 114 0 0 164 133 0
PD13398a 560 0 0 816 463 0
PD13399a 1074 0 0 936 0 0
PD13400a 264 45 0 264 355 0
PD13401a 1337 0 0 762 0 0
PD13402a 594 0 0 1642 896 0
PD13404a 1486 0 0 823 0 0
PD13405a 677 88 0 1777 0 0
PD13406a 590 0 0 1313 537 0
PD13407a 588 101 845 1262 0 0
PD13408a 662 178 0 2173 728 215
PD13409a 1587 0 0 495 0 0
PD13410a 1492 0 0 667 0 0
PD13411a 1900 0 0 1698 0 0
PD13412a 1401 0 4626 587 5006 0
PD14706a 2299 0 0 648 0 0
PD14707a 1476 0 0 843 0 0
PD14708a 1395 0 0 501 0 0
PD14709a 634 0 0 1706 0 110
PD14710a 823 0 0 941 0 0
PD14711a 798 0 0 1425 0 0
PD14712a 866 0 0 847 0 0
PD14713a 1406 174 0 1471 0 185
PD14714a 1833 0 0 1519 0 0
PD14716a 1590 0 0 1113 0 0
PD14717a 1850 0 0 730 0 0
PD14718a 1011 124 953 829 0 0
PD14719a 1702 0 0 955 0 0
PD14720a 704 0 0 1912 0 151
PD14721a 2090 0 0 1698 0 0
PD14722a 1724 0 2287 912 2960 274
PD14724a 2178 0 0 53 1802 0
PD14725a 1599 0 0 916 0 0
PD14726a 833 184 0 2464 0 0
PD14727a 1790 0 0 1011 0 0
PD14728a 1706 242 0 2699 1390 282
PD14729a 2082 170 0 1473 0 0
PD14730a 1872 162 0 1261 0 0
PD14731a 1290 0 0 2977 2456 414
PD14732a 922 0 0 1088 0 0
PD14733a 480 0 0 605 417 0
PD14734a 2146 154 0 1409 0 0
PD14735a 1927 0 0 491 0 0
PD14736a 1597 0 0 653 0 0
PD6204a_Illumina 524 101 0 1675 0 0
PD9168a 1570 0 0 1484 0 0
PD9169a 787 0 0 1656 677 0
PD9746a 1076 0 0 994 1372 157
PD9749a 1365 0 0 2029 0 0


















































































































SampleName Signature1 Signature2 Signature3 Signature5 Signature8 Signature13
PD11328a_clonal 917 203 0 2403 1355 116
PD11328a_early 31 9 0 124 70 9
PD11328a_late 74 29 0 255 273 15
PD11328a_subclonal 77 68 0 366 355 18
PD11329a_clonal 1329 85 0 1299 0 72
PD11329a_early 256 41 0 174 0 10
PD11329a_late 520 2 0 391 0 24
PD11329a_subclonal 306 19 0 865 0 33
PD11330a_clonal 604 70 0 758 681 88
PD11330a_early 1102 82 0 735 884 64
PD11330a_late 429 101 0 989 873 137
PD11330a_subclonal 0 3 0 0 7 9
PD11331a_clonal 469 0 0 300 0 0
PD11331a_early 791 0 0 634 0 0
PD11331a_late 205 0 0 124 0 0
PD11331a_subclonal 46 0 0 102 0 0
PD11332a_clonal 310 0 0 271 138 44
PD11332a_early 1064 80 0 901 693 76
PD11332a_late 300 115 0 501 819 135
PD11332a_subclonal 76 24 0 88 247 3
PD11333a_clonal 1626 0 0 1444 0 0
PD11333a_early 17 0 0 39 0 0
PD11333a_late 7 0 0 0 0 0
PD11333a_subclonal 99 0 0 221 0 0
PD11334a_clonal 1380 0 0 1285 0 0
PD11334a_early 12 0 0 0 0 0
PD11334a_late 7 0 0 0 0 0
PD11334a_subclonal 530 0 0 661 0 0
PD11335a_clonal 1031 0 5965 2710 0 194
PD11335a_early 47 0 102 95 0 18
PD11335a_late 0 0 320 83 0 0
PD11335a_subclonal 54 0 794 147 0 0
PD12337a_clonal 951 212 0 2687 0 174
PD12337a_early 6 1 0 85 0 8
PD12337a_late 5 0 0 24 0 6
PD12337a_subclonal 128 14 0 422 0 14
PD12806a_clonal 887 0 0 595 0 0
PD12806a_early 1 0 0 0 0 0
PD12806a_subclonal 190 0 0 114 0 0
PD12807a_clonal 38 11 0 84 66 0
PD12807a_subclonal 39 25 0 395 165 0
PD12808a_clonal 588 0 0 382 556 51
PD12808a_late 0 0 0 0 2 0
PD12808a_subclonal 467 0 0 295 1081 94
PD12809a_clonal 9 1 0 41 0 0
PD12809a_early 8 2 0 2 0 0
PD12809a_late 3 0 0 0 0 0
PD12809a_subclonal 49 5 0 142 0 0
PD12810a_clonal 383 87 0 580 828 0
PD12810a_subclonal 0 2 0 51 465 0
PD12811a_clonal 315 0 0 819 194 56
PD12811a_subclonal 39 0 0 463 272 47
PD12812a_clonal 24 5 0 73 110 4
PD12812a_early 17 1 0 21 5 0
PD12812a_late 4 5 0 0 50 6
PD12812a_subclonal 0 0 0 340 1555 152
PD12813a_clonal 1230 0 0 1296 0 0
PD12813a_subclonal 15 0 0 53 0 0
PD12814a_clonal 1435 0 0 1052 0 0
PD12814a_subclonal 78 0 0 104 0 0
PD12815a_clonal 411 0 0 827 0 0
PD12815a_late 0 0 0 1 0 0
PD12815a_subclonal 2 0 0 33 0 0
PD12816a_clonal 66 0 0 44 37 0
PD12816a_early 115 0 0 13 18 0
PD12816a_late 463 0 0 519 358 0
PD12817a_clonal 572 152 0 1857 0 0
PD12817a_early 0 0 0 2 0 0
PD12817a_subclonal 77 1 0 94 0 0
PD12818a_clonal 707 0 0 537 0 0
PD12818a_late 0 0 0 4 0 0
PD12818a_subclonal 39 0 0 17 0 0
PD12819a_clonal 1123 0 0 923 0 0
PD12819a_early 0 0 0 1 0 0
PD12820a_clonal 634 0 0 251 0 0
PD12820a_subclonal 1025 0 0 235 0 0
PD12821a_clonal 648 0 0 1062 0 0
PD12821a_subclonal 97 0 0 204 0 0
PD12822a_clonal 71 4 0 34 0 0
PD12822a_subclonal 22 9 0 52 0 0
PD12823a_late 12 0 0 0 0 0
PD12823a_subclonal 154 0 0 334 295 33
PD12824a_clonal 639 81 0 1382 0 111
PD12824a_early 50 7 0 216 0 5
PD12824a_late 54 8 0 114 0 4
PD12824a_subclonal 22 3 0 0 0 2
PD12825a_clonal 1342 0 0 1136 0 0
PD12825a_late 0 0 0 1 0 0
PD12826a_clonal 0 0 0 0 3 0
PD12826a_early 40 0 0 0 26 0
PD12826a_late 128 0 0 225 633 0
PD12828a_clonal 379 0 0 368 0 0
PD12828a_early 837 0 0 756 0 0
PD12828a_late 277 0 0 207 0 0
PD12828a_subclonal 12 0 0 0 0 0
PD12829a_clonal 811 85 0 1308 0 0
PD12829a_subclonal 68 13 0 178 0 0
PD12830a_clonal 517 0 0 1498 0 0
PD12830a_subclonal 298 0 0 341 0 0
PD12831a_clonal 713 0 0 431 0 0
PD12831a_early 363 0 0 190 0 0
PD12831a_late 101 0 0 67 0 0
PD12831a_subclonal 0 0 0 18 0 0
PD12832a_clonal 895 0 0 601 0 0
PD12832a_subclonal 216 0 0 159 0 0
PD12834a_clonal 495 73 0 1041 0 0
PD12834a_early 7 3 0 40 0 0
PD12834a_late 16 0 0 63 0 0
PD12834a_subclonal 81 25 0 300 0 0
PD12835a_subclonal 1224 0 0 795 0 0
PD12836a_clonal 83 0 0 12 0 0
PD12836a_early 1452 0 0 636 0 0
PD12836a_late 422 0 0 263 0 0
PD12836a_subclonal 2 0 0 1 0 0
PD12837a_clonal 221 0 0 228 0 0
PD12837a_subclonal 282 0 0 490 0 0
PD12838a_clonal 2114 0 0 720 0 0
PD12838a_early 4 0 0 0 0 0
PD12838a_late 5 0 0 1 0 0
PD12838a_subclonal 28 0 0 0 0 0
PD12840a_clonal 281 0 0 300 177 0
PD12840a_subclonal 95 0 0 525 398 0
PD12841a_clonal 571 39 0 619 0 0
PD12841a_early 2 0 0 0 0 0
PD12841a_late 2 0 0 5 0 0
PD12841a_subclonal 126 24 0 186 0 38
PD12842a_clonal 1311 0 0 1069 0 0
PD12842a_late 1 0 0 0 0 0
PD12842a_subclonal 187 0 0 394 0 0
PD12843a_clonal 660 132 0 1589 579 137
PD12843a_early 868 186 0 1902 987 128
PD12843a_late 378 110 0 989 574 83
PD12844a_clonal 7 15 0 191 0 0
PD12844a_early 476 100 0 1651 0 0
PD12844a_late 169 77 0 941 0 0
PD12844a_subclonal 0 0 0 16 0 0
PD12845a_clonal 1094 0 0 476 0 0
PD12845a_early 1088 0 0 511 0 0
PD12845a_late 1888 0 0 657 0 0
PD12845a_subclonal 2 0 0 23 0 0
PD13380a_clonal 309 140 966 1043 1283 0
PD13380a_subclonal 6 11 191 0 172 0
PD13381a_clonal 413 0 0 429 0 0
PD13381a_subclonal 956 0 0 839 0 0
PD13382a_clonal 877 0 0 898 716 0
PD13382a_subclonal 28 0 0 49 73 0
PD13383a_clonal 412 0 0 1028 243 0
PD13383a_subclonal 44 0 0 89 187 0
PD13384a_clonal 508 0 0 754 0 0
PD13384a_subclonal 208 0 0 136 0 0
PD13386a_clonal 322 0 0 509 0 0
PD13386a_subclonal 1 0 0 108 0 0
PD13387a_clonal 810 0 0 722 0 0
PD13387a_subclonal 28 0 0 71 0 0
PD13388a_clonal 467 0 0 209 0 0
PD13388a_subclonal 793 0 0 584 0 0
PD13389a_clonal 1344 0 0 838 0 0
PD13389a_late 0 0 0 2 0 0
PD13389a_subclonal 139 0 0 33 0 0
PD13390a_clonal 648 0 0 1000 0 0
PD13390a_early 20 0 0 9 0 0
PD13390a_late 54 0 0 0 0 0
PD13390a_subclonal 22 0 0 11 0 0
PD13391a_clonal 1326 0 0 670 0 0
PD13391a_early 42 0 0 7 0 0
PD13391a_late 83 0 0 0 0 0
PD13391a_subclonal 0 0 0 2 0 0
PD13392a_clonal 0 0 0 0 1 0
PD13392a_subclonal 108 0 0 49 111 0
PD13393a_early 1 0 0 0 0 0
PD13393a_late 3 0 0 0 0 0
PD13393a_subclonal 402 56 0 467 0 0
PD13394a_clonal 428 107 0 1807 0 0
PD13394a_early 0 4 0 0 0 0
PD13394a_late 0 0 0 4 0 0
PD13394a_subclonal 14 9 0 89 0 0
PD13395a_clonal 122 0 0 136 98 5
PD13395a_early 0 0 0 0 2 0
PD13395a_late 8 0 0 16 11 1
PD13396a_clonal 1140 0 0 569 0 0
PD13396a_subclonal 284 0 0 90 0 0
PD13398a_clonal 420 0 0 609 198 0
PD13398a_early 1 0 0 0 3 0
PD13398a_late 5 0 0 3 1 0
PD13398a_subclonal 3 0 0 0 35 0
PD13399a_clonal 341 0 0 344 0 0
PD13399a_subclonal 192 0 0 210 0 0
PD13400a_clonal 233 38 0 240 312 0
PD13400a_late 0 1 0 2 0 0
PD13401a_clonal 500 0 0 420 0 0
PD13401a_early 6 0 0 12 0 0
PD13401a_late 32 0 0 5 0 0
PD13401a_subclonal 461 0 0 215 0 0
PD13402a_clonal 340 0 0 579 145 0
PD13402a_early 0 0 0 1 0 0
PD13402a_late 4 0 0 2 0 0
PD13402a_subclonal 103 0 0 702 484 0
PD13404a_clonal 23 0 0 23 0 0
PD13404a_subclonal 1050 0 0 474 0 0
PD13405a_clonal 550 68 0 1433 0 0
PD13405a_early 6 0 0 15 0 0
PD13405a_late 0 3 0 19 0 0
PD13405a_subclonal 1 0 0 51 0 0
PD13406a_clonal 267 0 0 649 160 0
PD13406a_early 0 0 0 0 8 0
PD13406a_late 2 0 0 1 4 0
PD13406a_subclonal 24 0 0 95 62 0
PD13407a_subclonal 541 89 717 1156 0 0
PD13408a_clonal 524 116 0 1222 31 96
PD13408a_early 11 0 0 57 0 6
PD13408a_late 15 1 0 17 33 11
PD13408a_subclonal 38 37 0 602 594 82
PD13409a_clonal 1498 0 0 420 0 0
PD13409a_late 0 0 0 5 0 0
PD13410a_clonal 1211 0 0 492 0 0
PD13410a_subclonal 85 0 0 68 0 0
PD13411a_clonal 2 0 0 10 0 0
PD13411a_early 411 0 0 339 0 0
PD13411a_late 928 0 0 540 0 0
PD13411a_subclonal 316 0 0 561 0 0
PD13412a_clonal 1116 0 3499 0 3856 0
PD13412a_early 45 0 150 0 183 0
PD13412a_late 24 0 100 0 430 0
PD13412a_subclonal 161 0 520 0 1167 0
PD14706a_clonal 1929 0 0 633 0 0
PD14706a_subclonal 110 0 0 13 0 0
PD14707a_clonal 881 0 0 440 0 0
PD14707a_subclonal 321 0 0 190 0 0
PD14708a_clonal 1192 0 0 480 0 0
PD14708a_subclonal 38 0 0 10 0 0
PD14709a_clonal 33 0 0 84 0 6
PD14709a_subclonal 371 0 0 1141 0 72
PD14710a_clonal 387 0 0 538 0 0
PD14710a_subclonal 256 0 0 268 0 0
PD14711a_clonal 659 0 0 1265 0 0
PD14711a_subclonal 80 0 0 0 0 0
PD14712a_clonal 548 0 0 509 0 0
PD14712a_late 2 0 0 0 0 0
PD14712a_subclonal 34 0 0 47 0 0
PD14713a_clonal 809 36 0 853 0 73
PD14713a_early 32 0 0 35 0 2
PD14713a_late 102 6 0 10 0 10
PD14713a_subclonal 165 142 0 396 0 83
PD14714a_clonal 218 0 0 233 0 0
PD14714a_early 0 0 0 1 0 0
PD14714a_subclonal 817 0 0 635 0 0
PD14716a_clonal 954 0 0 823 0 0
PD14716a_subclonal 307 0 0 204 0 0
PD14717a_clonal 1214 0 0 547 0 0
PD14717a_subclonal 384 0 0 118 0 0
PD14718a_clonal 844 103 824 694 0 0
PD14718a_subclonal 61 3 56 49 0 0
PD14719a_clonal 1077 0 0 524 0 0
PD14719a_subclonal 304 0 0 222 0 0
PD14720a_clonal 649 0 0 1649 0 120
PD14720a_late 0 0 0 12 0 3
PD14720a_subclonal 0 0 0 6 0 0
PD14721a_clonal 318 0 0 382 0 0
PD14721a_early 1251 0 0 966 0 0
PD14721a_late 433 0 0 275 0 0
PD14722a_clonal 1286 0 1115 632 1998 149
PD14722a_early 28 0 98 27 44 1
PD14722a_late 36 0 113 20 112 10
PD14722a_subclonal 85 0 390 73 330 58
PD14724a_clonal 297 0 0 0 177 0
PD14724a_early 1184 0 0 141 831 0
PD14724a_late 510 0 0 0 633 0
PD14724a_subclonal 0 0 0 0 39 0
PD14725a_clonal 496 0 0 284 0 0
PD14725a_subclonal 43 0 0 67 0 0
PD14726a_clonal 257 62 0 716 0 0
PD14726a_subclonal 62 12 0 176 0 0
PD14727a_clonal 11 0 0 8 0 0
PD14727a_early 1017 0 0 669 0 0
PD14727a_late 677 0 0 265 0 0
PD14727a_subclonal 0 0 0 12 0 0
PD14728a_clonal 1211 106 0 1669 852 134
PD14728a_early 59 26 0 7 22 0
PD14728a_late 106 57 0 132 40 58
PD14728a_subclonal 0 15 0 221 203 71
PD14729a_clonal 360 38 0 212 0 0
PD14729a_early 575 38 0 430 0 0
PD14729a_late 1045 80 0 725 0 0
PD14730a_clonal 249 29 0 110 0 0
PD14730a_early 1064 88 0 713 0 0
PD14730a_late 469 32 0 366 0 0
PD14730a_subclonal 0 0 0 1 0 0
PD14731a_clonal 224 0 0 245 325 43
PD14731a_early 689 0 0 1568 794 174
PD14731a_late 312 0 0 1021 1206 159
PD14731a_subclonal 0 0 0 0 4 0
PD14732a_clonal 327 0 0 618 0 0
PD14732a_subclonal 195 0 0 156 0 0
PD14733a_clonal 193 0 0 449 170 0
PD14733a_subclonal 174 0 0 88 190 0
PD14734a_clonal 1813 117 0 1067 0 0
PD14734a_early 0 1 0 0 0 0
PD14734a_late 0 0 0 2 0 0
PD14734a_subclonal 42 20 0 74 0 0
PD14735a_clonal 1036 0 0 356 0 0
PD14735a_subclonal 311 0 0 60 0 0
PD14736a_clonal 12 0 0 14 0 0
PD14736a_subclonal 347 0 0 153 0 0
PD6204a_Illumina_ear 0 0 0 8 0 0
PD6204a_Illumina_lat 0 2 0 0 0 0
PD6204a_Illumina_sub 0 38 0 0 0 0
PD9168a_early 855 0 0 747 0 0
PD9168a_late 677 0 0 693 0 0
PD9169a_clonal 525 0 0 1666 0 0
PD9169a_subclonal 78 0 0 179 0 0
PD9746a_early 212 0 0 307 161 14
PD9746a_late 794 0 0 644 1142 147
PD9749a_clonal 836 0 0 1457 0 0
PD9749a_subclonal 42 0 0 203 0 0
PD9751a_clonal 458 0 0 1027 338 0












































































































































































































































































































































CDH12 0.000085 0.006 9.3 0.00061 7.3
ANTXR2 0.00033 0.012 7.7 0.0015 6.5
SPOP 0.0042 0.081 3.9 0.0016 4.8
IL6ST 0.0046 0.081 4.8 0.0014 6.2
ZFHX4 0.015 0.22 3.8 0.021 3.6
NCOA7 0.019 0.23 4.4 0.012 5
DLC1 0.031 0.26 3.8 0.11 2.8
PPAP2A 0.032 0.26 2.9 0.037 2.9
SENP6 0.034 0.26 3.7 0.1 2.8
MTUS1 0.037 0.26 3.7 0.078 3
LOH,	chr	13:46Mb 0.04 0.26 2.4 0.081 2.2
GRM1 0.05 0.29 4.4 0.077 3.8
PDE4D 0.061 0.33 2.8 0.028 3.4
CHD1 0.069 0.33 2.3 0.04 2.6
Gain,	chr	9:43Mb 0.07 0.33 2.2 0.08 2.1
LOH,	chr	1:235Mb 0.095 0.38 2.4 0.16 2.1
MTMR7 0.096 0.38 2.8 0.19 2.3
CDKN1B 0.097 0.38 2.1 0.087 2.3
MAP3K1 0.14 0.52 2.5 0.11 2.7
ROBO1 0.15 0.55 2.4 0.26 2
SLC4A4 0.16 0.56 2.4 0.32 1.9
LOH,	chr	6:88Mb 0.21 0.68 1.7 0.063 2.4
ETV3 0.28 0.74 2 0.45 1.6
LOH,	chr	8:23Mb 0.29 0.74 1.6 0.4 1.5
LOH,	chr	2:141Mb 0.29 0.74 1.8 0.39 1.7
ETS_status 0.3 0.74 0.64 0.24 0.6
AMBRA1 0.3 0.74 2.2 0.48 1.7
IFI16 0.34 0.74 2 0.55 1.6
LOH,	chr	12:12Mb 0.34 0.74 1.5 0.46 1.4
ACPP 0.35 0.74 2 0.32 2.1
LOH,	chr	5:100Mb 0.35 0.74 1.5 0.25 1.7
LOH,	chr	3:72Mb 0.36 0.74 0.63 0.23 0.5
PPP2R2A 0.38 0.74 1.7 0.53 1.5
RBM7 0.38 0.74 1.9 0.63 1.4
RYBP 0.38 0.74 0.62 0.4 0.63
LOH,	chr	16:79Mb 0.41 0.74 0.66 0.49 0.67
NCOR2 0.43 0.74 1.8 0.29 2.2
USP28 0.44 0.74 1.8 0.72 1.3
PPP4R2 0.45 0.74 0.46 0.42 0.43
FOXA1 0.45 0.74 1.5 0.16 2.1
TP53 0.45 0.74 1.4 0.19 1.9
ERG 0.46 0.74 0.75 0.28 0.64
ADAM28 0.47 0.74 1.6 0.86 1.1
NKX3.1 0.47 0.74 1.6 0.86 1.1
LOH,	chr	1:77Mb 0.47 0.74 1.5 0.56 1.4
LOH,	chr	10:92Mb 0.48 0.75 0.65 0.25 0.44
HD,	chr	10:90Mb 0.52 0.78 0.62 0.23 0.33
NEAT1 0.53 0.78 1.6 0.61 1.5
Gain,	chr	3:130Mb 0.55 0.8 1.4 0.6 1.4
FOXP1 0.58 0.8 1.3 0.57 1.3
TGFBR2 0.58 0.8 0.56 0.47 0.47
ZBTB16 0.64 0.87 1.4 0.95 1
LOH,	chr	17:7Mb 0.66 0.88 1.2 0.44 1.5
ZNF292 0.73 0.93 1.2 0.9 0.93
SHQ1 0.73 0.93 0.83 0.69 0.8
LOH,	chr	18:73Mb 0.73 0.93 1.2 0.82 1.1
TCF12 0.8 0.99 1.2 0.85 1.2
ROBO2 0.82 0.99 1.2 0.92 0.94
ARHGAP15 0.82 0.99 1.2 0.86 0.87
Gain,	chr	8:89Mb 0.87 1 0.93 0.92 1
HD,	chr	5:98Mb 0.89 1 1.1 0.83 1.2
APC 0.92 1 1.1 0.75 1.3
Gain,	chr	7:53Mb 0.93 1 1 0.9 1.1
MYST3 0.93 1 1.1 0.51 0.55
ASH1L 0.94 1 0.93 0.77 0.74
PTEN 0.96 1 1 0.44 0.67
TBX18 0.96 1 0.96 0.79 0.81
WGD 0.98 1 1 0.9 1.1
TBL1XR1 0.99 1 0.99 0.89 0.86
UBTF 1 1 1.3E-08 1 3.3E-09
GPATCH8 1 1 1.3E-08 1 3.2E-09
SUPPLEMENTARY TABLE 5
UniprotAccesstion Gene Symbol Source Subcellular_lolong_name node_label
P10275 AR input_list Nucl Androgen recAR
P15056 BRAF input_list Cyto Serine/threon   BRAF
P03372 ESR1 additional_enNucl Estrogen receER-alpha
O15379 HDAC3 additional_enNucl Histone deace  HDAC3
Q12809 KCNH2 input_list Cell membranPotassium vo      Kv11.1
Q02750 MAP2K1 additional_coCyto Protein Kinase
P04150 NR3C1 additional_enNucl Glucocorticoi  GR
P10276 RARA additional_enNucl Retinoic acid  RARA
P10826 RARB additional_enNucl Retinoic acid  RARB
P13631 RARG additional_enNucl Retinoic acid  RARG
P19793 RXRA additional_enNucl Retinoic acid  RXRA
P31749 AKT1 input_list Cyto RAC-alpha se  Akt1
Q13315 ATM input_list Nucl Serine-protei   ATM
Q5S007 LRRK2 input_list Cell membranLeucine-rich r    LRRK2
Q00987 MDM2 additional_coNucl E3 ubiquitin-protein ligase  
Q08499 PDE4D input_list Cyto cAMP-specific   PDE4D
P42336 PIK3CA input_list Cyto Phosphatidyli       PIK3CA
P42338 PIK3CB input_list Cyto Phosphatidyli       PIK3CB
P04637 TP53 input_list Nucl Cellular tumo   p53
P35869 AHR additional_enCyto Aryl hydrocar  AHR
P38398 BRCA1 additional_enNucl Breast cancer    BRCA1
P35222 CTNNB1 input_list Cyto Catenin beta-CTNNB1
P01112 HRAS input_list Cell membranGTPase HRas HRas
O75874 IDH1 input_list Cyto Isocitrate deh   IDH1
Q14643 ITPR1 input_list Org Memb Inositol 1,4,5-    IP3R1
Q14571 ITPR2 input_list Org Memb Inositol 1,4,5-    IP3R2
P05412 JUN additional_enNucl Transcription  Jun
Q13233 MAP3K1 input_list Cyto Mitogen-activ      MEKK1
O00255 MEN1 additional_enNucl Menin MEN1
O75376 NCOR1 input_list Nucl Nuclear recep   N-CoR1
Q9Y618 NCOR2 input_list Nucl Nuclear recep   SMRT
P22736 NR4A1 additional_enNucl Nuclear recep       Nur77
P27986 PIK3R1 input_list Cyto Phosphatidyli     PIK3R1
P63151 PPP2R2A input_list Cyto Serine/threon          PPP2R2A
P58335 ANTXR2 input_list Cell membranAnthrax toxin  ANTXR2
P25054 APC input_list Cell membranAdenomatous   APC
P27540 ARNT additional_enNucl Aryl hydrocar    ARNT
Q9NR48 ASH1L input_list Nucl Histone-lysine  ASH1L
P51587 BRCA2 input_list Nucl Breast cancer    BRCA2
O43439 CBFA2T2 additional_enNucl Protein CBFA2CBFA2T2
P55289 CDH12 input_list Cell membranCadherin-12 CDH12
Q9NYV4 CDK12 input_list Nucl Cyclin-depend   CDK12
O14646 CHD1 input_list Nucl Chromodoma   CHD-1
Q92793 CREBBP additional_enCyto CREB-binding CBP
Q96QB1 DLC1 input_list Cyto Rho GTPase-a   DLC1
Q96BY6 DOCK10 input_list Cell membranDedicator of c   DOCK10
P11308 ERG input_list Nucl Transcription   ERG
Q5FWF5 ESCO1 input_list Nucl N-acetyltrans  ESCO1
P41162 ETV3 input_list Nucl ETS transloca   ETV3
P55317 FOXA1 input_list Nucl Hepatocyte n   FOXA1
P55316 FOXG1 additional_enNucl Forkhead box  FOXG1
Q12778 FOXO1 input_list Nucl Forkhead box  FOXO1A
P98177 FOXO4 additional_enNucl Forkhead box  FOXO4
Q9H334 FOXP1 input_list Nucl Forkhead box  FOXP1
P15976 GATA1 additional_enNucl Erythroid tran  GATA1
P23769 GATA2 additional_enNucl Endothelial tr   GATA2
P51858 HDGF additional_enCyto Hepatoma-de   HDGF
P41235 HNF4A additional_enNucl Hepatocyte n   HNF4 alpha
P40189 IL6ST input_list Cell membranInterleukin-6   gp130
Q92794 KAT6A input_list Nucl Histone acety  MYST3
O75164 KDM4A additional_enNucl Lysine-specifi   JMJD2A
O15550 KDM6A input_list Nucl Lysine-specifi   UTX
Q8NEZ4 KMT2C input_list Nucl Histone-lysine  MLL3
O14686 KMT2D input_list Nucl Histone-lysine  MLL4
Q96PU5 NEDD4L input_list Cyto E3 ubiquitin-p   NEDD4L
Q99801 NKX3-1 input_list Nucl Homeobox pr  NKX3-1
O75925 PIAS1 additional_enNucl E3 SUMO-pro   PIAS1
O75928 PIAS2 additional_enNucl E3 SUMO-pro   PIAS2
P60484 PTEN input_list Cyto Phosphatidyli        PTEN
P06400 RB1 input_list Nucl Retinoblastom  Rb
Q68DV7 RNF43 input_list Cell membranE3 ubiquitin-p   RNF43
P12755 SKI additional_enNucl Ski oncogene SKI
Q15796 SMAD2 input_list Cyto Mothers agai    SMAD2
P84022 SMAD3 additional_enCyto Mothers agai    SMAD3
Q13485 SMAD4 input_list Cyto Mothers agai    SMAD4
P51532 SMARCA4 additional_enNucl Transcription  SMARCA4
O95238 SPDEF additional_enNucl SAM pointed    SPDEF
O43791 SPOP input_list Nucl Speckle-type  SPOP
O60907 TBL1X additional_enNucl F-box-like/WD   TBL1X
Q9BZK7 TBL1XR1 input_list Nucl F-box-like/WD   TBL1XR1
O15119 TBX3 input_list Nucl T-box transcr   TBX3
O15350 TP73 additional_enCyto Tumor protei  p73
Q05516 ZBTB16 input_list Nucl Zinc finger an     PLZF
Q9Y6X8 ZHX2 additional_enNucl Zinc fingers a    ZHX2
Q9NY61 AATF additional_enNucl Protein AATF AATF
Q9UKQ2 ADAM28 input_list Cell membranDisintegrin an     ADAM28
Q08117 AES additional_connectivity Amino-termin    AES
P05067 APP additional_connectivity Amyloid beta  APP
O14497 ARID1A input_list Nucl AT-rich intera    ARID1A
Q68CP9 ARID2 input_list Nucl AT-rich intera    ARID2
Q4LE39 ARID4B input_list Nucl AT-rich intera    ARID4B
Q76L83 ASXL2 input_list Nucl Putative Polyc    ASXL2
O95352 ATG7 input_list Cyto Ubiquitin-like   ATG7
P54253 ATXN1 additional_connectivity Ataxin-1 ataxin-1
Q8WY36 BBX additional_enNucl HMG box tran   HBP2
Q86V15 CASZ1 input_list Nucl Zinc finger pr    CASZ1
Q9ULB5 CDH7 additional_connectivity Cadherin-7 CDH7
P46527 CDKN1B input_list Nucl Cyclin-depend    p27Kip1
P17676 CEBPB additional_enNucl CCAAT/enhan    C/EBP-beta
Q9NZN8 CNOT2 additional_enNucl CCR4-NOT tra    NOT2
O75175 CNOT3 input_list Nucl CCR4-NOT tra    NOT3
Q6UUV9 CRTC1 additional_enNucl CREB-regulate    TORC1
Q96PT4 DUX3 additional_enNucl Putative doub    DUX3
O00716 E2F3 additional_enNucl Transcription  E2F3
Q7Z589 EMSY additional_enNucl BRCA2-intera     EMSY
O75593 FOXH1 additional_enNucl Forkhead box  FOXH1
O43524 FOXO3 additional_enCyto Forkhead box   FOXO3A
O00168 FXYD1 additional_connectivity PhospholemmPLM
P10071 GLI3 additional_enNucl Transcription   GLI3
Q96IK5 GMCL1 additional_connectivity Germ cell-less  GMCL1
Q9UKJ3 GPATCH8 input_list Cyto G patch doma   GPATCH8
Q13227 GPS2 additional_enNucl G protein pat   GPS2
P68431 HIST1H3A|HI additional_coNucl Histone H3.1 H3
Q5VVH5 IRAK1BP1 additional_enCyto Interleukin-1     IRAK1BP1
P13612 ITGA4 additional_connectivity Integrin alphaITGA4
Q92993 KAT5 additional_connectivity Histone acety  Tip60
Q9NZR2 LRP1B input_list Cell membranLow-density l    LRP1B
P43364 MAGEA11 additional_connectivity Melanoma-as   MAGE-A11
Q03112 MECOM additional_enNucl MDS1 and EV     EVI1
Q13465 MECOM additional_enNucl MDS1 and EV     MDS1
Q02078 MEF2A additional_enNucl Myocyte-spec    MEF2A
Q03111 MLLT1 additional_enNucl Protein ENL MLLT1
Q9ULD2 MTUS1 input_list Cyto Microtubule-    MTUS1
P01106 MYC additional_enNucl Myc proto-on  Myc
Q8NI08 NCOA7 input_list Nucl Nuclear recep   NCOA7
Q12857 NFIA additional_enNucl Nuclear facto   NFI-A
Q13952 NFYC additional_enNucl Nuclear trans     NFYC
O43929 ORC4 additional_connectivity Origin recogn    ORC4L
O14494 PLPP1|PPAP2input_list Cell membranPhospholipid   PPAP2A
P29590 PML additional_enNucl Protein PML PML
P67775 PPP2CA additional_connectivity Serine/threon       PPP2CA
P17612 PRKACA additional_coCyto cAMP-depend      PKACA
O75400 PRPF40A additional_coNucl Pre-mRNA-pr     FNBP3
P28749 RBL1 additional_enNucl Retinoblastom   Rb-like 1
Q9NVW2 RLIM input_list Nucl E3 ubiquitin-p   RNF12
Q9Y6N7 ROBO1 input_list Cell membranRoundabout h  ROBO1
Q9HCK4 ROBO2 input_list Cell membranRoundabout h  ROBO2
P62913 RPL11 input_list Nucl 60S ribosoma   RPL11
Q13950 RUNX2 additional_enNucl Runt-related   AML3
Q8N488 RYBP input_list Nucl RING1 and YY  RYBP
Q9GZR1 SENP6 input_list Nucl Sentrin-specif   SENP6
Q6PI26 SHQ1 input_list Cyto Protein SHQ1 SHQ1
Q96ST3 SIN3A additional_enNucl Paired amphi    SIN3A
O75182 SIN3B additional_enNucl Paired amphi    SIN3B
O15105 SMAD7 additional_enCyto Mothers agai    SMAD7
Q12824 SMARCB1 additional_enNucl SWI/SNF-rela          SMARCB1
P08047 SP1 additional_enNucl Transcription  SP1
P11831 SRF additional_enNucl Serum respon  SRF
Q08945 SSRP1 additional_enNucl FACT complex  SSRP1
O75528 TADA3 additional_enNucl Transcription   TADA3L
P05549 TFAP2A additional_enNucl Transcription  AP-2 alpha
O43294 TGFB1I1 additional_enExtracellular Transforming      Hic-5
P51668 UBE2D1 additional_connectivity Ubiquitin-con    UBE2D1
P17480 UBTF input_list Nucl Nucleolar tran   UBF
Q96RU2 USP28 input_list Nucl Ubiquitin carb   USP28
P25490 YY1 additional_enNucl Transcription    YY1
O15391 YY2 additional_enNucl Transcription  YY2
O95365 ZBTB7A additional_enNucl Zinc finger an     FBI1
P37275 ZEB1 additional_enNucl Zinc finger E-b   TCF8
Q15911 ZFHX3 input_list Nucl Zinc finger ho   ATBF1
Q9UKY1 ZHX1 additional_coNucl Zinc fingers a    ZHX1
O60481 ZIC3 additional_enNucl Zinc finger pr   ZIC3
Q14202 ZMYM3 input_list Nucl Zinc finger MY   ZNF261
Druggability_protein Synonyms Transcriptional_class description
1 DT AR TF Androgen rec
1 DT BRAF Serine/threon   
1 DT ER-alpha ER TF Estrogen rece
1 DT HDAC3 HD3 activator/repressor Histone deace  
1 DT Kv11.1 ERG-1|Eag-related protein 1|Ether-a-go-   Potassium vo      
1 DT Mek1 MP2K1_HUMAN, MAP2K1, MEK1, PRKMKDual specificit      
1 DT GR GR TF Glucocorticoid 
1 DT RARA RAR-alpha TF Retinoic acid  
1 DT RARB RAR-beta regulation Retinoic acid  
1 DT RARG RAR-gamma regulation Retinoic acid  
1 DT RXRA regulation Retinoic acid  
2 CT Akt1 PKB|PKB alpha RAC-alpha se  
2 CT ATM A-T mutated Serine-protei   
2 CT LRRK2 Leucine-rich r    
2 CT MDM2 MDM2 E3 ubiquitin-p   
2 CT PDE4D cAMP-specific   
2 CT PIK3CA PI3-kinase subunit alpha|PI3K-alpha|PI3K     Phosphatidyli       
2 CT PIK3CB PI3-kinase subunit beta|PI3K-beta|PI3Kb     Phosphatidyli       
2 AC-CT p53 TF Cellular tumo   
3 AC AHR Ah receptor|ATF Aryl hydrocar  
3 AC BRCA1 activator/repressor Breast cancer    
3 AC CTNNB1 TF Catenin beta-
3 AC HRas GTPase HRas
3 AC IDH1 IDH Isocitrate deh   
3 AC IP3R1 IP3R 1|InsP3R1|Type 1 InsP3 receptor Inositol 1,4,5-    
3 AC IP3R2 IP3R 2|InsP3R2|Type 2 InsP3 receptor Inositol 1,4,5-    
3 AC Jun AP1 TF Transcription  
3 AC MEKK1 MEK kinase 1|MEKK 1 Mitogen-activ      
3 AC MEN1 activator/repressor Menin
3 AC N-CoR1 N-CoR|N-CoRactivator/repressor Nuclear recep   
3 AC SMRT N-CoR2|SMRTactivator/repressor Nuclear recep   
3 AC Nur77 Nur77 regulation Nuclear recep       
3 AC PIK3R1 PI3-kinase regulatory subunit alpha|PI3-k            Phosphatidyli     
3 AC PPP2R2A Serine/threon          
4 Dr ANTXR2 CMG-2 Anthrax toxin  
4 Dr APC Protein APC Adenomatous   
4 Dr ARNT ARNT protein TF Aryl hydrocar    
4 Dr ASH1L huASH1 Histone-lysine  
4 Dr BRCA2 Breast cancer    
4 Dr CBFA2T2 activator/repressor Protein CBFA2
4 Dr CDH12 BR-cadherin|N-cadherin 2 Cadherin-12
4 Dr CDK12 CDC2-related protein kinase 7|CrkRS|hCDCyclin-depend   
4 Dr CHD-1 CHD-1 Chromodoma   
4 Dr CBP activator/repressor CREB-binding 
4 Dr DLC1 DLC-1|StARD12 Rho GTPase-a   
4 Dr DOCK10 Dedicator of c   
4 Dr ERG TF Transcriptiona   
4 Dr ESCO1 ECO1 homolog 1|EFO1p|ESO1 homolog N-acetyltrans  
4 Dr ETV3 PE-1 ETS translocat   
4 Dr FOXA1 HNF-3-alpha|TF Hepatocyte n   
4 Dr FOXG1 BF-1|BF-2|BFTF Forkhead box  
4 Dr FOXO1A TF Forkhead box  
4 Dr FOXO4 TF Forkhead box  
4 Dr FOXP1 MFH TF Forkhead box  
4 Dr GATA1 GATA-1|GF-1 TF Erythroid tran  
4 Dr GATA2 TF Endothelial tr   
4 Dr HDGF HDGF|HMG-1regulation Hepatoma-de   
4 Dr HNF4 alpha HNF-4-alpha|TF Hepatocyte n   
4 Dr gp130 IL-6 receptor subunit beta|IL-6R subunit Interleukin-6   
4 Dr MYST3 MYST-3 Histone acety  
4 Dr JMJD2A activator/repressor Lysine-specifi   
4 Dr UTX Lysine-specifi   
4 Dr MLL3 Lysine N-methyltransferase 2C Histone-lysine  
4 Dr MLL4 Lysine N-met  regulation Histone-lysine  
4 Dr NEDD4L E3 ubiquitin-p   
4 Dr NKX3-1 TF Homeobox pr  
4 Dr PIAS1 GBP activator/repressor E3 SUMO-pro   
4 Dr PIAS2 ARIP3|DIP|Mactivator/repressor E3 SUMO-pro   
4 Dr PTEN Phosphatidyli        
4 Dr Rb Rb activator/repressor Retinoblastom  
4 Dr RNF43 E3 ubiquitin-p   
4 Dr SKI activator/repressor Ski oncogene
4 Dr SMAD2 MAD homolo       TF Mothers again    
4 Dr SMAD3 MAD homolo       TF Mothers again    
4 Dr SMAD4 MAD homolo       activator/repressor Mothers again    
4 Dr SMARCA4 BAF190A activator/repressor Transcription  
4 Dr SPDEF Prostate-spec  TF SAM pointed    
4 Dr SPOP Speckle-type  
4 Dr TBL1X activator/repressor F-box-like/WD   
4 Dr TBL1XR1 activator/repressor F-box-like/WD   
4 Dr TBX3 T-box protein TF T-box transcri   
4 Dr p73 TF Tumor protein 
4 Dr PLZF activator/repressor Zinc finger an     
4 Dr ZHX2 AFP regulator TF Zinc fingers an    
AATF TF Protein AATF
ADAM28 ADAM 28|MDC-L|eMDC II Disintegrin an     
AES Amino enhan   activator/repressor Amino-termin    
APP AICD-50|AICDTF Amyloid beta  
ARID1A ARID domain-containing protein 1A|BAF2AT-rich intera    
ARID2 ARID domain-containing protein 2|BAF20AT-rich intera    
ARID4B ARID domain-containing protein 4B|Sin3   AT-rich intera    
ASXL2 Putative Polyc    
ATG7 APG7-like|hAGP7 Ubiquitin-like   
ataxin-1 Ataxin-1
HBP2 TF HMG box tran   
CASZ1 TF Zinc finger pro    
CDH7 Cadherin-7
p27Kip1 Cyclin-depend    
C/EBP-beta C/EBP beta |LTF CCAAT/enhan   
NOT2 activator/repressor CCR4-NOT tra    
NOT3 CCR4-NOT tra    
TORC1 TORC-1|Trans     TF CREB-regulate    
TF Putative doub    
E2F3 E2F-3 TF Transcription  
EMSY regulation BRCA2-interac    
Fast-1|Fast-2 TF Forkhead box  
FOXO3A TF Forkhead box  
PLM Phospholemm
GLI3 GLI3-190|GLI TF Transcriptiona   
GMCL1 Germ cell-less  
GPATCH8 G patch doma   
GPS2 GPS-2 activator/repressor G protein pat   
H3 Histone H3.1
IRAK1BP1 IRAK1-binding  regulation Interleukin-1     
ITGA4 Integrin alpha
Tip60 HIV-1 Tat interactive protein|Tip60 Histone acety  
LRP1B LRP-1B|LRP-DIT Low-density li    
MAGE-A11 CT1.11 activator/repressor Melanoma-as   
EVI1 EVI-1 activator/repressor MDS1 and EV     
MDS1 TF MDS1 and EV     
MEF2A TF Myocyte-spec    
MLLT1 regulation Protein ENL
MTUS1 Microtubule-a    
Myc bHLHe39 TF Myc proto-on  
NCOA7 activator/repressor Nuclear recep   
NFI-A CTF|NF-I/A|N   TF Nuclear facto   
NFYC NF-YC TF Nuclear trans     
ORC4L Origin recogn    
PPAP2A PAP-2a|PAP2a Phospholipid  
PML TF Protein PML
PPP2CA PP2A-alpha|RP-C Serine/threon       
PKACA PKA C-alpha cAMP-depend      
FNBP3 HIP-10 Pre-mRNA-pro     
Rb-like 1 p107 activator/repressor Retinoblastom   
RNF12 R-LIM activator/repressor E3 ubiquitin-p   
ROBO1 Roundabout h  
ROBO2 Roundabout h  
RPL11 60S ribosoma   
AML3 CBF-alpha-1|   TF Runt-related t   
RYBP APAP-1|DED-  activator/repressor RING1 and YY  
SENP6 Sentrin-specif   
SHQ1 Protein SHQ1 
SIN3A activator/repressor Paired amphip    
SIN3B activator/repressor Paired amphip    
SMAD7 MAD homolo             TF Mothers again    
SMARCB1 BAF47|hSNF5activator/repressor SWI/SNF-relat          
SP1 TF Transcription  
SRF SRF TF Serum respon  
SSRP1 FACT 80 kDa sinitiation_complex FACT complex  
TADA3L ADA3-like proTF Transcriptiona   
AP-2 alpha AP-2|AP2-alpTF Transcription  
Hic-5 Hic-5 activator/repressor Transforming      
UBE2D1 SFT Ubiquitin-con    
UBF UBF-1 TF Nucleolar tran   
USP28 Ubiquitin carb   
YY1 YY-1 TF Transcriptiona    
YY2 YY-2 TF Transcription  
FBI1 FBI-1|POK ery    TF Zinc finger an     
TCF8 TCF-8 activator/repressor Zinc finger E-b   
ATBF1 ZFH-3 TF Zinc finger ho   
ZHX1 TF Zinc fingers an    
ZIC3 TF Zinc finger pro   
ZNF261 Zinc finger MY   
ec_number location go_terms family cansar_link
 ceptor Nucleus, Cytoplasm nuclear horm   <a href="http://cansar.icr.ac.uk/cansar/m  
2.7.11.1 Nucleus, Cyto   cell body, cyto           TKL Ser/Thr p   <a href="http://cansar.icr.ac.uk/cansar/m  
 eptor Nucleus, Cytoplasm, Cell m            nuclear horm   <a href="http://cansar.icr.ac.uk/cansar/m  
3.5.1.98 Nucleus, Cyto   cytoplasm, cy               histone deace  <a href="http://cansar.icr.ac.uk/cansar/m  
 ltage-gated ch     Cell membrancell surface, p          potassium ch  <a href="http://cansar.icr.ac.uk/cansar/m  
2.7.12.2 Cytoplasm, cy                cytoplasm, cy                   STE Ser/Thr p   <a href="http://cansar.icr.ac.uk/cansar/m  
d receptor Cytoplasm, Nucleus, Mitoch              nuclear horm   <a href="http://cansar.icr.ac.uk/cansar/m  
  receptor alphaNucleus, Cytoactin cytoskel                nuclear horm   <a href="http://cansar.icr.ac.uk/cansar/m  
  receptor beta Nucleus, Nuc  cytoplasm, nu  nuclear horm   <a href="http://cansar.icr.ac.uk/cansar/m  
  receptor gam Nucleus integral comp          nuclear horm   <a href="http://cansar.icr.ac.uk/cansar/m  
  receptor RXR- Nucleus axon, nuclear           nuclear horm   <a href="http://cansar.icr.ac.uk/cansar/m  
2.7.11.1 Cytoplasm, N   cell-cell junct                  AGC Ser/Thr p   <a href="http://cansar.icr.ac.uk/cansar/m  
2.7.11.1 Nucleus, Cyto  cytoplasmic, D      PI3/PI4-kinase <a href="http://cansar.icr.ac.uk/cansar/m  
2.7.11.1 Membrane, C                              amphisome, a                                                                      TKL Ser/Thr p   <a href="http://cansar.icr.ac.uk/cansar/m  
6.3.2.- Nucleus, nucl    cytoplasm, cy          MDM2/MDM  <a href="http://cansar.icr.ac.uk/cansar/m  
3.1.4.53 Apical cell me           apical plasma           cyclic nucleot   <a href="http://cansar.icr.ac.uk/cansar/m  
2.7.1.153 cytosol, lame         PI3/PI4-kinase <a href="http://cansar.icr.ac.uk/cansar/m  
2.7.1.153 Cytoplasm, N cytosol, interc         PI3/PI4-kinase<a href="http://cansar.icr.ac.uk/cansar/m  
 r antigen p53 Cytoplasm, Nucleus, Nucleu                    p53 family <a href="http://cansar.icr.ac.uk/cansar/m  
 bon receptor Cytoplasm, N cytoplasm, cytosolic aryl hy             <a href="http://cansar.icr.ac.uk/cansar/m  
6.3.2.- Nucleus, Chro    BRCA1-A complex, BRCA1-B                        <a href="http://cansar.icr.ac.uk/cansar/m  
 -1 Cytoplasm, N                     adherens junc                                                                    beta-catenin <a href="http://cansar.icr.ac.uk/cansar/m  
Cell membrane, Cell memb           Ras family <a href="http://cansar.icr.ac.uk/cansar/m  
1.1.1.42 Cytoplasm, Pecytoplasm, cy       isocitrate and   <a href="http://cansar.icr.ac.uk/cansar/m  
 -trisphosphate   Endoplasmic  calcineurin co                                InsP3 recepto  <a href="http://cansar.icr.ac.uk/cansar/m  
 -trisphosphate   Endoplasmic  cell cortex, en                    InsP3 recepto  <a href="http://cansar.icr.ac.uk/cansar/m  
 factor AP-1 Nucleus cytosol, nucle            bZIP family <a href="http://cansar.icr.ac.uk/cansar/m  
2.7.11.25 cytoplasm, cySTE Ser/Thr p   <a href="http://cansar.icr.ac.uk/cansar/m  
Nucleus chromatin, cleavage furrow                <a href="http://cansar.icr.ac.uk/cansar/m  
 ptor corepress  Nucleus membrane, n             N-CoR nuclea    <a href="http://cansar.icr.ac.uk/cansar/m  
 ptor corepress  Nucleus histone deace              N-CoR nuclea    <a href="http://cansar.icr.ac.uk/cansar/m  
 ptor subfamily     Cytoplasm, N cytoplasm, nu    nuclear horm  <a href="http://cansar.icr.ac.uk/cansar/m  
nositol 3-kinase regulatory  cell-cell junct                   PI3K p85 subu  <a href="http://cansar.icr.ac.uk/cansar/m  
nine-protein phosphatase 2A       cytosol, nucle      phosphatase     <a href="http://cansar.icr.ac.uk/cansar/m  
  receptor 2 Cell membran     endoplasmic                 ATR family <a href="http://cansar.icr.ac.uk/cansar/m  
s polyposis co  Cell junction,              adherens junc                                           adenomatous    <a href="http://cansar.icr.ac.uk/cansar/m  
 bon receptor  Nucleus cytoplasm, nucleoplasm, nu       <a href="http://cansar.icr.ac.uk/cansar/m  
2.1.1.43 Nucleus, Cell    bicellular tigh          Histone-lysine  <a href="http://cansar.icr.ac.uk/cansar/m  
 r type 2 suscep  Nucleus, Cyto      BRCA2-MAGE-D1 complex,          <a href="http://cansar.icr.ac.uk/cansar/m  
 2T2 Nucleus nucleus CBFA2T famil <a href="http://cansar.icr.ac.uk/cansar/m  
Cell membranintegral component of mem   <a href="http://cansar.icr.ac.uk/cansar/m  
2.7.11.22 Nucleus, Nuc  cyclin K-CDK1             CMGC Ser/Th    <a href="http://cansar.icr.ac.uk/cansar/m  
3.6.4.12 Nucleus, Cytocytoplasm, nuSNF2/RAD54  <a href="http://cansar.icr.ac.uk/cansar/m  
2.3.1.48 Cytoplasm, N cytoplasm, histone acetyltr           <a href="http://cansar.icr.ac.uk/cansar/m  
 activating prot  Cytoplasm, Ce     caveola, cortical actin cytos        <a href="http://cansar.icr.ac.uk/cansar/m  
  cytokinesis protein 10 extracellular e   DOCK family <a href="http://cansar.icr.ac.uk/cansar/m  
al regulator ERNucleus, Cytocytoplasm, in    ETS family <a href="http://cansar.icr.ac.uk/cansar/m  
2.3.1.- Nucleus, Chrochromatin, nuacetyltransfer  <a href="http://cansar.icr.ac.uk/cansar/m  
 tion variant 3 Nucleus nuclear chrom        ETS family <a href="http://cansar.icr.ac.uk/cansar/m  
 uclear factor 3Nucleus microvillus, nucleolus, nucle<a href="http://cansar.icr.ac.uk/cansar/m  
 x protein G1 Nucleus nucleus <a href="http://cansar.icr.ac.uk/cansar/m  
 x protein O1 Cytoplasm, N cytoplasm, cytosol, mitocho   <a href="http://cansar.icr.ac.uk/cansar/m  
 x protein O4 Cytoplasm, N cytoplasm, cytosol, nucleop  <a href="http://cansar.icr.ac.uk/cansar/m  
 x protein P1 Nucleus nucleoplasm, nucleus <a href="http://cansar.icr.ac.uk/cansar/m  
 nscription fact Nucleus nucleoplasm, nucleus, trans      <a href="http://cansar.icr.ac.uk/cansar/m  
 ranscription fa  Nucleus cytosol, mast cell granule, n     <a href="http://cansar.icr.ac.uk/cansar/m  
erived growth Cytoplasm, N cytoplasm, ex      HDGF family <a href="http://cansar.icr.ac.uk/cansar/m  
 uclear factor 4Nucleus cytoplasm, nu     nuclear horm   <a href="http://cansar.icr.ac.uk/cansar/m  
 receptor subu  Cell membran  ciliary neurot                            type I cytokin   <a href="http://cansar.icr.ac.uk/cansar/m  
2.3.1.48 Nucleus, Nuc       Golgi apparat           MYST (SAS/M  <a href="http://cansar.icr.ac.uk/cansar/m  
1.14.11.- Nucleus cytoplasm, nu     JHDM3 histon   <a href="http://cansar.icr.ac.uk/cansar/m  
1.14.11.- Nucleus histone meth      UTX family <a href="http://cansar.icr.ac.uk/cansar/m  
2.1.1.43 Nucleus histone meth      Histone-lysine  <a href="http://cansar.icr.ac.uk/cansar/m  
2.1.1.43 Nucleus histone meth      Histone-lysine  <a href="http://cansar.icr.ac.uk/cansar/m  
6.3.2.- Cytoplasm cytoplasm, cytosol, extrace     <a href="http://cansar.icr.ac.uk/cansar/m  
 rotein Nkx-3.1 Nucleus intracellular, NK-3 homeob  <a href="http://cansar.icr.ac.uk/cansar/m  
6.3.2.- Nucleus speck    nuclear speck     PIAS family <a href="http://cansar.icr.ac.uk/cansar/m  
6.3.2.- Nucleus speck     nuclear speck     PIAS family <a href="http://cansar.icr.ac.uk/cansar/m  
3.1.3.16 Cytoplasm, N     apical plasma membrane, c                              <a href="http://cansar.icr.ac.uk/cansar/m  
ma-associated Nucleus chromatin, nu         retinoblastom    <a href="http://cansar.icr.ac.uk/cansar/m  
6.3.2.- Cell membran      endoplasmic           ZNRF3 family <a href="http://cansar.icr.ac.uk/cansar/m
Nucleus centrosome,               SKI family <a href="http://cansar.icr.ac.uk/cansar/m  
 nst decapenta   Cytoplasm, N activin respon                  dwarfin/SMA  <a href="http://cansar.icr.ac.uk/cansar/m
 nst decapenta   Cytoplasm, N cytoplasm, cy                     dwarfin/SMA  <a href="http://cansar.icr.ac.uk/cansar/m  
 nst decapenta   Cytoplasm, N activin respon               dwarfin/SMA  <a href="http://cansar.icr.ac.uk/cansar/m
3.6.4.- Nucleus extracellular s               SNF2/RAD54  <a href="http://cansar.icr.ac.uk/cansar/m  
  domain-conta    Nucleus nucleus ETS family <a href="http://cansar.icr.ac.uk/cansar/m  
 POZ protein Nucleus, Nuc  Cul3-RING ub       Tdpoz family <a href="http://cansar.icr.ac.uk/cansar/m  
D repeat-conta   Nucleus nucleoplasm,      WD repeat EB  <a href="http://cansar.icr.ac.uk/cansar/m  
D repeat-conta   Nucleus nucleoplasm,      WD repeat EB  <a href="http://cansar.icr.ac.uk/cansar/m  
 iption factor TNucleus nucleus <a href="http://cansar.icr.ac.uk/cansar/m  
 n p73 Nucleus, Cytocell junction,             p53 family <a href="http://cansar.icr.ac.uk/cansar/m  
  d BTB domain   Nucleus cytosol, nucle             krueppel C2H    <a href="http://cansar.icr.ac.uk/cansar/m  
  nd homeobox   Nucleus cytoplasm, nu    ZHX family <a href="http://cansar.icr.ac.uk/cansar/m  
Nucleus, nucl centrosome,       AATF family <a href="http://cansar.icr.ac.uk/cansar/m  
3.4.24.- Cell membran  extracellular region, integra      <a href="http://cansar.icr.ac.uk/cansar/m  
nal enhancer o  Nucleus nucleus WD repeat Gr  <a href="http://cansar.icr.ac.uk/cansar/m  
  A4 protein Membrane, Membrane, cla  APP family <a href="http://cansar.icr.ac.uk/cansar/m  
 active domain-   Nucleus nBAF complex, npBAF comp       <a href="http://cansar.icr.ac.uk/cansar/m  
 active domain-   Nucleus BAF-type complex, nucleop   <a href="http://cansar.icr.ac.uk/cansar/m  
 active domain-   Nucleus, Cytocytoplasm, nucleoplasm, nu<a href="http://cansar.icr.ac.uk/cansar/m  
 comb group p  Nucleus nucleoplasm Asx family <a href="http://cansar.icr.ac.uk/cansar/m  
 modifier-acti   Cytoplasm, Pr  axoneme, cyt    ATG7 family <a href="http://cansar.icr.ac.uk/cansar/m  
Cytoplasm, N cytoplasm, in          ATXN1 family <a href="http://cansar.icr.ac.uk/cansar/m  
  nscription fact  Nucleus cytoplasm, nucleoplasm <a href="http://cansar.icr.ac.uk/cansar/m  
  otein castor h  Nucleus cytoplasm, intracellular me   <a href="http://cansar.icr.ac.uk/cansar/m  
Cell membranintegral component of mem   <a href="http://cansar.icr.ac.uk/cansar/m  
dent kinase in  Nucleus, Cyto  Cul4A-RING E         CDI family <a href="http://cansar.icr.ac.uk/cansar/m  
ncer-binding p  Nucleus, CytoCHOP-C/EBP c          bZIP family <a href="http://cansar.icr.ac.uk/cansar/m  
 anscription com   Cytoplasm, N CCR4-NOT co            CNOT2/3/5 fa<a href="http://cansar.icr.ac.uk/cansar/m  
 anscription com   Cytoplasm, N   CCR4-NOT co          CNOT2/3/5 fa<a href="http://cansar.icr.ac.uk/cansar/m  
ed transcriptio   Cytoplasm, N cytoplasm, de         TORC family <a href="http://cansar.icr.ac.uk/cansar/m  
 ble homeobox  Nucleus nucleus paired homeo  <a href="http://cansar.icr.ac.uk/cansar/m  
 factor E2F3 Nucleus cytoplasm, nu    E2F/DP family<a href="http://cansar.icr.ac.uk/cansar/m  
cting transcrip   Nucleus nucleoplasm <a href="http://cansar.icr.ac.uk/cansar/m  
 x protein H1 Nucleus activin responsive factor co        <a href="http://cansar.icr.ac.uk/cansar/m  
 x protein O3 Cytoplasm, cy  cytoplasm, cytosol, membr   <a href="http://cansar.icr.ac.uk/cansar/m  
man Membrane chloride chan           FXYD family <a href="http://cansar.icr.ac.uk/cansar/m  
al activator GLNucleus, Cyto    axoneme, cili               GLI C2H2-type   <a href="http://cansar.icr.ac.uk/cansar/m  
 s protein-like 1Nucleus matr nuclear envelope, nuclear m<a href="http://cansar.icr.ac.uk/cansar/m  
  ain-containing protein 8 <a href="http://cansar.icr.ac.uk/cansar/m  
  hway suppressor 2 nucleoplasm, transcriptiona   <a href="http://cansar.icr.ac.uk/cansar/m  
Nucleus, Chromosome histone H3 fa <a href="http://cansar.icr.ac.uk/cansar/m  
 receptor-asso     Cytoplasm, N cytoplasm, in  IRAK1BP1 fam<a href="http://cansar.icr.ac.uk/cansar/m  
 a-4 Membrane cell surface, e          integrin alpha  <a href="http://cansar.icr.ac.uk/cansar/m  
2.3.1.48 Nucleus, Nuc     NuA4 histone                   MYST (SAS/M  <a href="http://cansar.icr.ac.uk/cansar/m
 ipoprotein rec   Membrane integral comp     LDLR family <a href="http://cansar.icr.ac.uk/cansar/m  
ssociated antig  Nucleus, Cytocytoplasm, mitochondrion,  <a href="http://cansar.icr.ac.uk/cansar/m  
  VI1 complex loc   Nucleus, Nuc  aggresome, cytoplasm, cyto          <a href="http://cansar.icr.ac.uk/cansar/m  
  VI1 complex locus protein MDS1 <a href="http://cansar.icr.ac.uk/cansar/m  
cific enhancer  Nucleus cytoplasm, nu       MEF2 family <a href="http://cansar.icr.ac.uk/cansar/m  
Nucleus cytoplasm, nucleolus, nucle      <a href="http://cansar.icr.ac.uk/cansar/m  
associated tum   Mitochondrio               extracellular s            MTUS1 family<a href="http://cansar.icr.ac.uk/cansar/m  
 ncogene prote Nucleus, nucl   cytosol, nucleolus, nucleop    <a href="http://cansar.icr.ac.uk/cansar/m  
 ptor coactivato  Nucleus intracellular, OXR1 family <a href="http://cansar.icr.ac.uk/cansar/m  
 r 1 A-type Nucleus cell junction,  CTF/NF-I fam <a href="http://cansar.icr.ac.uk/cansar/m  
 cription facto    Nucleus CCAAT-bindin       NFYC/HAP5 s  <a href="http://cansar.icr.ac.uk/cansar/m  
 ition complex  Nucleus actin cytoskel                ORC4 family <a href="http://cansar.icr.ac.uk/cansar/m  
3.1.3.4 Cell membranextracellular e         PA-phosphata    <a href="http://cansar.icr.ac.uk/cansar/m  
Nucleus, Nuc              cytoplasm, cytosol, early en                   <a href="http://cansar.icr.ac.uk/cansar/m  
3.1.3.16 Cytoplasm, N       chromosome                  PPP phosphat  <a href="http://cansar.icr.ac.uk/cansar/m  
2.7.11.11 Cytoplasm, Ce         calcium chann                                      AGC Ser/Thr p   <a href="http://cansar.icr.ac.uk/cansar/m  
ocessing facto    Nucleus speck   cytoplasm, m          PRPF40 family<a href="http://cansar.icr.ac.uk/cansar/m  
ma-like protein Nucleus nucleoplasm,   retinoblastom    <a href="http://cansar.icr.ac.uk/cansar/m  
6.3.2.- Nucleus cytoplasm, cy      RNF12 family <a href="http://cansar.icr.ac.uk/cansar/m  
 homolog 1 Cell membran    axon, cell surf        ROBO family <a href="http://cansar.icr.ac.uk/cansar/m  
 homolog 2 Membrane axolemma, ce        ROBO family <a href="http://cansar.icr.ac.uk/cansar/m  
 l protein L11 Nucleus, nucl cytoplasm, cy         ribosomal pro   <a href="http://cansar.icr.ac.uk/cansar/m  
 transcription f  Nucleus cytoplasm, nuclear chroma      <a href="http://cansar.icr.ac.uk/cansar/m  
  Y1-binding pro Nucleus, Cyto   cytoplasm, nucleoplasm <a href="http://cansar.icr.ac.uk/cansar/m  
3.4.22.68 Nucleus cytoplasm, nupeptidase C48 <a href="http://cansar.icr.ac.uk/cansar/m  
  homolog Cytoplasm, cy   cytoplasm, cy  SHQ1 family <a href="http://cansar.icr.ac.uk/cansar/m  
 pathic helix pr  Nucleus, Nuc  cytoplasm, intercellular brid             <a href="http://cansar.icr.ac.uk/cansar/m  
 pathic helix pr  Nucleus autosome, cytoplasm, nucle          <a href="http://cansar.icr.ac.uk/cansar/m  
 nst decapenta   Nucleus, Cytocentrosome,            dwarfin/SMA  <a href="http://cansar.icr.ac.uk/cansar/m  
ted matrix-ass         Nucleus nBAF complex              SNF5 family <a href="http://cansar.icr.ac.uk/cansar/m  
 factor Sp1 Nucleus, Cytocytoplasm, nu      Sp1 C2H2-typ    <a href="http://cansar.icr.ac.uk/cansar/m  
 nse factor Nucleus cytoplasm, nuclear chroma   <a href="http://cansar.icr.ac.uk/cansar/m  
 x subunit SSRPNucleus, Nuc   chromosome     SSRP1 family <a href="http://cansar.icr.ac.uk/cansar/m  
al adapter 3 Nucleus Ada2/Gcn5/A               NGG1 family <a href="http://cansar.icr.ac.uk/cansar/m  
 factor AP-2-a Nucleus centrosome,         AP-2 family <a href="http://cansar.icr.ac.uk/cansar/m  
 growth factor    Cell junction,      cytoplasm, cy      paxillin family<a href="http://cansar.icr.ac.uk/cansar/m  
2.3.2.23 Cytoplasm cytoplasm, cy       ubiquitin-con   <a href="http://cansar.icr.ac.uk/cansar/m  
 nscription fact  Nucleus, nucl fibrillar center, nucleolus, n  <a href="http://cansar.icr.ac.uk/cansar/m  
3.4.19.12 Nucleus, nucl cytoplasm, nu     peptidase C19 <a href="http://cansar.icr.ac.uk/cansar/m  
al repressor p  Nucleus matr Ino80 comple    YY transcripti   <a href="http://cansar.icr.ac.uk/cansar/m  
 factor YY2 Nucleus cytoplasm, nu     YY transcripti   <a href="http://cansar.icr.ac.uk/cansar/m  
  d BTB domain   Nucleus nucleus <a href="http://cansar.icr.ac.uk/cansar/m  
  box-binding ho  Nucleus cytoplasm, nu     delta-EF1/ZFH    <a href="http://cansar.icr.ac.uk/cansar/m  
  omeobox prote  Nucleus, Cytocytoplasm, intracellular me          <a href="http://cansar.icr.ac.uk/cansar/m  
  nd homeobox   Nucleus nucleoplasm, ZHX family <a href="http://cansar.icr.ac.uk/cansar/m  
  otein ZIC 3 Nucleus, Cytocytoplasm, nu  GLI C2H2-type   <a href="http://cansar.icr.ac.uk/cansar/m  
  YM-type prote  Nucleus cytoplasm, nucleoplasm <a href="http://cansar.icr.ac.uk/cansar/m  
nearest_drugnumber_of_3    number_of_3    number_of_d    number_of_d    ligand_drugg screened_com
100.00|P1027  106 91 47 47 95 0
100.00|P1505 60 57 50 51 93 1413
100.00|P0337 193 182 105 105 94 5689
100.00|O153 1 0 0 0 93 1769
100.00|Q128 10 0 0 0 96 12236
100.00|Q027 41 41 38 39 92 1798
100.00|P0415 47 21 13 14 94 3419
100.00|P1027 24 22 3 9 88 606
100.00|P1082 24 22 5 9 94 567
100.00|P1363 24 22 1 9 88 512
100.00|P1979 83 60 43 47 89 812
32.41|O1492 38 30 15 30 95 3479
 molecular-targ  0 0 0 0 84 137
33.59|P42685 2 2 0 0 94 802
 molecular-targ  83 53 8 8 82 1426
72.23|P27815 75 72 37 70 95 2627
 molecular-targ  21 14 18 18 97 3777
 molecular-targ  2 2 2 2 96 1483
 molecular-targ  157 45 20 21 78 616
 molecular-targ  1 0 0 0 75 159
 molecular-targ  27 0 0 0 98 36
 molecular-targ  35 0 20 21 59 44
 molecular-targ  179 171 105 105 78 91
 molecular-targ  21 21 10 10 59 74
28.50|P21817 7 3 4 5 91 46
23.56|P21817 3 1 0 2 89 6
 molecular-targ  7 0 0 0 89 356
28.85|O6067 0 0 0 0 70 136
 molecular-targ  28 23 15 15 70 68
 molecular-targ  8 1 0 0 78 38
 molecular-targ  12 1 0 0 80 75
34.83|P19793 17 9 15 15 83 8
 molecular-targ  42 2 5 5 84 192
 molecular-targ  1 0 1 1 78 2
 molecular-targ  4 0 1 1 66
 molecular-targ  20 0 1 1 94 0
 molecular-targ  22 2 1 1 59 11
 molecular-targ  7 6 5 5 84
 molecular-targ  2 0 0 0 84 0
 molecular-targ  8 0 1 2 73
 molecular-targ  0 0 0 0 59
32.23|O6067 5 4 4 4 59
 molecular-targ  10 0 4 4 83
 molecular-targ  84 34 19 23 93 135
 molecular-targ  8 0 1 2 95
 molecular-targ  0 0 0 0 97
 molecular-targ  9 0 0 0 67 48
 molecular-targ  1 1 1 1 83
 molecular-targ  0 0 0 0 59
 molecular-targ  2 0 0 0 59
 molecular-targ  0 0 0 0 59
 molecular-targ  8 0 0 0 91 7
 molecular-targ  8 0 0 0 59 0
 molecular-targ  5 0 1 1 59 0
 molecular-targ  15 0 0 1 59 0
 molecular-targ  16 0 1 1 59 0
 molecular-targ  4 0 2 2 59
43.46|P19793 7 2 3 3 86 18
 molecular-targ  8 1 3 3 82 3
 molecular-targ  9 2 3 3 59 0
 molecular-targ  65 56 51 57 68 51
 molecular-targ  14 12 14 14 82 10
 molecular-targ  7 3 2 3 97 1
 molecular-targ  5 3 1 3 93 1
 molecular-targ  24 1 4 8 59
 molecular-targ  1 0 0 0 59
 molecular-targ  1 0 0 0 59
 molecular-targ  3 0 1 1 59
 molecular-targ  6 4 3 3 59 0
 molecular-targ  15 1 8 8 81 10
 molecular-targ  1 0 1 1 59
 molecular-targ  3 0 0 1 68
 molecular-targ  9 0 1 2 59 3
 molecular-targ  12 0 2 3 59 3
 molecular-targ  7 0 2 2 59 0
 molecular-targ  8 3 1 2 86 48
 molecular-targ  2 0 0 0 59
 molecular-targ  15 0 1 1 59
 molecular-targ  4 0 0 1 59
 molecular-targ  4 0 1 1 59
 molecular-targ  1 0 1 1 63
 molecular-targ  22 0 7 9 59
 molecular-targ  2 0 0 0 59 0
 molecular-targ  2 0 0 0 73
 molecular-targ  0 0 0 0 59
 molecular-targ  0 0 0 0 59
 molecular-targ  2 0 0 0 59
 molecular-targ  121 9 4 4 87 424
 molecular-targ  3 0 0 0 91
 molecular-targ  0 0 0 0 71
 molecular-targ  1 0 0 0 59
 molecular-targ  0 0 0 0 71
 molecular-targ  0 0 0 0 89 2
 molecular-targ  6 0 2 2 72
 molecular-targ  1 0 0 0 71
 molecular-targ  0 0 0 0 59
 molecular-targ  2 0 0 1 59
 molecular-targ  3 0 0 0 59
 molecular-targ  12 0 0 0 88
 molecular-targ  4 0 0 0 59
 molecular-targ  4 0 0 0 59
 molecular-targ  0 0 0 0 59 0
 molecular-targ  0 0 0 0 59
 molecular-targ  0 0 0 0 59
 molecular-targ  3 0 0 0 59
 molecular-targ  0 0 0 0 75
 molecular-targ  10 0 0 0 91 3
 molecular-targ  1 0 0 0 59
 molecular-targ  2 0 0 0 59
 molecular-targ  0 0 0 0 59
 molecular-targ  0 0 0 0 59
 molecular-targ  1 0 0 0 59
 molecular-targ  218 65 3 3 59
 molecular-targ  0 0 0 0 63
27.64|P08514 6 3 3 3 93 1660
 molecular-targ  3 1 1 1 59 25
 molecular-targ  0 0 0 0 86
 molecular-targ  0 0 0 0 59
 molecular-targ  0 0 0 0 59 0
 molecular-targ  0 0 0 0 59 0
 molecular-targ  9 1 0 0 59
 molecular-targ  5 0 0 0 59 0
 molecular-targ  0 0 0 0 72
 molecular-targ  7 0 0 0 59 36
 molecular-targ  0 0 0 0 59
 molecular-targ  0 0 0 0 60
 molecular-targ  3 0 0 0 59
 molecular-targ  0 0 0 0 59
 molecular-targ  0 0 0 0 59
 molecular-targ  5 0 0 0 59 0
 molecular-targ  16 6 1 1 65 59
29.29|O1492 188 158 162 162 84 1931
 molecular-targ  10 0 0 0 95
 molecular-targ  4 0 0 0 73
 molecular-targ  0 0 0 0 90
29.41|P11362 6 0 0 0 85
26.75|P21802 6 0 0 0 59
 molecular-targ  2 0 0 0 75
 molecular-targ  23 0 0 0 59 1
 molecular-targ  2 0 0 0 59
 molecular-targ  0 0 0 0 59 0
 molecular-targ  3 0 0 0 59
 molecular-targ  9 0 0 0 84
 molecular-targ  8 0 0 0 71
 molecular-targ  7 0 0 0 59
 molecular-targ  1 0 0 0 59 0
 molecular-targ  5 0 0 0 59 37
 molecular-targ  3 0 0 0 59
 molecular-targ  1 0 0 0 59
 molecular-targ  0 0 0 0 59
 molecular-targ  0 0 0 0 59
 molecular-targ  0 0 0 0 59
 molecular-targ  53 0 0 3 64
 molecular-targ  7 0 0 0 59
 molecular-targ  2 0 0 0 72 1
 molecular-targ  3 1 0 0 59
 molecular-targ  1 0 0 0 59
 molecular-targ  2 0 0 0 59
 molecular-targ  1 0 0 0 91
 molecular-targ  4 0 0 0 68
 molecular-targ  4 0 0 0 59
 molecular-targ  2 0 0 0 59
 molecular-targ  0 0 0 0 63












































































UniprotAccesstion Uniprot accedssion of the main gene product
Gene Symbol HUGO gene Symbol
Source The surce of the protein in the networ: input_list: prote                           
Subcellular_localisation Summary term indicating main subcellular localisation
long_name Full name of protein
node_label Label as shown in the network
Druggability_Class Druggability class: DT: Target of approved drug; CT: Tar                          
protein Protein product symbol
Synonyms Other synomyms
Transcriptional_class For transcription factors, subclassificaton
description Full description of prorein product
ec_number For enzymes, the Enzyme Classification 
location Expanded detail of subcellular localisation
go_terms Gene Ontology terms
family Protein family
cansar_link Link to live report in canSAR for this protein
nearest_drug_target List of closest homologous drug targets
number_of_3d_structure within 75% homThe number of 3D structures within 75% homology.
number_of_3d_structure_with_small_mo    The number of 3D protein stryctures that have been so                 
number_of_druggable_3d_structures wit   The number of druggable structures identified in canSA                       
number_of_druggable_3d_structures wit   The number of druggable structures identified in canSA                         
ligand_druggability_percentile_rank Rank of druggability based on chemical information alo                    
screened_compounds The number of published compouneds tested
screened_compounds_active at 50 nM or The number of published compounds showing 50nM a   
         ein product of gene identified as a key altered gene in this study;  additional_connectivity: key di           
        rget of drug under clinical investgation; AC: Target of compound in preclinical or discovery phase           
         olved in complex with a small molecule ligand - this could be either a cofactor or inhibitor
       AR that are within 90% homology of the protein - this is in effect direct evidence for the protein c    
       AR that are within 75% homology of the protein - this is a sufficiently close homology that the dru       
       one - 10% indicates it is in the top most druggable proteins based on chemical rather than protein  
       ctivity or better
                         rect interacting protein; additional_enriched: key enriched transcription factor (see online metho
                       exploration; Dr: none of the above but predicted druggable using canSAR
                          containing a druggable cavity
                         uggability mapping by homology is highly reliable
                        n structure information
                                   ods)
SUPPLEMENTARY TABLE 6
Cell Line
22RV Drug and targets 22RV
22RV AKT inhibitor VIII Target: AKT1, AKT2, AKT3 -1.03
22RV AS605240 Target: PI3Kgamma ns
22RV AZD6482 Target: PI3Kbeta ns
22RV AZD8055 Target: MTORC1, MTORC2 -0.23
BPH-1 CP466722 Target: ATM -0.30
BPH-1 Dactolisib Target: PI3K (Class 1), MTORC1, MTORC2 -0.43
BPH-1 GSK690693 Target: AKT1, AKT2, AKT3 ns
BPH-1 Idelalisib Target: PI3Kdelta ns
DU-145 KU-55933 Target: ATM ns
DU-145 MK-2206 Target: AKT1, AKT2 ns
LNCaP-Clone-FGC Nutlin-3a (-) Target: MDM2 -0.84
LNCaP-Clone-FGC Omipalisib Target: PI3K (class 1), MTORC1, MTORC2 ns
LNCaP-Clone-FGC OSI-027 Target: MTORC1, MTORC2 ns
LNCaP-Clone-FGC PI-103 Target: PI3Kalpha, DAPK3, CLK4, PIM3, HIPK2 ns
LNCaP-Clone-FGC Pictilisib Target: PI3K (class 1) ns
LNCaP-Clone-FGC PIK-93 Target: PI3Kgamma ns
LNCaP-Clone-FGC Serdemetan Target: MDM2 ns


























    
Data from the Genomics of Drug Sensitivity in Cancer (GDSC)-  public d          
values are shown as z-scores for drugs that act on targets within the Pca              


















Clone-FGC PC-3 PWR-1E VCAP
-1.07 ns -1.17 -0.36 ns -1.00
ns ns ns ns ns -0.99
ns ns -1.46 ns -0.28 ns
ns ns -0.78 -0.33 ns ns
-0.31 ns -0.54 ns ns -0.58
ns ns -0.63 -2.14 ns ns
ns ns -3.31 -0.56 ns -1.48
ns ns -2.07 ns ns ns
-0.21 -2.56 ns -0.60 -0.60 -0.11
ns -1.28 -1.44 -0.42 ns ns
-0.41 ns -1.86 ns ns ns
ns ns -0.63 -0.30 ns -1.36
ns ns -1.22 -1.17 ns -0.27
ns ns ns -0.82 ns -1.12
ns ns -0.91 -0.51 -0.18 ns
ns ns -0.20 -0.59 ns -0.61
ns ns -2.33 ns ns -1.68
ns ns ns -0.70 ns -1.14
not sensitive marginal sensitive
Cell line, Sensitivity in Z-score
            dataset provided by the Sanger Instiute  (http://www.cancerrxgene.org). Sensitivity 
             a druggable disease network identified in our study, and that have been tested on 
      
SUPPLEMENTARY TABLE 7
fig1_order fig2_order Sanger ID ICGC sample ID ICGC Donor ID
1 62 PD12337a 0096_CRUK_PC_0096_M1 0096_CRUK_PC_0096
2 61 PD11335a 0022_CRUK_PC_0022_M1 0022_CRUK_PC_0022
3 59 PD13412a 0095_CRUK_PC_0095_M1 0095_CRUK_PC_0095
4 54 PD11330a 0017_CRUK_PC_0017_M1 0017_CRUK_PC_0017
5 60 PD11328a 0015_CRUK_PC_0015_M1 0015_CRUK_PC_0015
6 56 PD11332a 0019_CRUK_PC_0019_M1 0019_CRUK_PC_0019
7 53 PD11329a 0016_CRUK_PC_0016_M1 0016_CRUK_PC_0016
8 58 PD11334a 0021_CRUK_PC_0021_M1 0021_CRUK_PC_0021
9 57 PD11333a 0020_CRUK_PC_0020_M1 0020_CRUK_PC_0020
10 55 PD11331a 0018_CRUK_PC_0018_M1 0018_CRUK_PC_0018
11 74 PD12843a 0060_CRUK_PC_0060_T1 0060_CRUK_PC_0060
12 63 PD14722a 0098_CRUK_PC_0098_M1 0098_CRUK_PC_0098
13 65 PD14731a 0107_CRUK_PC_0107_M1 0107_CRUK_PC_0107
14 5 PD12845a 0062_CRUK_PC_0062_T1 0062_CRUK_PC_0062
15 50 PD14728a 0104_CRUK_PC_0104_M1 0104_CRUK_PC_0104
16 85 PD12812a 0029_CRUK_PC_0029_T1 0029_CRUK_PC_0029
17 86 PD13380a 0063_CRUK_PC_0063_T1 0063_CRUK_PC_0063
18 23 PD12808a 0025_CRUK_PC_0025_T1 0025_CRUK_PC_0025
19 46 PD14721a 0097_CRUK_PC_0097_M1 0097_CRUK_PC_0097
20 25 PD13411a 0094_CRUK_PC_0094_T1 0094_CRUK_PC_0094
21 30 PD13388a 0071_CRUK_PC_0071_T1 0071_CRUK_PC_0071
22 47 PD14724a 0100_CRUK_PC_0100_M1 0100_CRUK_PC_0100
23 67 PD13408a 0091_CRUK_PC_0091_T1 0091_CRUK_PC_0091
24 78 PD12844a 0061_CRUK_PC_0061_T1 0061_CRUK_PC_0061
25 51 PD14729a 0105_CRUK_PC_0105_M1 0105_CRUK_PC_0105
26 45 PD14734a 0110_CRUK_PC_0110_T1 0110_CRUK_PC_0110
27 18 PD9746a 0009_CRUK_PC_0009_T1 0009_CRUK_PC_0009
28 71 PD12817a 0034_CRUK_PC_0034_T1 0034_CRUK_PC_0034
29 102 PD13381a 0064_CRUK_PC_0064_T1 0064_CRUK_PC_0064
30 87 PD13395a 0078_CRUK_PC_0078_T1 0078_CRUK_PC_0078
31 64 PD14726a 0102_CRUK_PC_0102_M1 0102_CRUK_PC_0102
32 103 PD13382a 0065_CRUK_PC_0065_T1 0065_CRUK_PC_0065
33 69 PD12811a 0028_CRUK_PC_0028_T1 0028_CRUK_PC_0028
34 83 PD9749a 0012_CRUK_PC_0012_T1 0012_CRUK_PC_0012
35 101 PD12842a 0059_CRUK_PC_0059_T1 0059_CRUK_PC_0059
36 17 PD14706a 0113_CRUK_PC_0113_T1 0113_CRUK_PC_0113
37 12 PD12830a 0047_CRUK_PC_0047_T1 0047_CRUK_PC_0047
38 109 PD14714a 0122_CRUK_PC_0122_T1 0122_CRUK_PC_0122
39 100 PD12838a 0055_CRUK_PC_0055_T1 0055_CRUK_PC_0055
40 52 PD14730a 0106_CRUK_PC_0106_M1 0106_CRUK_PC_0106
41 90 PD14713a 0120_CRUK_PC_0120_T1 0120_CRUK_PC_0120
42 68 PD13394a 0077_CRUK_PC_0077_T1 0077_CRUK_PC_0077
43 49 PD14727a 0103_CRUK_PC_0103_M1 0103_CRUK_PC_0103
44 92 PD12810a 0027_CRUK_PC_0027_T1 0027_CRUK_PC_0027
45 66 PD12809a 0026_CRUK_PC_0026_T1 0026_CRUK_PC_0026
46 88 PD13402a 0085_CRUK_PC_0085_T1 0085_CRUK_PC_0085
47 13 PD12836a 0053_CRUK_PC_0053_T1 0053_CRUK_PC_0053
48 73 PD9169a 0005_CRUK_PC_0005_T1 0005_CRUK_PC_0005
49 6 PD9168a 0004_CRUK_PC_0004_T1 0004_CRUK_PC_0004
50 9 PD12835a 0052_CRUK_PC_0052_T1 0052_CRUK_PC_0052
51 15 PD13401a 0084_CRUK_PC_0084_T1 0084_CRUK_PC_0084
52 77 PD12824a 0041_CRUK_PC_0041_T1 0041_CRUK_PC_0041
53 98 PD12828a 0045_CRUK_PC_0045_T1 0045_CRUK_PC_0045
54 8 PD12814a 0031_CRUK_PC_0031_T1 0031_CRUK_PC_0031
55 99 PD12837a 0054_CRUK_PC_0054_T1 0054_CRUK_PC_0054
56 110 PD14718a 0126_CRUK_PC_0126_T1 0126_CRUK_PC_0126
57 76 PD13407a 0090_CRUK_PC_0090_T1 0090_CRUK_PC_0090
58 34 PD12820a 0037_CRUK_PC_0037_T1 0037_CRUK_PC_0037
59 11 PD12813a 0030_CRUK_PC_0030_T1 0030_CRUK_PC_0030
60 72 PD12834a 0051_CRUK_PC_0051_T1 0051_CRUK_PC_0051
61 111 PD14720a 0128_CRUK_PC_0128_T1 0128_CRUK_PC_0128
62 19 PD13387a 0070_CRUK_PC_0070_T1 0070_CRUK_PC_0070
63 82 PD12840a 0057_CRUK_PC_0057_T1 0057_CRUK_PC_0057
64 22 PD13389a 0072_CRUK_PC_0072_T1 0072_CRUK_PC_0072
65 10 PD14707a 0114_CRUK_PC_0114_T1 0114_CRUK_PC_0114
66 32 PD14716a 0124_CRUK_PC_0124_T1 0124_CRUK_PC_0124
67 24 PD12829a 0046_CRUK_PC_0046_T1 0046_CRUK_PC_0046
68 39 PD13396a 0079_CRUK_PC_0079_T1 0079_CRUK_PC_0079
69 36 PD12832a 0049_CRUK_PC_0049_T1 0049_CRUK_PC_0049
70 7 PD14719a 0127_CRUK_PC_0127_T1 0127_CRUK_PC_0127
71 35 PD12825a 0042_CRUK_PC_0042_T1 0042_CRUK_PC_0042
72 79 PD9751a 0014_CRUK_PC_0014_T1 0014_CRUK_PC_0014
73 105 PD13393a 0076_CRUK_PC_0076_T1 0076_CRUK_PC_0076
74 43 PD14717a 0125_CRUK_PC_0125_T1 0125_CRUK_PC_0125
75 4 PD12806a 0023_CRUK_PC_0023_T1 0023_CRUK_PC_0023
76 89 PD13405a 0088_CRUK_PC_0088_T1 0088_CRUK_PC_0088
77 84 PD12807a 0024_CRUK_PC_0024_T1 0024_CRUK_PC_0024
78 48 PD14725a 0101_CRUK_PC_0101_M1 0101_CRUK_PC_0101
79 75 PD13383a 0066_CRUK_PC_0066_T1 0066_CRUK_PC_0066
80 3 PD12821a 0038_CRUK_PC_0038_T1 0038_CRUK_PC_0038
81 108 PD14709a 0116_CRUK_PC_0116_T1 0116_CRUK_PC_0116
82 81 PD13406a 0089_CRUK_PC_0089_T1 0089_CRUK_PC_0089
83 29 PD14735a 0111_CRUK_PC_0111_T1 0111_CRUK_PC_0111
84 21 PD12818a 0035_CRUK_PC_0035_T1 0035_CRUK_PC_0035
85 16 PD13404a 0087_CRUK_PC_0087_T1 0087_CRUK_PC_0087
86 NA PD6204a 0001_CRUK_PC_0001_T1 0001_CRUK_PC_0001
87 38 PD13391a 0074_CRUK_PC_0074_T1 0074_CRUK_PC_0074
88 1 PD14736a 0112_CRUK_PC_0112_T1 0112_CRUK_PC_0112
89 2 PD13399a 0082_CRUK_PC_0082_T1 0082_CRUK_PC_0082
90 80 PD14711a 0118_CRUK_PC_0118_T1 0118_CRUK_PC_0118
91 33 PD12819a 0036_CRUK_PC_0036_T1 0036_CRUK_PC_0036
92 31 PD13410a 0093_CRUK_PC_0093_T1 0093_CRUK_PC_0093
93 104 PD13390a 0073_CRUK_PC_0073_T1 0073_CRUK_PC_0073
94 28 PD14708a 0115_CRUK_PC_0115_T1 0115_CRUK_PC_0115
95 40 PD13409a 0092_CRUK_PC_0092_T1 0092_CRUK_PC_0092
96 27 PD12822a 0039_CRUK_PC_0039_T1 0039_CRUK_PC_0039
97 26 PD12831a 0048_CRUK_PC_0048_T1 0048_CRUK_PC_0048
98 112 PD14732a 0108_CRUK_PC_0108_T1 0108_CRUK_PC_0108
99 93 PD12841a 0058_CRUK_PC_0058_T1 0058_CRUK_PC_0058
100 91 PD13384a 0067_CRUK_PC_0067_T1 0067_CRUK_PC_0067
101 107 PD13398a 0081_CRUK_PC_0081_T1 0081_CRUK_PC_0081
102 95 PD12816a 0033_CRUK_PC_0033_T1 0033_CRUK_PC_0033
103 41 PD14710a 0117_CRUK_PC_0117_T1 0117_CRUK_PC_0117
104 37 PD13386a 0069_CRUK_PC_0069_T1 0069_CRUK_PC_0069
105 42 PD14712a 0119_CRUK_PC_0119_T1 0119_CRUK_PC_0119
106 94 PD12815a 0032_CRUK_PC_0032_T1 0032_CRUK_PC_0032
107 44 PD14733a 0109_CRUK_PC_0109_T1 0109_CRUK_PC_0109
108 20 PD13392a 0075_CRUK_PC_0075_T1 0075_CRUK_PC_0075
109 97 PD12826a 0043_CRUK_PC_0043_T1 0043_CRUK_PC_0043
110 14 PD13400a 0083_CRUK_PC_0083_T1 0083_CRUK_PC_0083
111 96 PD12823a 0040_CRUK_PC_0040_T1 0040_CRUK_PC_0040
112 106 PD13397a 0080_CRUK_PC_0080_T1 0080_CRUK_PC_0080
PELICAN ID EGA Accession Source
A21-19888-LRib5MassMet EGAN00001202474 PELICAN
A34-19956-LiverMet3 EGAN00001202462 PELICAN









PB133-20219-NAD Pelvic LN MET EGAN00001375298 PELICAN
PB635-20237-NAD Pelvic LN Met EGAN00001375314 PELICAN
EGAN00001250309 NDS (Oxford)




PB50-20217-NAD Pelvic LN MET EGAN00001375296 PELICAN
EGAN00001195729 ICR (Sutton)
EGAN00001195703 CRI (Cambridge)
PB273-20223-NAD Pelvic LN MET EGAN00001375300 PELICAN
EGAN00001195725 ICR (Sutton)
EGAN00001250307 NDS (Oxford)















PB556-20235-NAD Pelvic LN Met EGAN00001375312 PELICAN
EGAN00001250349 CRI (Cambridge)
EGAN00001195709 CRI (Cambridge)






































































Sample type Sample organ Age at tumour collection
adt-met left rib 5 70
adt-met liver 66
adt-met abdominal paraaortic lymph node 64
adt-met right superficial inguinal lymph node 82
adt-met right iliac lymph node 74
adt-met right rib 8 72
adt-met left humerus bone marrow 48
adt-met right axillary lymph node 69
adt-met mediastinal lymph node 68
adt-met right subdural 67
primary Prostate 88
non-adt-met Pelvic Lymph Node 70
non-adt-met Pelvic Lymph Node 64
primary Prostate 83




non-adt-met Pelvic Lymph Node 69
primary Prostate 59
primary Prostate 61
non-adt-met Pelvic Lymph Node 53
primary Prostate 65
primary Prostate 70















non-adt-met Pelvic Lymph Node 65
primary Prostate 52
primary Prostate 66






































































PSA at tumour collection Gleason Pathological t stage Biochemical recurrence
99 5+4 T4
40 5+4 T4
8.5 4+3 T2 1
10.6 4+3 T3 0
6.7 4+5 T3 0
10.9 3+4 T3 1
16.8 3+4 T3 1
16.2 4+3 T3 1
107 5+4 T3
5.8 3+4 T3 1
51.1 3+4 T2 0
4.4 3+4 T2 0
12 3+4 T3 0
8.6 3+4 T3 1
12.8 3+4 T3 0
5 3+4 T3 1
35.7 3+4 T2 0
15.1 3+4 T3 0
6.87 3+4 T3 1
7.1 4+3 T2 0
8.38 4+3 T3 0
4.5 4+3 T3 1
7 4+3 T2 0
7 3+5 T3 1
18.3 3+3 T3 1
12.1 4+3 T2 1
11 3+4 T2 1
8.5 3+4 T3 1
9.27 4+3 T2 0
7.38 3+4 T2 0
6 3+3 T3 0
7.5 3+4 T3 0
7.2 4+3 T2 1
10.4 3+4 T3 0
8.2 3+4 T2 0
15.8 3+3 T3 0
7.07 4+3 T3 0
11 3+4 T3 1
8.9 3+4 T2 0
8.65 4+3 T2 0
4.8 4+3 T3 1
5.83 3+4 T2 0
5.75 3+4 T3 0
9.7 3+4 T3 0
5.4 3+4 T3 1
13 4+3 T2 0
5.63 3+3 T3 0
17 4+3 T3 0
6.1 3+4 T2 0
9.1 3+4 T2 0
7.63 3+4 T3 0
12.4 3+4 T2 0
97 4+3 T2 0
7.3 3+4 T3 0
9.61 3+4 T3 0
7.8 3+4 T2 1
11.4 3+4 T2 0
10.7 3+4 T3 0
20.74 3+5 T2 0
3.8 3+4 T3 0
11.13 3+4 T3 0
13.6 4+3 T2 0
10.31 3+4 T3 0
7.25 4+3 T3 1
8.6 3+4 T2 0
6.9 3+4 T2 0
6.07 3+4 T3 0
4 3+4 T3 0
42.83 4+3 T3 1
8.8 4+3 T3 1
11.9 3+3 T2 0
7.8 3+4 T2 0
6.3 3+4 T3 1
7 3+4 T3 0
12.1 4+3 T3 1
5.43 4+3 T3 0
10 4+3 T3 1
5.2 3+4 T2 0
11.9 3+4 T3 0
10.3 3+4 T3 0
8.3 3+4 T2 0
3.2 3+4 T2 0
7.1 3+4 T3 0
7.57 3+4 T3 0
5.4 3+4 T3 0
8 3+4 T2 1
28 3+4 T3 0
9 3+4 T3 0
5.9 3+4 T2 0
7.8 3+4 T3 0
7.7 3+4 T2 0
4.3 3+3 T3 0
Follow up Sequence coverage Cellularity Ploidy ETS positive Battenberg status
31.168 0.8879469 2.6129 no yes
55.6349 0.794 2.1832 no yes
56.2832 0.8976817 2.1898 yes yes
60.873 0.327 4.9185 yes yes
72.0131 0.93 2.2937 no yes
55.7188 0.824 3.8892 yes yes
63.8777 0.8 2.804 yes yes
70.0629 0.753 2.1154 yes yes
53.8279 0.772 2.3603 yes yes
54.3952 0.896 3.9017 yes yes
68.2543 0.1327743 4.4868 no yes
69.3941 0.6562474 2.482 no yes
57.8208 0.6227155 3.8177 no yes
62.7755 0.7075184 4.1396 yes yes
63.7608 0.5190688 1.99 yes yes
231 57.5147 0.6299532 2.1753 no yes
1246 49.4257 0.81098 2.332 no yes
1596 81.5937 0.7315538 2.0555 yes yes
50.8255 0.7068444 3.8775 yes yes
1240 103.611 0.2282811 3.3818 yes yes
42 56.2595 0.7146315 2.0582 yes yes
68.2616 0.7575697 3.8226 yes yes
461 54.8458 0.8876603 2.6087 no yes
56.0296 0.7863649 4.2441 no yes
56.8823 0.3518549 3.7638 yes yes
982 58.4852 0.6130416 2.4175 yes yes
1503 46.5969 0.3269423 3.9782 yes yes
1568 75.8161 0.6947852 2.3655 no yes
861 54.8251 0.4886241 2.1483 no yes
139 48.833 0.2928916 2.4505 no yes
88.0622 0.7522268 1.9434 no yes
1092 47.9624 0.5435194 2.1736 no yes
1108 66.0939 0.6430273 1.9862 no yes
3102 48.1899 0.5504923 2.1605 no yes
1281 71.0824 0.54395 2.0972 no yes
639 63.7698 0.6309904 2.2266 yes yes
1282 55.8186 0.5664677 1.9983 yes yes
1042 63.1209 0.3536998 2.1131 no yes
98 57.2926 0.3979055 2.3503 no yes
61.7085 0.6257645 3.966 yes yes
1567 67.4508 0.8243116 1.922 no yes
53 55.3672 0.6742534 2.1377 no yes
65.0003 0.4602516 4.2688 yes yes
1988 61.7287 0.4855316 2.1614 no yes
1192 65.272 0.5514199 2.142 no yes
725 60.2786 0.7430892 2.1295 no yes
1732 56.7202 0.3411305 4.2647 yes yes
1703 49.5837 0.8253155 2.249 no yes
1485 46.2282 0.3846632 5.0003 yes yes
2410 60.3372 0.5061917 2.0067 yes yes
1103 98.7059 0.5693289 2.0877 yes yes
455 49.0305 0.6237579 2.5298 no yes
1435 76.8805 0.5132007 3.8533 no yes
1605 78.7609 0.8038008 2.0895 yes yes
1694 57.1343 0.4592892 2.1574 no yes
962 66.1064 0.57163 2.1208 no yes
610 60.1169 0.2768668 2.2644 no yes
1336 65.1874 0.5866868 2.1763 yes yes
1478 70.0784 0.5939939 2.0956 yes yes
2395 69.3372 0.5405621 2.2087 no yes
949 60.1544 0.2859 2.3336 no yes
1029 51.2779 0.6461844 2.0507 yes yes
1370 60.462 0.6957791 2.1585 no yes
931 48.978 0.5814945 2.1414 yes yes
1154 55.7188 0.5405533 2.1403 yes yes
1009 61.0135 0.6229427 2.0737 yes yes
1373 69.5849 0.6335656 2.0119 yes yes
1351 82.082 0.6003663 2.0062 yes yes
910 69.1117 0.5525659 2.1295 yes yes
1000 61.5416 0.532787 2.0207 yes yes
2226 56.837 0.246433 2.788 yes yes
5 49.384 0.5004422 2.2818 no yes
1281 63.9073 0.52523 2.1076 no yes
821 63.5043 0.6283428 2.0392 yes yes
711 59.0325 0.8284161 2.0282 yes yes
692 57.1309 0.7711552 2.1273 no yes
409 60.2388 0.5998768 2.0839 no yes
70.1226 0.6600904 2.0513 yes yes
1207 57.9645 0.4302704 2.4245 no yes
2048 53.9335 0.5288179 2.0402 yes yes
1063 65.5659 0.2962172 2.5969 no yes
857 56.2484 0.729429 2.0892 no yes
722 54.2026 0.5492461 2.0896 yes yes
955 56.6229 0.4112793 2.0381 yes yes
1045 60.2229 0.6117868 2.0872 yes yes
2198 27.2141 0.48167 2.2952 no yes
1317 57.8395 0.1895289 2.615 yes yes
540 55.5093 0.5191865 1.9407 yes yes
68 51.7051 0.5805523 2.0717 yes yes
614 59.7155 0.6382734 2.1451 no yes
3327 78.7577 0.100931 2.5521 yes yes
1694 103.225 0.4181382 2.1426 yes yes
642 50.8752 0.4556534 2.3492 no yes
1108 63.5958 0.6915431 2.0345 yes yes
1366 50.5219 0.2197996 2.5013 yes yes
1535 74.9148 0.2442819 2.125 yes yes
51 72.9105 0.6091219 3.3681 yes yes
1084 53.1289 0.4181697 2.3438 no yes
1348 58.0269 0.6306792 2.4705 no yes
1134 50.9903 0.7880881 2.1128 no yes
465 57.265 0.378287 2.1498 no yes
1402 76.7009 0.2285832 3.3951 no yes
1086 69.9879 0.5311579 2.1287 yes yes
1095 57.1239 0.3999533 2.1649 yes yes
1122 59.1506 0.3920645 2.148 yes yes
456 50.1649 0.3646071 2.3496 no yes
827 56.6248 0.6186164 2.1761 yes yes
1358 61.8726 0.4433831 2.0948 yes yes
1731 58.3241 0.1927425 4.7141 no yes
1157 60.5998 0.1530631 2.4647 yes yes
1654 57.0562 0.902111 3.4678 no yes
1236 58.9659 no No
no.subs no.indels Complex Del Ins no.svs Inversion Translocation Deletion
17448 867 23 381 463 443 151 141 92
16107 2606 152 ### 701 345 60 155 83
11944 1734 109 ### 560 729 39 51 144
8720 1050 16 690 344 193 59 48 58
7008 1256 44 450 762 388 48 36 44
6106 1322 25 806 491 172 48 58 51
5950 1159 18 393 748 155 42 26 74
4604 1714 21 ### 598 297 72 63 79
3959 762 16 227 519 86 28 24 24
3495 641 10 246 385 145 42 42 34
9778 1145 8 599 538 200 58 68 21
8157 1167 45 814 308 181 46 57 61
7137 995 47 680 268 179 48 70 50
6955 796 6 397 393 121 43 31 18
6319 944 16 440 488 221 43 29 74
6195 655 37 466 152 43 9 19 12
4892 672 39 475 158 44 9 19 11
4519 460 13 258 189 75 18 24 23
4242 512 3 306 203 69 22 23 17
4181 589 16 273 300 83 24 14 38
4119 464 9 240 215 52 13 23 11
4033 546 10 295 241 196 53 23 101
3956 531 10 284 237 300 105 110 48
3883 717 12 457 248 193 50 89 40
3725 505 3 200 302 89 26 16 42
3709 534 5 261 268 141 34 37 54
3599 242 2 125 115 77 14 23 28
3589 554 9 346 199 164 66 63 7
3548 296 7 181 108 10 2 3 3
3523 283 4 192 87 47 15 21 9
3481 673 12 403 258 69 15 37 8
3426 448 9 244 195 35 18 8 5
3410 593 11 293 289 394 148 142 58
3394 520 6 263 251 58 18 12 21
3393 497 7 261 229 36 8 5 20
3377 535 9 258 268 79 23 24 21
3369 641 7 449 185 30 11 5 11
3352 344 9 168 167 41 10 11 15
3315 426 10 226 190 127 44 45 25
3295 510 4 219 287 86 20 28 30
3236 425 4 230 191 38 16 12 3
3212 594 7 277 310 192 65 76 24
3145 607 8 241 358 149 38 27 77
3141 430 11 275 144 81 30 35 10
3132 593 6 274 313 112 38 54 4
3132 309 5 178 126 33 12 8 12
3122 482 9 250 223 47 14 17 13
3120 32 0 24 8 132 43 59 16
3054 350 5 192 153 62 14 13 29
3042 342 10 155 177 44 10 16 11
3021 536 19 288 229 56 12 19 23
3015 401 7 249 145 112 38 42 16
3013 511 11 285 215 55 17 15 19
2980 651 13 333 305 26 6 9 5
2945 420 4 257 159 34 8 10 13
2917 529 6 323 200 100 40 40 10
2796 266 9 139 118 118 48 46 8
2787 378 5 151 222 56 16 16 15
2785 378 7 217 154 44 7 14 18
2779 487 13 280 194 150 61 59 4
2767 258 7 145 106 11 0 4 6
2734 363 7 180 176 53 20 18 11
2730 434 5 250 179 33 13 13 4
2720 370 4 182 184 149 42 40 55
2709 266 5 138 123 35 6 13 15
2703 298 8 177 113 32 10 8 12
2699 495 14 254 227 73 32 23 9
2670 367 6 175 186 12 4 5 1
2666 464 7 242 215 11 3 3 4
2657 382 6 183 193 33 7 15 8
2654 214 6 131 77 15 2 7 5
2607 307 7 180 120 92 25 33 19
2587 328 8 199 121 91 32 15 35
2580 347 5 174 168 51 22 11 9
2555 485 8 231 246 85 22 22 35
2542 410 6 224 180 291 92 85 71
2516 332 10 192 130 36 14 14 1
2515 417 7 205 205 123 29 28 58
2499 313 3 181 129 84 23 33 15
2487 365 2 178 185 84 27 10 44
2450 239 7 152 80 99 33 34 16
2440 294 3 179 112 42 14 16 5
2418 263 2 111 150 35 8 16 9
2321 239 4 138 97 26 6 12 4
2309 260 9 145 106 43 13 14 11
2300 190 0 107 83 72 22 43 2
2255 226 3 117 106 25 6 7 7
2250 199 2 111 86 103 19 18 59
2239 326 11 200 115 105 24 31 38
2223 355 10 209 136 146 55 56 15
2209 369 9 194 166 17 5 5 5
2159 472 5 250 217 27 10 11 3
2127 224 5 132 87 66 12 19 27
2084 329 5 159 165 42 11 10 17
2082 288 8 146 134 54 6 14 28
2072 362 5 198 159 35 10 10 14
2038 535 8 241 286 74 13 21 34
2010 213 4 133 76 28 13 4 8
1898 340 8 212 120 50 13 20 15
1884 233 4 126 103 80 33 28 14
1839 277 11 158 108 69 22 28 10
1795 252 5 150 97 11 2 0 8
1764 265 10 140 115 43 10 18 12
1752 188 5 78 105 26 7 8 9
1713 214 7 112 95 21 5 9 6
1523 185 1 136 48 112 39 35 20
1502 178 7 93 78 8 2 3 2
1491 198 3 95 100 14 2 5 7
1161 110 8 57 45 8 3 1 2
928 106 3 63 40 5 1 1 3
923 114 4 65 45 6 3 1 0



















































































































Sanger ID Battenberg status Included_in_subclonal_analysis
PD11328a yes yes
PD11329a yes yes
PD11330a yes yes
PD11331a yes yes
PD11332a yes yes
PD11333a yes yes
PD11334a yes yes
PD11335a yes yes
PD12337a yes yes
PD13412a yes yes
PD14721a yes yes
PD14722a yes no
PD14724a yes yes
PD14725a yes yes
PD14726a yes yes
PD14727a yes yes
PD14728a yes yes
PD14729a yes yes
PD14730a yes yes
PD14731a yes yes
PD12806a yes yes
PD12807a yes yes
PD12808a yes yes
PD12809a yes yes
PD12810a yes yes
PD12811a yes yes
PD12812a yes yes
PD12813a yes yes
PD12814a yes yes
PD12815a yes yes
PD12816a yes yes
PD12817a yes yes
PD12818a yes yes
PD12819a yes no
PD12820a yes yes
PD12821a yes yes
PD12822a yes no
PD12823a yes no
PD12824a yes yes
PD12825a yes yes
PD12826a yes no
PD12828a yes yes
PD12829a yes yes
PD12830a yes yes
PD12831a yes yes
PD12832a yes yes
PD12834a yes yes
PD12835a yes yes
PD12836a yes no
PD12837a yes yes
PD12838a yes yes
PD12840a yes yes
PD12841a yes yes
PD12842a yes yes
PD12843a yes no
PD12844a yes yes
PD12845a yes yes
PD13380a yes yes
PD13381a yes yes
PD13382a yes yes
PD13383a yes no
PD13384a yes yes
PD13386a yes yes
PD13387a yes yes
PD13388a yes yes
PD13389a yes yes
PD13390a yes yes
PD13391a yes no
PD13392a yes no
PD13393a yes yes
PD13394a yes yes
PD13395a yes yes
PD13396a yes yes
PD13397a no no
PD13398a yes yes
PD13399a yes yes
PD13400a yes no
PD13401a yes yes
PD13402a yes yes
PD13404a yes no
PD13405a yes yes
PD13406a yes yes
PD13407a yes no
PD13408a yes yes
PD13409a yes no
PD13410a yes yes
PD13411a yes no
PD14706a yes yes
PD14707a yes yes
PD14708a yes yes
PD14709a yes no
PD14710a yes yes
PD14711a yes yes
PD14712a yes yes
PD14713a yes yes
PD14714a yes yes
PD14716a yes yes
PD14717a yes yes
PD14718a yes yes
PD14719a yes yes
PD14720a yes no
PD14732a yes no
PD14733a yes yes
PD14734a yes yes
PD14735a yes yes
PD14736a yes yes
PD6204a_Illumina yes yes
PD9168a yes yes
PD9169a yes yes
PD9746a yes yes
PD9749a yes yes
PD9751a yes yes
